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Abstract 
 
BACKGROUND: Hospital formularies are usually the gatekeepers for pharmaceutical 
drugs. Typical majority members of hospital formularies are physicians, although most 
of the time the formulary is chaired by a pharmacist. As German hospitals are struggling 
with a difficult economic environment the question arises: what kind of decision-making 
criteria are applied when pharmaceutical drugs should be added to the formulary list? 
Information regarding this topic is scarce due to the sensitive topic of decision-making.  
 
OBJECTIVES: Build a single decision-making framework which will be created to 
explain hospital drug funding decision-making and identify underlying mechanisms 
which explain processes and structures. The results can be used by hospitals to initiate 
knowledge sharing and provide a basis to analyse local formulary committee decision-
making practice. Additionally, they can be used by the pharmaceutical industry to better 
adapt to the specific needs of the hospital decision-makers. 
  
METHODS: In this study, a mixed-methods approach has been used to confirm and 
further detail a preliminary hospital formulary decision-making framework derived from 
literature. An online survey was used to get insights on the structure of German hospital 
formularies and the relative importance of different decision-criteria. Additional semi-
structured expert interviews were used to get in-depth information on the underlying 
mechanisms which influence decision-making on drug funding.  
 
RESULTS: Decisions for or against a pharmaceutical drug are influenced by a variety 
of perceived objective and specifically subjective criteria.  
Despite a consistency in a dominant, high impact role of pharmacists and lead 
physicians every hospital formulary member has different relative weighting of decision 
criteria. Drug funding decision-making in German hospital formularies is highly 
individual but usually starts with a quasi-rational preference influenced by a mixture of 
analytic and intuitive criteria. The decision to use more analytic or more intuitive criteria 
is influenced by a variety of factors. The two most important ones are uncertainty and 
power. The resulting individual preference is then challenged and adapted in a group 
decision-making process. 
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1 Introduction 
 
1.1 Background to healthcare decision-making 
The complexity in healthcare decision-making comes from many external and internal 
factors which influence the final decision. These factors which have impact on these 
decisions are a mixture of perceived objective and subjective criteria (Atienza, Merino & 
Varela, 2008). Objective criteria in the context of this thesis mean criteria which can be 
measured, such as results of clinical trials or costs for a pharmaceutical drug. Subjective 
criteria in the context of this thesis mean criteria which cannot be measured, such as 
personal experience, expert's advice, public pressure or political interests. 
They can include the personal experience of decision-makers as well as influence from 
groups potentially involved in the decision-making process, for instance patient groups, 
healthcare experts or the pharmaceutical industry (Armstrong et al., 2008; Wirtz et al., 
2005). Public pressure on decisions can derive out of patient group activities or 
comparisons between different country healthcare systems (Gallego et al., 2008; 
Kapiriri, Norheim & Martin, 2007). Besides perceived objective criteria on drug funding 
decisions, such as clinical evidence or economic evaluation, also perceived subjective 
criteria such as personal experience of hospital physicians or pharmacists might be 
important for the decision-making. All in all this represents the complexity which can be 
found in drug funding decisions and which is a challenge for decision-makers. 
 
1.1.1 Definition of local, regional and national decision-making 
One important differentiation of healthcare decision-making is the level at which 
healthcare decisions are being taken. In the literature, healthcare decisions are 
distinguished by three different levels: national, regional or local (Drummond, 2004; van 
Velden, Severens & Novak, 2005). Regional and local decision-making are sometimes 
defined differently and therefore the differentiation is not consistent for all studies. Some 
researchers define the hospital as the local level (Peacock, Mitton, Bate, McCoy, & 
Donaldson, 2009) and some researchers look into more details and define single people 
in the hospital, such as physicians, as the local level (Kapiriri, Norheim & Martin, 2009). 
13 
 
Hence, for this thesis the following definitions will be used: Decision-makers at national 
level include Health Technology Assessment (HTA) authorities, reimbursement 
agencies or other mostly governmental driven agencies responsible for pharmaceutical 
drug funding decisions. Decision-makers at regional level include pharmaceutical 
therapeutic committees, formulary committees which either work on a country's regional 
level (in case of regional budget responsibility for example) or on a hospital level. Local 
decision-makers include physicians, pharmacists, nurses who take healthcare decision on 
a local level in their offices, pharmacies or in hospitals for specific patients. Figure 1 
illustrates the different levels of healthcare decision-making. 
 
 
 
 
 
 
Figure 1: Key influencing elements for drug funding decisions. (Adapted from Atienza et al., 2008). 
 
 
1.1.2 Hospital formulary committees 
The hospital formulary committee is a group of experts who meet regularly to decide on 
different questions such as the listing of pharmaceutical drugs onto the formulary list. 
Experts here mean hospital employees with a medical, economic or other special 
knowledge about the formulary’s topics of interest, such as the inclusion of 
pharmaceutical drugs. Even if reasonable amounts of information exist for decision-
making of pharmaceutical drug listing on national or regional health insurance level, the 
information regarding the specific regional hospital level is scarce. This might be the 
case owing to the sensitive topic and less pressure for transparency on the hospital level. 
However, some research on hospital formularies and hospital formulary decision-
14 
 
making exist for countries like France, Canada, the Netherlands, UK or Germany (Fijn, 
Brouwers, Knaap & De Jong-Van den Berg, 1999; Gallini, Juillard-Condat, Saux & 
Taboulet, 2011; Jenkings & Barber, 2004; Martin, Hollenberg, MacRae, Madden & 
Singer, 2003; Thürmann, Harder & Steioff, 1997). Despite the published research, the 
decision-making process for pharmaceutical drug listing of formulary committees is “far 
from clear” (Dean et al., 2013, p.465). Studies about this topic are quite homogenous in 
terms of hospital formulary structure, activities or members, but there is heterogeneity in 
terms of the decision-making process and applied decision-making criteria. The majority 
of the studies agreed in one single, important point: the decision-making process for 
listing a pharmaceutical drug in hospital formularies is not transparent (Dean et al., 
2013; Fijn et al., 1999; Gallego et al., 2009). 
 
The composition of members of a hospital formulary can vary significantly. Basic 
members of a hospital formulary and mostly similar across all countries are pharmacists 
and physicians. From formulary to formulary the involvement of nurses, financial 
administrators, pharmacologists, patients and hospital administration is different. 
Whereas nurses, pharmacologists and hospital administration are part of some hospital 
formularies it is very seldom that financial administrators or patients are involved (Plet 
et al., 2013; Späth, Charavel, Morelle & Carrere, 2003). Typically physicians are in the 
majority due to representation of all medical departments and the key person in the 
hospital formulary committee is usually the hospital pharmacist who is often chairing 
the committee (Fijn et al., 1999). Sometimes additional pharmacists are members of the 
formulary committee.  
 
Independent of the respective country, hospital formulary committees have between 
three to 14 committee members not including possible subgroups with additional 
members (Fijn et al., 1999). For Germany a higher number was reported with a range 
from four to 40 members and a median of twelve (Thürmann et al., 1997). Fijn et al. 
(1999) showed in their study that approximately one third of the committees had also 
nurses as members. However, this is not true for all countries and was also not 
confirmed for Germany (Thürmann et al., 1997). The composition is not necessarily the 
15 
 
same in every hospital or every country. For example, the French Clinical Pharmacy 
Association does suggest including also members of the hospital management (besides 
physicians, pharmacists and nurses) (Späth et al., 2003). The only identified study for 
Germany by Thürmann et al. (1997) did not consider other stakeholders and 
concentrated only on the clinical members and the hospital pharmacist. 
 
1.2 Objectives of this research 
Hospital formulary decision-makers do not only use objective but also subjective criteria 
to come to their decisions on drug funding (Barasa et al., 2014; Eddama & Coast, 2008; 
Koopmanschap et al., 2010; Niezen et al., 2009). Understanding about those applied 
decision criteria is limited. Especially the understanding of the most important decision 
criteria for decision-makers and the relative importance of each of the criteria varies 
(Barasa et al., 2014; Eddama & Coast, 2008; Koopmanschap et al., 2010; Niezen et al., 
2009). Additionally, current research revealed gaps in the understanding of the relative 
importance of the respective stakeholder groups to the final decision-making. Some of 
the hospital formulary committee members, such as pharmacists or physicians, 
apparently have important roles and a certain (high) degree of influence on decision-
making (Alsultan, 2011; Fijn et al., 1999). Details of the relative importance and the 
degree of influence remain vague. The existing literature only provides an indistinct 
picture of the motives or objectives of the different stakeholder groups, even though this 
seems to be essential for a better understanding of hospital formulary decision-making. 
Hence, it is not surprising that current research does not show or define any framework 
describing this process and the relationship between different stakeholders and decision 
criteria.  
Outcomes of the literature review should be used to construct a model framework 
encompassing the different decision criteria and the different stakeholders in order to 
provide a theoretical explanation of this relationship as well as the decision-making 
process. This research aims to assess whether the conceptual framework holds in 
practice and identifies what changes are required to represent hospital formulary 
committee decision-making in the specific German context. The descriptive, conceptual 
framework of the hospital formulary committee decision-making process and the 
16 
 
identification of underlying mechanism which explain processes and structures will help 
hospitals to better understand their own process, compare it to processes of other 
hospitals and to identify opportunities for improvement. Additionally, the 
pharmaceutical industry can better adapt to the specific needs of the hospital decision-
makers.  
 
Hence, this research concentrates on the following questions: 
RQ-1. What are the criteria in funding decisions for pharmaceutical drugs in 
hospital formulary committees? 
RQ-2. What is the relative importance of each of those criteria in funding 
decisions for pharmaceutical drugs in hospital formulary committees? 
RQ-3. What is the level of influence of each stakeholder group on drug funding 
decisions of hospital formulary committees? 
RQ-4. What are the motives and objectives of decision-makers when applying 
quantitative and qualitative criteria for drug funding decisions in 
hospitals? 
Research questions “RQ-1” to “RQ-4” are the guiding questions in order to fulfil the 
following research objectives: 
RO-1. Identify and assess the criteria used in funding decisions for 
pharmaceutical drugs in hospital formulary committees. 
RO-2. Identify and assess the relative importance of the different criteria used in 
funding decisions for pharmaceutical drugs in hospital formulary 
committees. 
RO-3. Evaluate the influence of each stakeholder group on drug funding 
decisions of hospital formulary committees. 
RO-4. Identify and evaluate the motives and objectives of decision-makers when 
making funding decisions for pharmaceutical drugs in hospital formulary 
committees. 
RO-5. Construct a hospital formulary committee decision-making framework for 
German hospitals as a basis for future research. 
RO-6. Identify and assess the potential implications for stakeholders.  
17 
 
1.3 Structure of this thesis 
 
The structure of this thesis is shown in Figure 2. 
 
Discussion and conclusion
Quantitative and qualitative 
data analysis
Research methods and 
methodology
Research Strategy
Literature Review on 
group decision-making
Literature Review on 
healthcare decision-making 
Preliminary hospital formulary 
decision-making framework
Introduction
Final hospital formulary decision-
making framework  
 
Figure 2: Structure of the thesis. 
 
The first part (chapter 1) is an introduction to the topic of this thesis. Background of 
healthcare decision-making, research questions and research objectives are introduced. 
 
In the next part (sections 2.1 and 2.2) a literature review on healthcare decision-making 
and hospital formulary decision-making is conducted. This part discusses the issues 
around the use of perceived objective and subjective decision-making criteria generally 
for healthcare decision-making and specifically for hospital formularies. It concludes 
with the construction of a preliminary hospital formulary decision-making framework. 
 
The following part (sections 2.3 and 2.4) is a second literature review on group decision-
making in order to understand the wider question of decision-making. It discusses 
theories and models on shared preferences, shared knowledge and centrality. Those 
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concepts are considered for the adaptation of the preliminary hospital formulary 
decision-making framework. 
 
The next part (chapter 3) refers to the research strategy. The underlying research 
philosophy and a rationale for the use of a mixed-methods approach are provided. 
Following this, the next part (chapter 4) describes the research methods and 
methodologies. This chapter refers to sampling for the survey and the interviews as well 
as to validity and reliability.  
The next part (sections 4.10 to 4.14) provides a description of the data analysis, 
transcription strategy and ethics. In chapter 5 the results of the survey data analysis are 
given. Accordingly chapter 6 provides the results of the expert interview data analysis 
and chapter 7 summarises the results of the company market research interview data 
analysis. 
 
Chapter 8 merges the outcomes of the literature review, the quantitative and the 
qualitative analyses and discusses similarities and differences. It refers to the balance 
between intuitive and analytic decision-making, decision-makers in the hospital 
formulary committee and the group dynamics and impact on decision-making. This 
chapter concludes with the construction of the final hospital formulary decision-making 
framework. 
 
Chapter 9 discusses implications for stakeholders which can be derived from the 
propositions of the discussion part and the limitations of this research. The thesis closes 
with a section on limitations, the conclusions and thoughts on potential future research. 
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2 Literature Review 
 
In order to locate specific healthcare decision-making in hospital formulary committees, 
the literature review concentrated on healthcare decision-making, particular hospital 
formulary decision-making and concludes in a preliminary conceptual framework.  
 
The strengths of a systematic literature review are “the narrow focus of the question, the 
comprehensive search for evidence, [and] the criterion-based selection of relevant 
evidence” (Collins & Fauser, 2005, p.103). Those strengths are useful in order to 
understand the very specific question of hospital formulary decision-making but less 
useful for the wider question of understanding relevant decision-making theories and 
models.  Thus, a second systematic literature review was required to improve the 
understanding on group decision-making and related theories and models. The topics 
which were seen as relevant based on the results of the first systematic review on 
healthcare and hospital formulary decision-making were:  
1. Objective versus subjective decision-making: Healthcare decisions are based 
on different criteria which can be perceived as objective, such as data from 
clinical trials, the price of a pharmaceutical drug, etc. and those criteria that can 
be perceived as subjective, such as the clinical experience of a physician.  
 
2. Group decision-making: Hospital formularies are always a group of experts, 
who decide on the funding of a pharmaceutical drug together.  
 
The second systematic review should help to identify theories or models which could be 
used to make the preliminary framework more precise and to broaden the focus of the 
literature review.  
 
This is the rationale behind the decision to separate the literature review into two 
constitutive parts: one part which covers the specific topic of healthcare and hospital 
formulary decision-making and one part which covers a wider understanding of models 
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and theories about perceived objective and subjective decision-making and group 
decision-making (Figure 3). 
 
 
Figure 3: The literature review process. 
 
 
2.1 Healthcare and hospital decision-making 
In this first part of the literature review, research knowledge about hospital formulary 
structures, applied processes and applied decision-making criteria are analysed and 
critically evaluated. A specific focus was on the use of perceived objective and 
perceived subjective criteria in drug funding decision-making and more specifically drug 
funding decision-making in hospitals. In order to have a comprehensive picture of 
criteria used in drug funding decisions this review includes quantitative and qualitative 
research.  
 
2.1.1 Search strategy 
The first step in this literature review included a search via EBSCO with general search 
terms (described later) on the following databases: Business Source Corporate Plus, 
Biomedical Reference Collection Corporate, Medline, Health Technology Assessments 
and a searching via Science Direct. From the resulting list of 6,219 papers all abstracts 
were screened for relevant information on the research questions RQ-1 to RQ-4. The 
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remaining 612 articles were fully read and assessed in regards to inclusion and exclusion 
criteria described below. The reference lists of these papers where then used to identify 
further publications pertinent to the review’s objectives which had not been identified 
through the first procedure. Again, their abstracts were screened, doubles eliminated, 
resulting in a total of 44 publications for this part of the literature review. Figure 4 is 
showing this as an overview. 
 
 
Figure 4: Flowchart of the systematic literature review. 
 
 
The whole searching process is described in more detail in the following sections.  
 
 
22 
 
EBSCO and Science Direct 
Within EBSCO databases of interest were identified as Business Source Corporate Plus, 
because of its comprehensive coverage of management journals, Biomedical Reference 
Collection Corporate and Medline, as both databases are a comprehensive source for 
medical and pharmaceutical journals. Finally the Health Technology Assessments 
database was included, as it covers health economic related papers. 
 
In a first step the search terms used in EBSCO and Science Direct on all abstracts were 
different combinations of “healthcare” and “decision*” and “making*” and the search 
was restricted to peer-reviewed academic journals in order to utilise a high quality level 
of literature.  
 
Different additional search terms were discussed with a health economist and those were 
applied in additional search rounds. The full list of search terms and restrictions 
regarding the type of literature as well as the single results for each search attempt are 
summarized in Table 1. 
  
 
 
Table 1: Details of the literature review database search (DB = database, Sub DBs = Sub database). 
 
 
2
3
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Inclusion and exclusion criteria 
Table 2 shows the inclusion and exclusion criteria, which are explained below. 
  
Topic Inclusion criteria Exclusion criteria
Relevant stakeholder 
groups 
groups with direct influence on drug reimbursement 
or pricing decisions on different decision levels 
(payers, politicians, HTAs, pharmacists, physicians) 
and indirect influence, such as pharmaceutical 
companies or patient organisations. none
Study topic
research on decision making in health care systems, 
specifically concentrating on rational or non-rational 
criteria used by healthcare decision makers
research on construction of new economic models to 
support decision making or the efficacy of existing 
economic models
Timeframe all studies since 1980 studies before 1980
Research type
qualitative and quantitative research in scholarly peer 
reviewed journals, clearly described study 
methodology, literature reviews
qualitative and quantitative research in books, grey 
literature, unclear study methodology, opinion papers
Language scope English or German all other languages
Geographical scope all countries none  
Table 2: Inclusion and exclusion criteria used in the literature review. 
 
 
Relevant stakeholder groups 
One objective of the literature review is to find out the research status for key criteria 
used by drug funding decision-makers who are directly responsible for drug funding 
or pricing decisions, such as members of a hospital formulary. For this research, 
groups with indirect influence (e.g. the pharmaceutical industry or patient groups) 
were classified as a possible decision criterion. Their activities, such as lobbying 
activities by patient groups, influence decision-makers who can directly influence 
drug funding decisions. Hence, literature regarding groups with direct and indirect 
influence on the decision-making process was considered.  
 
 
Study topic 
Another aim of this literature review is to assess the research which deals with 
perceived objective and subjective decision criteria beyond the cost-only perspective. 
Therefore research done on economic models or the effectiveness of existing 
economic models is not the focus of this review or the thesis and consequently one of 
the exclusion criteria.  
Excluded from the final list were papers with research work that concentrated only 
on the assessment or optimization of economic methods like cost-benefit-analysis or 
cost-effectiveness analysis.  Even though the results of these analyses might have an 
impact on drug funding decisions all of these studies did not explain the interaction 
with other decision criteria nor the relationships between decision-makers. 
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Time Frame 
Originally the time frame for this literature review was limited to studies published 
later than the year 2000. The rationale behind this decision was the assumption that 
there was so much development in the last 14 years in the practical field that it does 
not make sense to include older studies. Finally the researcher decided to broaden the 
time frame in order to include also studies between the years 1980 and 2000, because 
of the scarcity of research done specifically with a focus on hospital formularies. 
Even with the broader scope, the number of research studies with this special focus 
was low. 
 
Research type 
In order to look at the most current research with a high quality standard it was 
decided to only look at research published in academic journals. For this reason grey 
literature was excluded. Books were excluded in order to have a very recent view on 
the discussions around the topic of criteria used in drug funding decisions. 
 
Language scope 
Due to the language limitations of the researcher the language scope was limited to 
research done in English or German. 
 
Geographical scope 
There was no limitation regarding the geographical scope of research, because the 
aim of the literature review was to get the broadest picture possible for healthcare 
decision-making and hospital formulary decision-making. However, the geographical 
scope might be “naturally” limited by the language scope. Countries would be 
excluded due to this limitation, when English or German is not the standard language 
for research.  
 
Referenced research papers 
To complete the picture of relevant research work all abstracts of referenced research 
papers of the resulting list of papers were also screened for further indication whether 
the respective paper investigates drug funding decision-making processes or criteria 
preferences of health decision-makers. If a reference matched these criteria it was 
fully read and inclusion and exclusion criteria were used to determine the relevance 
of the paper. After eliminating doubles the end result was 44 relevant papers 
(Appendix 1) which will be discussed in detail in the next section. 
26 
 
2.1.2  Number of studies, geographical spread and methodologies 
One result of the review is that not much research work is done in general on the 
importance of decision-making criteria used in drug funding decision-making 
considering the final list of 44 papers. Noticeable was also the lack of research for 
Germany. 
 
In the last 13 years, except for 2002, 2010 and 2011, research output has been 
relatively constant with two to five studies each year, demonstrating continued if 
reduced interest in healthcare decision-making. Between 2003 and 2009 the interest 
in healthcare decision-making seemed to be higher (Figure 5).   
 
 
Figure 5: A constant interest in healthcare decision-making during the last 13 years. 
 
 
 
Another finding of the review was a geographical research prioritization (Figure 6). 
The most discussed country in the relevant studies were the USA (17%) followed by 
UK (16%), the Netherlands (16%), Canada (16%) and Australia (10%). All other 
countries were discussed in seven or less studies (less than 10% each country).  
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Figure 6: Countries in focus of healthcare decision-making research. 
 
 
Apart from literature reviews (14 out of the 44 relevant papers), empirical studies 
were predominantly surveys (ten out of 44 papers) or done via interviews (eight out 
of 44 papers). Other approaches included mixed-methods approaches, observations 
or retrospective data analysis (Figure 7).  
 
Figure 7: Top three research methods: Literature review, survey or interview. 
 
 
This becomes more interesting, when looking at the distribution between quantitative 
and qualitative research methods (Figure 8). Both methods are well-balanced with a 
small tendency towards qualitative approaches demonstrating that there is not only 
one correct way to investigate the decision-making phenomenon. This also 
encourages the use of a mixture of quantitative and qualitative research methods for 
further empirical work.  
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Figure 8: Balanced use of quantitative and qualitative research methods. 
 
Many of the studies which used only quantitative research methods focused on the 
identification of decision patterns and the importance of single decision-criteria, such 
as health economic evaluations (Alsultan, 2011; Odedina, Sullivan, Nash & 
Clemmons, 2002). Additionally one of the main areas of investigation was the 
structure of hospital formularies (Dranove, Hughes & Shanley, 2013; Fijn, Brouwers, 
Knaap & De Jong-Van Den Berg, 1999). This is in contrast to the studies which used 
qualitative research methods and focused on explanations of more complex 
structures of healthcare decision-making, such as power relationships (Gibson, 
Martin & Singer, 2005) or priority setting not only limited to one single decision 
criteria (Martin, Pater & Singer, 2001; Vuorenkoski, Toiviainen & Hemminki, 2003).   
 
The study of Koopmanschap, Stolk and Koolman (2010) in particular is interesting 
as it was the only study identified which combines quantitative methods with 
qualitative methods. The authors discussed their quantitative findings with an expert 
panel. However, the study's relevance is limited because chosen criteria for the 
discrete choice analysis were potentially biased by the uniform thought process of 
health technology assessment experts rather than considering alternatives. Even 
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though they are experts in health economics, they all come from a similar direction 
of thought which questions whether they were open for a variety of criteria.  
 
Topics of interest 
There is no trend in the specific sub topics of drug funding decision-making, but five 
main areas of interest can be observed (see Figure 9): 
1. Importance and use of several criteria (with no specific focus) on drug 
funding decisions  
2. Impact of political and social factors on drug funding decisions 
3. Importance and use of economic evaluations or other economic issues 
4. Structure of the formulary or the drug funding decision process 
5. The use of tools to support decision-making 
 
Research on several decision criteria (with no specific criterion) was focussed on in 
14 studies which was the most discussed topic with 32% (Al, Feenstra & Brouwer, 
2003; Baltussen & Niessen, 2006; Dakin, Devlin & Odeyemi, 2006). The second and 
third most frequent topics were the importance and use of economic evaluations in 
the decision process with 30% (Eddama & Coast, 2008, 2009; PausJenssen, Singer & 
Detsky, 2003) and the importance of political and social factors for the decision 
process with 18% (Vuorenkoski, Toiviainen & Hemminki, 2003; Wirtz, Cribb & 
Barber, 2005). As a single decision criterion, health economic evaluations gained a 
lot of attention from researchers, which is probably derived from the ethical 
discussion if cost containment influences the quality of healthcare. Researchers were 
also interested in finding explanations for healthcare decision-making through 
identification of political or social factors, such as hierarchical dependencies 
(Dranove et al., 2003; Gibson et al., 2005).  
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Figure 9: Three topics are of greater interest compared to the other ones. 
 
 
The following sections will analyse and discuss detailed results of the systematic 
literature review initially referring to healthcare decision-making in general and 
finally concluding in decision-making in hospital formularies. 
 
 
2.1.3 Decision-making criteria with perceived objectivity 
 
Clinical trials data 
Probably the most important criterion for drug funding decision-makers is clinical 
evidence (data from clinical trials) (Jenkings & Barber, 2004; Vuorenkoski, 
Toivianinen & Hemminki, 2003, 2008; Hutchings, 2009; Walkom, Robertson, 
Newby & Pillay, 2006). The quality of presented clinical evidence is carefully 
evaluated by decision-makers and is a key criterion (Vuorenkoski et al., 2008). An 
explanation for the dominance of clinical evidence is probably the high level of 
perceived objectivity serving the scientific background of decision-makers. Clinical 
trials are highly regulated and follow strict rules which should prevent any external 
influence by involved parties, similar to a laboratory experiment.  
 
The assumption of an objectivity of a clinical trial is only part of the truth. Based on 
practical experience, this is shown in the demand of decision-making bodies of 
requesting "real world" data. Decision-making bodies, specifically on the national 
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level, realised that the efficacy of a pharmaceutical drug which is shown in a clinical 
trial is probably on a lower evidence level than the efficacy in real life and outside 
the controlled environment of a clinical trial (Garrison et al., 2007). 
 
Economic evaluations 
Much research is focused on the importance and use of economic evaluations for 
drug funding decisions. A reason for this focus could be either the origin of the 
researchers, since many are health economists or that economic evaluations have an 
increasingly important role in regards to drug funding decisions. However, one 
common result in all studies is that economic evaluations have only low or medium 
influence on decisions (Eddama & Coast, 2008, 2009; van Velden, Severens & 
Novak, 2005).  
 
The possible reasons vary. In some cases it appears that economic evaluations lack 
credibility in relation to their accuracy and objectivity. Therefore, they are seen with 
caution when it comes to drug funding decision-making (Hoffmann & von der 
Schulenburg, 2000; Walley, Barton, Cooke & Drummond, 1997). The ability of 
economic evaluations to provide reliable decision-making support is challenged 
because of the presumed missing accuracy, as economic evaluations always rely on 
assumptions (Walkom et al., 2006). Economic evaluations are often conducted by 
pharmaceutical companies or their consultants. Decision-makers have a certain level 
of mistrust in studies conducted by industry, who are applying for drug funding 
(Eddama & Coast, 2008).  
 
In addition to a perceived lack of scientific rigour and mistrust in studies conducted 
by industry-related service providers, economic evaluations appear to not adequately 
consider other important perspectives. Respondents of a study conducted in Thailand 
for example had general doubts in regards to the usefulness of economic evaluations. 
They believed that economic evaluations do not consider important aspects like 
ethical considerations, availability of alternative treatments or political pressure 
(Teerawattananon & Russell, 2008).  
 
Even though the results of one study conducted with key decision-makers in Finland 
came to the conclusion that decisions are made technically (based mostly on 
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scientifically and economic criteria) and non-politically from the perspective of 
decision-makers, the authors of the study suspected other influencing factors like 
outside stakeholders (pharmaceutical companies, patient groups) to have an impact 
on final decisions (Vuorenkoski et al., 2003). This influence could be in the form of 
marketing or lobbying activities as well as through pressure by patient groups. 
 
Budget impact as a decision criterion 
Budget impact means to “estimate the financial consequences of adoption and 
diffusion of a new health-care intervention within a specific health-care setting” 
(Mauskopf et al., 2007, p. 337). It is another criterion often discussed in recent 
literature and is perceived to be important for the decision-making process (Cohen, 
Stolk & Niezen, 2007; Dakin, Devlin & Odeyemi, 2006; Koopmanschap et al., 2010; 
Niezen, de Bont, Busschbach, Cohen & Stolk, 2009).  
 
Despite being a discussed topic in literature and a possible important criterion, 
decision-makers refuse to openly admit that budget impact is considered in drug 
funding decisions. Budget impact as a pure cost calculation is perceived to lack a 
scientific base in comparison with other economic considerations like cost-
effectiveness which consider efficacy of different treatment alternatives in a model 
(Niezen et al., 2009). Decision-makers often prefer the more scientific tool to justify 
decisions. Some decision-makers for example are influenced by the budget impact 
criterion but provide other criteria, such as cost-effectiveness or clinical evidence as 
the rationale for their decisions in order to have a solid base for justification towards 
the public and to avoid criticism (Niezen et al., 2009).  
 
To conclude, clinical evidence seems to be very important but often it is not 
sufficient to decide only on this information (Garrison et al., 2007). Economic 
evaluations appear to be controversial as a decision criterion (Eddama & Coast, 
2008). Budget impact is perceived to be less objective and decision-makers believe 
that it lacks scientific rigor (Niezen et al., 2009).  
 
2.1.4 Decision-making criteria with perceived subjectivity 
Drug funding decisions are decided not only by perceived objective, technical or 
economic evidence, but also decided by perceived subjective criteria, such as 
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feelings, political driven pressure, personal experience or the severity of disease 
(Armstrong, Mitton, Carleton & Shoveller, 2008; Barasa, Molyneux, English & 
Cleary, 2014; Cohen et al., 2007; Dakin et al., 2006; Eddama & Coast, 2008; 
Gallego, Fowler & van Gool, 2008; Jenkings & Barber, 2004; Koopmanschap et al., 
2010; Niezen et al., 2009; Teerawattananon & Russell, 2008; van Velden et al., 
2005; Vuorenkoski et al., 2003, 2008; Wirtz, Cribb & Barber, 2005; Walkom et al., 
2006).  The importance of perceived subjective criteria increases if other data is 
limited or if the perceived objective data is of low quality in terms of scientific rigor 
(Leung, Halpern & West, 2012). 
 
Baltussen and Niessen (2006) describe the priority setting in drug funding decision-
making as an ad-hoc decision derived out of the different multidisciplinary factors 
and the inability of decision-makers to cover all of these. Ad-hoc in this respect 
refers to a decision where all decision criteria are evaluated without any structure or 
ranking. Baltussen and Niessen (2006) see a risk of cognitive overload for the 
decision-maker who is required to handle and assess the information flood. On the 
other hand they describe a “rational priority setting” process in which all the different 
decision criteria have different but specific relative importance weights resulting in a 
rank order (Figure 10). 
 
 
Figure 10: Ad hoc priority setting versus rational priority setting (Baltussen & Niessen, 2006). 
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Personal or local experience as a decision criterion 
A study by Wirtz et al. (2005) on decision-making by the National Health Service 
(NHS) in the UK verifies the existence of perceived subjective and intangible 
criteria. This study identified two dimensions having significant impact on drug 
funding decisions. The first dimension relates to personal aspects, like subjectivity 
and is described with the personal experience of patients or doctors. The second 
dimension relates to political aspects described in the next section.  
 
Decision-makers stated that positive personal experience of the drug, either from 
patients themselves or from physicians, has the potential to change an assessment 
positively. Adding to that, policy makers also mentioned the potential influence of 
excitement about the novelty of a new health technology (e.g. drug) (Wirtz et al., 
2005). This is confirmed by another study by Armstrong et al. (2008) where non-
scientific criteria such as clinical experience derived from clinical practice showed a 
significant weight in drug funding decisions. The decision-makers even considered 
the clinical practice as a fully legitimate reason to overcome the uncertainty of 
limited scientific data. In addition, this also confirms the doubts about the infallibility 
of clinical trials data and challenges the perceived objectivity. Decision-makers want 
to hear about perceived subjective information, such as personal experiences with the 
pharmaceutical drug. Some research (Armstrong et al., 2008; Wirtz et al., 2005) 
allows the conclusion that this criterion has significant weight in decision-making. 
This is emphasized by the research method Armstrong et al. (2008) applied. They 
used several information sources, such as meeting documentation, interview data and 
information taken during meeting observations for their conclusions. With this 
approach, several perspectives were considered and allowed a broad perspective on 
the subject. Wirtz et al. (2005) also used a research method which allowed the 
researchers to consider many perspectives for their outcomes. They conducted 
twenty in-depth interviews with different decision-makers. 
 
Political aspects as decision criteria 
In one study objections were raised against long discussions with stakeholders to 
avoid jeopardizing long-term relationships (Wirtz et al., 2005). Decision-makers also 
have to navigate the active pressure from clinicians on drug funding decisions with 
the maintenance of these relationships. In this case, it is pressure from influential 
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clinicians who would like to see a drug being approved for the formulary or to 
prioritise specific requests (Armstrong et al., 2008). This has been confirmed by 
other studies from Australia, Norway, Canada and Uganda which revealed pressure 
from clinicians, patient groups or politicians as influential criteria (Gallego et al., 
2008; Kapiriri, Norheim & Martin, 2007). Protection of long-term relationships and 
avoiding discussions with influential members of the formulary committee assumes 
some kind of “hidden agenda” for the committee members. This needs to be 
considered for the outcomes of the thesis.  
 
The importance of pressure from patient groups is not specifically analysed in the 
relevant studies but still relevant from a practitioner's experience. One prominent 
case is the “trastuzumab case”1 where patient and political pressure finally led to 
funding of trastuzumab without prior approval from the appraisal agencies 
responsible for assessment of economic evaluations of drugs (e.g. NICE for the UK) 
(Simoens, 2007). 
 
Gibson et al. (2005) focused in their research on the impact of power differences in a 
hospital operational planning committee. The strong influence of senior members of 
the committee was apparent, with more junior members referring to the hurdle for 
them to vote openly against proposals from senior members whom they directly 
report to. The study also mentions a potentially disproportionate impact of committee 
members who are rhetorically strong and the general feeling that disagreement or 
discussion is not welcome.  
 
The studies focusing on political aspects differentiate between two criteria which 
influence decision-making (Armstrong et al., 2008; Gibson et al., 2005; Wirtz et al., 
2005): 
 Relationships with external stakeholders or key people, such as politicians, 
patient groups or the pharmaceutical industry.  
                                                 
1
 Trastuzumab is a monoclonal antibody for the treatment of early-stage breast 
cancer. The funding was heavily discussed in the UK in 1999-2002 due to the high 
cost of this treatment.  
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 Relationships with internal stakeholders, such as important and politically 
strong people in the decision-making group. 
 
 
Other criteria discussed in the relevant literature 
Depending on the respective country and the healthcare system, the severity of 
disease or burden of disease also appears to be a criterion used in decision-making, 
although this criterion is not mentioned very often. Hutchings (2009) found this to be 
relevant especially in France, while this aspect is less recognized in the UK due to 
the assessment methodology of the national health technology assessment authority 
(NICE). Even more distinct was the result in a study conducted by Koopmanschap et 
al. (2010) which clearly showed a high level of severity of disease changed the 
willingness to reimburse a drug significantly. The study used a discrete choice 
experiment (DCE), a quantitative research method, to elicit preferences of healthcare 
decision-makers on the national level but did not challenge the outcomes. The DCE 
is a very artificial decision situation inherent to the method, especially if conducted 
on its own without any further discussions on the results. In addition, severity of 
disease might be of less importance if a decision-maker has direct budget 
responsibility and the consequence of a positive decision is a budget impact, as 
usually is the case in a hospital (Koopmanschap et al., 2010; Niezen et al., 2009). 
 
Health related quality of life is a subjective measure of the health status of 
individuals and it is reported as a decision criterion of importance (Wu, Sause & 
Zacker, 2005). The study of Wu, Sause and Zacker (2005) showed that parts of the 
interviewed formulary committee members (33.9%) endorsed their willingness to 
pay a premium, in contrast to 37.5% who were not willing to pay any additional 
money. Even though some decision-makers are convinced of the importance of 
health related quality of life, the study also revealed that in total, efficacy, safety and 
costs are preferred and more important as already shown in other studies (Hutchings, 
2009; Jenkings & Barber, 2004; Vuorenkoski et al., 2003, 2008; Walkom et al., 
2006). 
 
Besides the already mentioned criteria the relevant literature shows some evidence of 
additional criteria. For example, ethical reasons (with reference to life-saving 
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treatments or equity of access) or the availability of alternative treatments seemed to 
be also utilized by decision-makers (Teerawattananon & Russell, 2008) but were 
mentioned only in one study of the relevant literature. 
 
It is also possible that decision-makers were unaware or not willing to comment on 
additional decision factors like influence through indirect lobbying methods as also 
assumed by the authors of one study (Vuorenkoski et al., 2003).  
 
Open use of perceived subjective criteria: a question of accountability and 
justification 
One reason why it is difficult to get information on other criteria than perceived 
objective criteria is the reluctance of decision-makers on all levels to openly 
acknowledge the use of perceived subjective criteria. Behind this is the issue for 
decision-makers that they are accountable for many difficult allocation decisions and 
accountability needs to be defendable against legal and public challenges (Wirtz et 
al., 2005). It is much easier to defend a decision if the decision-maker can explain 
how the process has led to the specific decision. In practice this means that decision-
makers try to defend their decisions with a robust decision process (Wirtz et al., 
2005) and with the use of rigorous and objective scientific data (Jenkings & Barber, 
2004; Walkom et al., 2006). As a result, written decisions as part of drug funding 
decision documentation are mostly justified with scientific or economic reasons 
independent of how many other subjective, intangible criteria have been adopted 
(Dean et al., 2013). This has also been a result of a literature review on the use of 
pharmacoeconomics in decision-making which included 31 studies (Walkom et al., 
2006). A study in Finland where the outcome suspects a very objective driven 
decision process assumed that decision-makers tend to be very technical and 
scientific in order to avoid blame because of unpopular decisions (Vuorenkoski et al., 
2003). 
 
This previous section discussed the findings in regards to the different criteria that 
decision-makers balance in making a drug funding decision. However there are a 
variety of decision-makers dependent on the national healthcare system and place of 
operation (national, regional or local).  
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Besides the use of perceived objective and subjective criteria in decision-making, the 
different levels (national, regional or local) also appear to have differences in 
applying decision criteria. In the following sections, the literature was analysed with 
a focus on the difference in importance and use of criteria by national and regional 
decision-makers. Because this thesis focused on group decision-making in hospital 
formularies, only the decision-making process on the national and the regional level 
is relevant. As described above, local decision-making refers to decision-making of 
individual people, such as a physician who decides on a treatment of a patient. 
Hence, local decision-making is not group decision-making. 
 
2.1.5 Differences between the decision levels 
Some of the studies only concentrated their research on one decision level like the 
regional level (Jenkings & Barber, 2004) and others focused on more than one level 
(Vuorenkoski et al., 2003). The result of these studies let assume that all decision 
levels have different objectives which can differ slightly or significantly, depending 
on the individual structure of the respective healthcare systems. Hence, the role of 
the decision-maker varies and healthcare decision-making is not only done with 
different criteria but also on different levels of a healthcare system with a respective 
focus depending on each level. Al, Feenstra and Brouwer (2003) expressed this 
variety and differences in healthcare decision-making with one sentence: “THE 
decision maker does not exist” (p. 35). As a consequence these studies also show that 
each decision level might have different importance weightings for the decision 
criteria and also might have adopted a different subset of criteria.  
2.1.5.1 National Level 
On a national level, national agencies should have a focus on the societal impact of 
their decisions and criteria will be viewed at a broader level. The decision-makers on 
the national level have a greater focus on politics and legal issues where this differs 
to objectives on a local or regional level (van Velden et al., 2005). From a 
practitioner's view it is surprising that there appears to be consensus in the literature 
of a very small influence of economic evaluations on the national level (Eddama & 
Coast, 2008; van Velden et al., 2005). In practice, economic evaluations are mostly 
required for drug funding applications and commonly used on the national level 
(Drummond et al., 1999).  
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In contrast to the low or moderate importance of economic evaluations, the identified 
literature (Dakin et al., 2006) sees an increase in importance of national budget 
impact as a criterion for drug funding decisions. More and more countries require 
inclusion of budget impact calculations in their reimbursement dossiers before 
approving market access and funding. It is becoming increasingly important because 
a drug can be cost-effective, but still funding might be rejected out of an 
unfavourable budget impact situation (Cohen et al., 2007).  
 
Even if evidence is rare, also on the national level there seems to be more decision 
criteria which are relevant for healthcare decision-making besides the pure economic 
focus. George, Harris and Mitchell (2001) reviewed reimbursement decisions from 
1991 to 1996 submitted to the Australian Pharmaceutical Benefits Advisory Board 
(PBAC), which is the national reimbursement agency. The main outcome of this 
analysis was the confirmation of consequent use of health economic measures. 
However, they also found hints which endorse the use of additional decision criteria. 
They emphasized the fact that the PBAC has guidelines which clearly define 
additional criteria, such as the "community need or benefit" or treatment of 
"significant medical conditions" (PBAC Guidelines for preparing submissions to the 
Pharmaceutical Benefits Advisory Committee, Version 4.4, p.5). 
 
Justification of a decision is another important point that decision-makers on a 
national level bear in mind during the process of decision-making. The importance of 
public pressure as an influential criterion decreased with a more regional level of 
decision-making. On the regional level the importance of public opinion is less 
influential as compared to the national level. This could be explained with the 
dependency of national policy makers to the public regarding their re-election 
(Teerawattananon & Russell, 2008). This suggests that national decision-makers 
have the perceived expectations from the public in mind and consider these in their 
decision-making scheme. Unfortunately an indication on the level of impact of 
public pressure on drug funding decision cannot be clearly seen in the relevant 
literature. 
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2.1.5.2 Regional Level 
The regional level has different challenges. At this level the decision-makers think 
very clearly about the local situation (of a region or a hospital) (Jenkings & Barber, 
2004). This means that every decision focuses on the direct impact on the regional 
level. This can lead to different decisions as the regional level is not significantly 
impacted by public pressure because decision-makers are not dependent on public re-
election (Teerawattananon & Russell, 2008). In contrast, local pressure exists from 
influential individuals. From the observations on the regional level, it is valid to 
assume that pressure from physicians play an important role at the regional level. 
Three studies (Armstrong et al., 2008; Gallego et al., 2008, Martin et al., 2001) 
confirmed these assumptions. Pressure is not necessarily always direct pressure, but 
it can also mean that decision-makers try to avoid arguments with colleagues because 
they are afraid to harm their relationships with them (Wirtz et al., 2005). 
 
The impact of economic evaluations and budget impact could be expected to be high 
due to the nature of the decision-making process being under budget constraints. 
Despite this assumption there is only little evidence that speaks for a moderate 
influence of economic evaluations on the regional level (van Velden et al., 2005). In 
a study by PausJenssen, Singer and Detsky (2003) conducted in a formulary 
committee in Ontario, Canada, formal economic evaluations had only a minor 
impact, but economic considerations in general became of greater importance if 
higher costs were expected. It is easy to assume that decision-makers in a hospital 
have local issues (of the hospital) in mind and might consider a broader impact only 
in a second step after evaluating every argument that is locally relevant. A UK based 
study with regional decision-makers even speaks of a “disconnect” between 
economic evaluations and the decisions which are essential for regional decision-
makers (Eddama & Coast, 2009, p.269) and explains a low impact on decision-
making. 
 
In regards to budget impact, the expectation of a moderate to high influence on the 
decision-making is being confirmed by research. Since budget impact calculations 
are aimed for a specific healthcare context (Mauskopf et al., 2007) it is applicable for 
the hospital situation. Even though in many cases decision-makers (on a regional 
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level) refuse to openly admit the use of budget impact, the importance and influence 
appears to be evident (Gallego et al., 2008; Niezen et al., 2009).  
 
2.1.6 Decision-making supportive methods 
The last sections have shown that healthcare decisions are complex multi-criteria 
decisions usually taken by a group (on the national and regional level). Presumably 
due to the complexity, decision-making lacks a certain level of transparency, which 
is criticized by researchers (Armstrong et al., 2008; Dean et al., 2013; Fijn et al., 
1999; Plet, Hallas, Nielsen & Kjeldsen, 2013). 
 
Hence, one of the main goals of theory development in the context of healthcare 
decision-making on drug funding is to increase transparency of the decision-making 
process to improve the understanding of formulary decisions. Very often this is tied 
to the goal of reducing the influence of perceived subjective decision criteria 
(Walkom et al, 2006) which can be seen in some methods developed with the aim to 
assign relative weighting to decision criteria.  
 
Systems of Objectified Judgment Analysis (SOJA) is a methodological framework 
which assumes a standard set of decision criteria including relative weighting done 
by an expert panel which ensures the adaptation to the local situation (Janknegt & 
Steenhoek, 1997; Walkom et al, 2006). Another very recent framework to support 
hospital formulary decision-making on drug funding is part of a project called 
Formulary Leveraged Improved Prescribing (FLIP) conducted in the USA and 
described in the paper of Schiff et al. (2012). This framework is structured in six 
domains where each domain consists of detailed questions which should support 
committee members in evaluating pharmaceutical drugs. None of the domains or the 
connected questions possesses a relative importance and the framework does not 
consider adding importance weights. 
 
The important decision-making criteria from other studies can also be recognized in 
the domains of Schiff et al. (2012), such as efficacy, safety or cost issues. But they 
are only used as a check-list for decision-makers and suggest transparency. 
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Another decision-making supportive method is Multi Criteria Decision Analysis 
(MCDA) which is increasingly utilized in healthcare decisions (Baltussen & Niessen, 
2006; Baltussen, Youngkong, Paolucci & Niessen, 2010). 
 
Devlin and Sussex (2011) defined MCDA as “a set of methods and approaches to aid 
decision-making, where decisions are based on more than one criterion, which make 
explicit the impact on the decision of all the criteria applied and the relative 
importance attached to them”(p. 4). There are several different MCDA approaches 
but most of them make use of a value measurement model or weighted sum approach 
(Thokala & Duenas, 2012).  This comprises of creating a value V(1)…V(n) for n 
decision alternatives where the alternative 1 is preferred if V(1) > V(i) with (i) 
representing any other possible alternative. V(i) is considering all criteria for the 
respective alternative. The equation for this function is: 

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iw  represents the relative importance and )(avi represents the score of the alternative 
a for criterion (i) (Thokala & Duenas, 2012). This equation has a pre-requisite that 
for every criterion a relative importance has been set as well as a score for each 
criterion on the respective alternative. If pre-requisites are fulfilled the result is an 
overall score for each decision alternative which makes it then easy for the decision-
maker to choose. The pre-requisites already show the weakness of MCDA. It is not 
only necessary to determine scores for each criterion on the respective alternative but 
it is also compulsory to define a relative importance compared to other criteria, 
which requires a good understanding of the relationships between the different 
criteria. Thokala and Duenas (2012) summarize all main issues regarding MCDA: 
The decision-makers need to find consensus on the selection of criteria, the relative 
importance and the score for each criterion. 
 
A general issue with the decision-making support methods is the motivation of such 
tools to reduce decision-making only to perceived objectivity. For example, Janknegt 
and Steenhoek (1997) stipulate in their SOJA methodology to exclude “these factors 
[such as emotions] as much as possible in the decision-making process” (p.550). 
Moreover, they believe that SOJA’s main advantage is that “all emotional, financial 
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and other non-rational selection criteria are excluded and that drug decision making 
is based solely on rational criteria” (p. 559). This might be an explanation why the 
use of such methods is limited in hospital formulary decision-making, since literature 
(Dranove et al., 2003; Gallego, Taylor & Brien, 2009; Gibson et al., 2005; Martin et 
al., 2001; Wirtz et al., 2005) shows evidence that hospital formulary decision-making 
is not only based on perceived objective criteria.  
 
An implementation issue with most of these methods as well as with SOJA or FLIP 
is the consensus on relative weighting of decision criteria (Janknegt, 2001). 
Therefore SOJA for example is often supported by software packages where all 
formulary committee members provide their individual weight for each decision 
criteria with the purpose of receiving an individual preference list. This individual 
preference list can then be compared with the other member’s preference lists and 
should finally lead to a consensus. Hence, although SOJA focuses only on perceived 
objective decision criteria, it is basically a subjective method (Janknegt et al., 2007). 
This decreases transparency again, since the decision-making is done in a second 
step by discussion between the formulary committee members and theoretically 
involves new (hidden) criteria or at least refined criteria assessment which leads to 
the consensus.  
 
Additional issues around those decision-making support methods are complexity, 
required time for development, maintenance and analysis and the possible 
manipulation as stated in a Dutch study by Fijn et al. (1999). The interest of hospital 
formulary committees is reflected in the awareness and knowledge about those 
methods. Most of the hospital formulary committees (97%) which participated in the 
study of Fijn et al. (1999) were familiar with supportive methods such as SOJA. On 
the other hand, the actual usage of only 16% of all study participants also reflects the 
low acceptance of those methods. 
 
In spite of these issues, all methods or frameworks (e.g. SOJA, MCDA) which try to 
provide a standard set of decision criteria are similar in the key criteria applied. This 
suggests a possibility of designing a general pharmaceutical drug funding decision-
making framework. And it is a motivation and justification to define a framework 
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which describes not only the perceived objective part of hospital formulary decision-
making, but also considers other important criteria. 
 
There is no evidence that these frameworks are used by German hospital formularies 
and the identified literature does not provide any hint on the reasons why these kind 
of decision-making supportive methods are not used. 
 
2.1.7 Conclusions for healthcare decision-making 
 
Use of perceived objective and subjective criteria 
Current research shows the existence of perceived subjective criteria being 
considered in addition to perceived objective criteria in drug funding decision-
making. 
Identified major criteria have been: 
 Efficacy and safety of a pharmaceutical drug, proven by data from clinical 
trials. 
 Health economic evaluations 
 Personal or local experience, which refers to feedback on the drug value from 
trusted individuals such as physicians, pharmacists or patients. 
 Budget impact calculations, which show a possible monetary impact on a 
given, constraint budget based on the population likely to take the drug and 
estimated drug costs. 
 Political aspects which consider pressure from external forces like influential 
clinicians or patient groups on the decision-making process or on specific 
decision-makers. This also includes the objective of decision-makers to 
secure important relationships. 
 Severity of disease which tries to explain the impact of the disease on the 
patient. 
 
The most discussed criteria are health economic evaluations. Although many 
healthcare systems require this as formal criteria for reimbursement applications, 
research implies only a low to moderate impact of economic evaluations, specifically 
on the regional level (e.g. hospital). 
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Each decision level is different 
The general use of perceived subjective criteria seems to be independent of the 
decision level, because the widespread use of such criteria on a national and regional 
level has been shown in the relevant literature. Although both levels use such criteria, 
the relative importance of specific criteria varies and is often highly dependent on the 
respective decision level and healthcare system.  
 
Political aspects seem to be relevant on both levels although from different 
perspectives. On the national level this could be pressure from patient groups 
whereas influential clinicians can be the main factor on the regional level, as this 
level is confronted less often with patient groups.  
 
From a research perspective, budget impact appears to be moderately important on 
the national level. Practitioner's experience and new healthcare system changes (shift 
of budget responsibility towards the regional level) lead to the conclusion that the 
importance of budget impact as a decision criterion on the national level will even 
further decrease. On the contrary the importance of budget impact should increase on 
the regional level. 
 
In contrast to the national level there is a high influence of reported local and 
personal experience on the regional level. Physician's life experiences with drug 
efficacy or hospital staff experience with handling drugs appear to have impact on 
drug funding decisions.  
 
Economic evaluations are perceived to be of low impact on the national level and 
with only moderate impact on the regional level. Practitioners have a different 
opinion on this; especially on the national level they see economic evaluation as a 
major criterion for drug funding decisions (Heitzman, Shapurji, Poulin & Lesser, 
2009; Janus, Natanek, Evers & Dewhurst, 2007). 
 
Each decision level has its own subset of important criteria 
Figure 1 illustrated the complexity of funding decisions for drugs. If the results of the 
literature review are added to this basic model of drug funding decision-making this 
leads to an extended version of the displayed funding for drugs decision process. In 
46 
this framework, shown in Figure 11, it is considered that every decision level has its 
own subset of decision criteria and that also the structure of the country healthcare 
system has impact on decision-making. The relative importance of each criterion as 
well as the general importance needs to be considered separately because it can differ 
significantly for each level. There might be also the possibility that some criteria 
which are important for one level are not taking into consideration on a different 
level. 
 
Nonetheless, not only every decision level has its own subset of criteria but also on 
each single level, individual decision-makers have their own subset of decision-
criteria which they apply to the decision-making process. 
 
Country healthcare system
Healthcare decisions
(e.g. drug funding)
Decision makers
National
Regional
Mostly group decisions
e.g. Governmental reimbursement agency
Mostly group decisions
e.g. hospital formulary committee
1. Clinical evidence
2. Economic evaluation
3. Experts’ advice
4. Data on local activity
5. Personal experience
6. Public pressure
7. Political interests
8. Industry
Influenced by
1. Clinical evidence
2. Political interests
3. Personal experience
4. Economic evaluation
5. Experts’ advice
6. Public pressure
Influenced by
 
 
Figure 11: Extended healthcare decision-making framework for drug funding.  
(adapted from Atienza et al., 2008). 
 
 
The past sections of this literature review showed the complexity of healthcare 
decision-making. The next sections will focus on the main topic of this research: 
decision-making in hospital formulary committees. The extended healthcare 
decision-making framework for drug funding (Figure 11) will be adapted to the 
results of the specific situation of hospital formularies. 
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2.1.8 Hospital formulary committees – the regional level  
2.1.8.1 Complexity of formulary decisions 
Formulary committees are challenged with complex decision situations characterized 
by uncertainties in available information and the assumptions which are basis for 
some of the evidence as well as the varying amounts of available evidence. Clinical 
uncertainties around the efficacy of pharmaceutical drugs and connected financial 
implications for the hospital are two of the main considerations for committees 
(Williams & Bryan, 2007). All hospital formulary committees need to balance 
different criteria to be able to make reasonable decisions on whether or not to accept 
a pharmaceutical drug on to their hospital formulary list. Due to the nature of such 
funding decisions, formulary committees have to assess the trade-off between the 
benefits, risks and costs.  
 
Formulary committee members face even more complexity when considering 
exceptionally expensive pharmaceutical drugs for orphan diseases. Usually the trade-
off here involves a balance between a major benefit for a small group of patients and 
a smaller benefit for a large group of patients as hospital budgets often are restricted 
(Gallego et al., 2009). In the same study physicians also reported the dilemma of 
focusing on the patient’s needs on the one hand but considering a restricted hospital 
budget on the other hand. This concern is supported by the general importance of 
budget impact for healthcare decision-making reported by other studies (Cohen et al., 
2007; Dakin et al., 2006; Koopmanschap et al., 2010; Niezen et al., 2009). 
 
2.1.8.2 Criteria used in hospital formulary decisions 
The above sections about healthcare decision-making represent the variety of criteria 
used by decision-makers. They use perceived objective criteria, such as data from 
clinical trials or health economic evaluations, but they also make use of perceived 
subjective criteria, such as recommendations from physicians or experience in other 
hospitals. This is not only true on the national level, but also on the regional level, 
which refers to hospital decision-making (Armstrong et al., 2008; Gallego et al., 
2008; Gibson et al., 2005; Jenkings & Barber, 2004). And these subsets of decision 
criteria are highly individual, which is one of the outcomes of a study by PausJenssen 
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et al. (2003) where members of a formulary committee in Canada acknowledged that 
decision-making is also dependent on the individual "set of values"(p.290) of each 
formulary committee member. This individuality challenges many of the conducted 
studies with a pure positivistic background since every prediction of a decision 
outcome is fallible. The use of individual subsets of decision criteria makes decision-
making in hospital formularies a complex phenomenon with a high level of 
unpredictability. For people, who like to apply a math formula to those kinds of 
decisions, this might be a disadvantage. But it can be an advantage considering that 
different views and opinions have a chance to influence decision-making.  
 
Table 3 shows a summary of all decision criteria identified by studies of the above 
literature review with a focus on hospital formulary committee decision-making. 
This demonstrates that most of the studies only identified the main criteria: efficacy, 
safety and costs. Depending on the study, additional criteria were identified but not 
consistently for all studies. One explanation for this is the focus of some research 
studies on specific topics, such as health economic evaluations. Another explanation 
might be the applied research methodology. If a study used a survey as the stand-
alone research method, it was more difficult to get in-depth information on any 
underlying structures, such as the impact of influential formulary members. For 
example, in the study of Fijn et al. (1999), pharmacists were named by 42% of the 
participants of a survey as the most influential members of the hospital formulary 
committee. However, the study did not provide any in-depth information on the 
reasons for this strong influence. 
 
   
Author Efficacy Safety
Economic 
data and 
costs
Type of 
pharmaceutical 
drug
Administration/ 
Practical criteria
Emotional 
criteria and 
clinical 
experience
Patient's 
quality of 
life
Relationships 
to the pharma 
industry
Decision-
making 
guidelines
Knowledge 
sharing
Advocates 
and power 
relationships Other
Alsultan (2011) x x x x
Fijn et al. (1999) x x x x x
Gallego et al. (2009) x x x x x x x
Janknegt (2001) x x x x x
Jenkings and Barber (2004) x x x x x x x - Patient demand
Martin et al. (2003) x x x x x x x
Mittmann and Knowles (2009) x x x x x x
- value added services
- bundling of services
Motheral et al. (2000) x x x x x - Patient demand
Odedina et al. (2002) x x x x x x
Späth et al. (2003) x x x x x
Williams and Bryan (2007) x x x x
Haslé-Pham et al. (2005) x x x x
Plet et al. (2012) x x x x x - treatment guidelines
Dranove et al. (2003) x x x
Gibson et al. (2005) x x - tight timelines  
Table 3: Identified decision-making criteria in hospital formulary committees. 
 
 
 
4
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The following sections will reflect in more detail on the main decision criteria identified 
by research on hospital formulary decision-making and thus evaluate the importance of 
those criteria for the decision-making process on the regional level. As already 
mentioned in the healthcare decision-making part of this literature review, there is no 
doubt about the importance of clinical trials data. Hence, this was not further explored.   
 
Economic data and costs 
Health economic evaluations, and specifically cost-effectiveness analyses (CEA), are 
used seldom in decision-making at the hospital level (Gallego et al., 2009; Williams & 
Bryan, 2007). Although a literature review by Walkom et al. (2006) showed 
considerable variance in the regular use of economic evaluations in hospital formulary 
decision-making, varying from 23% (Kulsomboon et al, 2001) to 86% (Odedina et al., 
2002) the general impact of such data is limited.  
 
One of the issues around the data provided to hospital formulary committees is the lack 
of local adaptation. Very often the data used is in a general way instead of adapting to 
the local hospital situation which makes it very difficult for the decision-makers of a 
formulary committee (Späth et al., 2003; Walkom et al., 2006; Williams & Bryan, 
2007). This in particular is valid for health economic studies where cost assumptions are 
mostly general and not adapted to the hospital situation (Haslé-Pham et al., 2005).  
 
One result from a study by Odedina et al. (2002) is notable as it showed a (slight) 
positive correlation between the use of health economic data in decision-making and the 
perceived ease of making a decision by the formulary committee members. The 
explanation by the authors of the study is the perceived objective nature of quantitative 
data from health economic analyses which seem to simplify the decision-making due to 
a potential easier justification. Odedina et al. (2002) only asked pharmacists in their 
study. This could be the reason for this outcome since pharmacists could use economic 
arguments against a potential medical argumentation of a physician. Additionally, the 
objective nature of health economic evaluations can also be challenged. In different 
studies, (Späth et al., 2003; Walkom et al., 2006) formulary committee members raised 
concerns about the amount and possible bias of assumptions accompanying health 
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economic evaluations. Odedina et al. (2002) might be wrong in the assumption of the 
objective nature from health economic evaluations due to the fact that those evaluations 
are often designed in cooperation with industry and thus can be biased (Bell et al., 
2006). Likewise, if a hospital formulary member does not have the required expertise to 
fully assess such a model, which is another main obstacle identified by literature (Haslé-
Pham et al., 2005; Späth et al., 2003), the meaning to the hospital context of health 
economic models is difficult to understand.  
 
An explanation for the positive correlation between the use of health economic 
evaluations and the ease of decision-making in the Odedina et al. (2002) study could 
therefore be that external groups (e.g. politicians, patients) have the perception of 
objectivity of health economic evaluations and that decision-makers make use of that. If 
this is the case, a health economic evaluation would serve as justification for a decision 
and makes it easier for hospital formulary committee members to find an official reason 
for their decisions. This is supported by the fact that decisions by hospital formulary 
committees are seldom published or properly documented. 
The decision-making documentation is often not available outside of the committee and 
often only the decision is provided in the documentation, but not the reasons nor the 
process of decision-making (Martin et al., 2003). In most cases, only the perceived 
objective evidence, such as clinical study outcomes or costs but not the perceived 
subjective data, such as assumptions or recommendations of colleagues are mentioned 
(Dean et al., 2013). This is critical as it does not reflect the full picture of the decision-
making process and an external person gets a completely different and incomplete idea 
of the rationale behind a decision. As shown before, decision-makers use perceived 
subjective criteria, such as feelings, political driven pressure, personal experience or the 
severity of disease as basis for their decision-making (Armstrong et al., 2008; Eddama & 
Coast, 2008; Gallego et al., 2008; Vuorenkoski et al., 2003, 2008; Wirtz et al., 2005). 
Those decision criteria are not visible if they are not mentioned in the decision 
documentation and thus the true rationale behind a decision is hidden. 
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Type of pharmaceutical drug 
The type of a pharmaceutical drug is one criterion which influences the decision-making 
process in hospitals. Formulary committee members consider different aspects in the 
decision-making process if the drug is used for treatment of a severe disease and no 
comparable alternatives are available. Very often, those drugs are very expensive due to 
a limited number of potential patients. A study conducted by Gallego et al. (2009) in 
public hospitals in Australia focused on such pharmaceutical drugs. The participants in 
this study generally felt that besides clinical data, costs were sometimes the most 
influential decision criterion. Still, in cases where formulary committee members had to 
decide on treatments for severe diseases with no alternatives, lack of clinical data or 
issues related to treatment costs decreased in importance.  
 
To further support the possible importance of the drug type for the relative criteria 
weighting another study considered different therapeutic classes. Motheral et al. (2000) 
asked hospital formulary committee members to rate the importance of 
pharmacoeconomic information by therapeutic drug class.  
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Figure 12: Relative importance of pharmacoeconomic data for different therapeutic drug classes  
(Motheral et al., 2000). 
 
 
The result shows a different relative importance between the different classes (Figure 
12). Here the question arises if the type of pharmaceutical drug determines the choice or 
relative importance of decision criteria. 
 
Administration/ Practical criteria 
Administration of a pharmaceutical drug and practical criteria, such as ease of 
preparation or application, is only mentioned in a few research papers (Martin et al., 
2003; Odedina et al., 2002; Plet et al., 2013). The relative importance of this criterion 
was medium ranked compared to other criteria or not considered. In the latter cases, the 
study participants revealed administrational or practical considerations during decision-
making but did not provide details on the importance. This leads to the assumption that 
administrational or practical criteria have a minor impact in hospital formulary decision-
making. Nonetheless, the reason for this underrepresentation in the identified studies 
might also derive from the selection of study participants as well as the number of the 
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concerned group of users in hospital formulary committees.  In studies where those 
decision criteria were mentioned, usually one representative of the concerned user 
group, such as a nurse, was part of the respondent group (Martin et al., 2003; Plet et al., 
2013).  
 
Emotional criteria and clinical experience 
Current research confirms the use of perceived subjective criteria such as ethics or 
clinical experience in decision-making of hospital formulary committees (Wirtz et al., 
2005). Janknegt (2001) names some of the decision criteria more precisely and talks 
about "emotional factors"(p.50), "unconscious factors"(p.50) or "other factors"(p.50) 
instead of subjective criteria. 
Especially the incompleteness of available data, lack of local adaptation and the 
uncertainties around presented evidence lead to decisions which are achieved by 
discussion and consensus instead of simply applying a math formula (Wirtz et al., 2005). 
This finding suggests a general critique towards supportive decision-making methods, 
such as SOJA, FLIP or MCDA. All of these methods, which were described in detail 
above, try to quantify the decision-making process with application of a proposed math 
formula. In contrast to this, many studies (for example: Armstrong et al., 2008; Eddama 
& Coast, 2008; Gallego et al., 2008; Vuorenkoski et al., 2003, 2008; Wirtz et al., 2005) 
confirm that the decision-making process involves also perceived subjective criteria and 
a high individuality in regards to the relative importance of such criteria. This questions 
the sense of the supportive decision-making methods which is presumably reflected in 
the limited acceptance and practical use.  
In addition, this finding confirms the assumption that lack of perceived objective criteria 
and uncertainty about the presented information leads to the usage of other criteria. It is 
also important that pharmaceutical drug funding decisions have impact on patients, 
physicians and clinical staff which adds an emotional component to the complex 
decision situation enticing committee members to consider perceived subjective criteria 
(Janknegt, 2001).  
 
Authors like Janknegt (2001) argue that decision-making should be made on a rational 
level and they are critical on the use of perceived subjective criteria in decision-making. 
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Perceived objective criteria are appreciated more due to the educational background of 
hospital formulary committee members, most of them coming from a scientific 
background. In fact, Walkom et al. (2006) remark that due to the sensitive nature of drug 
funding, studies with such a research focus tend to present a picture of rational decision-
making (using only perceived objective criteria) since the respondents who are involved 
in the decision-making might want to present the process in good light. 
 
But even these authors recognize that decisions usually involve "emotional 
factors"(Janknegt, 2001, p.50) not necessarily assuming that committee members are 
fully aware of the impact of such factors on their decision-making. This actually shows 
the issue around the question how decision-making should be conducted. On the one 
hand, if Janknegt (2001) speaks about a "rational level"(p.50), he stipulates a 
"transparent process"(p.50) without perceived subjective criteria and with a clear criteria 
definition. On the other hand he agrees that perceived subjective criteria are applied in 
the decision-making process. So why should it be wrong to use them and what makes 
the perceived objective criteria more valuable for a good decision? An example for this 
can be found in an Australian study by Gallego et al. (2009). Members of Drug 
Therapeutic Committees who decide on drug funding of high cost medicines in public 
hospitals refer to case reports for pharmaceuticals with little evidence and thus showing 
only marginal benefits. This means that the perceived objective criteria only show weak 
evidence of efficacy. In spite of this weak perceived objective evidence, the committee 
members describe an impact on their decision-making behaviour in terms of being more 
tolerant due to the "serious potential outcome of doing nothing" (Gallego et al., 2009, 
p.30). This shows that in situations of lack of perceived objective information, hospital 
formulary members use alternative decision criteria which also can be of perceived 
subjectivity. Additionally, none of the identified studies, either in favour of or against 
using perceived subjective criteria, studied the quality of decision-making. Hence, 
decision-making comprising the use of perceived subjective criteria is not inferior to 
decision-making limited to the use of perceived objective criteria. Conversely it can 
theoretically be superior, but this is also not shown by the identified studies. 
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Patient's quality of life 
The patient’s quality of life is another criterion which is mentioned in some studies 
(Haslé-Pham et al., 2005; Späth et al., 2003; Walkom et al., 2006). Späth et al. (2003) 
hypothesized that the importance of patient’s quality of life is derived from a potential 
positive effect on the hospital’s external “image”. This means, that they assumed that an 
increase of patient’s quality of life leads to a positive external opinion about the hospital 
and in consequence to a higher attractiveness for new patients.  
 
However, they did not further challenge or question the importance of this criterion. In 
fact, the importance of patient’s quality of life is not challenged by any of the identified 
studies. Haslé-Pham et al. (2005) concentrated in their study on two specific criteria: 
medico-economic studies and patient reported outcome studies, covering patient´s 
quality of life information. Hospital formulary committee members were very interested 
in both criteria but the influence on decision-making was only moderate. The authors of 
this study explained the high interest but low impact scenario with the lack of 
methodological knowledge by the hospital formulary committee members which is 
needed to make the right interpretations.  Except for the potential positive impact on the 
hospital’s reputation, none of the studies explained a rationale why patient´s quality of 
life information could be of importance for decision-making. Thus, the importance of 
this criterion is not clear. 
 
Relationships to the pharmaceutical industry 
The influence of the pharmaceutical industry on the decision-making process cannot be 
a direct one, since representatives of the industry are not members of the hospital 
formulary committees. Still, there is an indirect influence due to relationships between 
the industry and the hospital or single members of the formulary committee, such as 
sponsorships or clinical studies. The impact on decision-making of such relationships 
and the relative importance of this criterion is vaguely described in the literature. Only 
three of the studies (Dranove et al., 2003; Jenkings & Barber, 2004; Späth et al., 2003) 
picked this topic as a theme and two out of three studies used qualitative research 
methods with the possibility to get more in-depth information on a topic with high 
sensitivity. The study by Dranove et al. (2003) which used a survey as the research 
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method, counted the number of sales force visits and identified a positive correlation 
between this and the possibility of making a positive adoption decision for a 
pharmaceutical drug. The research method did not provide any chance to analyse this 
phenomenon more thoroughly and to find an explanation for the impact of sales force 
visits on decision-making.   
 
Späth et al. (2003) recognized that relations between the pharmaceutical industry and the 
decision-makers influence the decision of those committees. An explanation provided by 
the authors of the study is the applied study method. Späth et al. (2003) used qualitative 
interviews and content topic analysis which appears to be a better research method for 
this sensitive topic of drug funding decision-making compared to pure quantitative 
approaches. Unfortunately, they neither explained the level of influence on decision-
making nor the reason why decision-makers are influenced by those relationships.  
 
More insights on the possible influence of relationships between the industry and 
hospital formulary committees provided a third study by Jenkings and Barber (2004), 
which showed that hospital formulary committees seem to adapt their discussion 
behaviour dependent on the relationship between the industry and the hospital. This does 
not mean that such a relationship impacts a decision always positively. Pressure from the 
industry´s sales force or potential bribing was seen critically and usually led to a more 
rigid evaluation of the pharmaceutical drug.  
 
Decision-making guidelines 
The hospital formulary committee decision-making process to list pharmaceutical drugs 
is sometimes regulated by hospital guidelines. Decision-making guidelines exist in order 
to inform members of a hospital formulary. They are supposed to make the decision-
making process transparent, which can be challenged due to the fact that most of the 
guidelines are not very precise in their regulations and leave a lot of space for 
interpretation (Fijn et al., 1999; Plet et al., 2013). Those guidelines can include a 
description of the decision-making process, roles, responsibilities and decision-making 
criteria as well as the relative importance of such criteria. The existence of decision-
making guidelines varies from country to country and hospital to hospital. Most of the 
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time there is no guideline and in cases where a guideline is available, the criteria which 
should be used in the decision-making process are often not explicitly mentioned or 
there is no information on relative importance (Martin et al., 2003; Mittmann & 
Knowles, 2008; Plet et al., 2013).  
 
Knowledge sharing 
The majority of drug funding requests to a hospital formulary committee are 
accompanied by a documentation package, which is supposed to provide information for 
each case to the members of the committee. This documentation package is compiled 
and then distributed to all members of the formulary committee to inform decision-
making (Haslé-Pham et al., 2005; Jenkings & Barber, 2004). It includes clinical trial 
results, additional medical publications, relevant guidelines and the application form of 
the pharmaceutical company although the concrete content varies. The information 
sources for evidence in the documentation package varied depending on the country. 
Frequently official health technology assessment agency (such as NICE in the UK or G-
BA in Germany) reports, published literature and published literature sponsored by 
industry were brought up as primary information sources (Williams & Bryan, 2007). 
Odedina et al. (2002) also showed that hospital data was considered as an important 
source for pharmacoeconomic analysis. 
 
Two studies confirm the leading role of a pharmacist to compile this documentation 
package (Haslé-Pham et al., 2005; Jenkings & Barber, 2004), whereas the other studies 
do not mention the responsible person for the documentation. The studies usually did not 
further investigate the importance of the provided documentation package and the 
impact on the decision-making process. This is relevant due to the possible dominance 
of pharmacists regarding the influence on the content of the documentation package 
shown in the two studies mentioned. If the documentation package had a strong 
influence on decision-making, the pharmacists automatically would have a strong 
influence on decision-making, too. Decision-makers seem to have concerns with the 
level of available information in advance of a committee meeting (Gibson et al., 2005). 
They criticized the short timeframe between availability of information and the decision-
making as well as the completeness of information. Again, both factors are mainly 
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influenced by the person who is in charge of compiling the information. If some 
decision-makers have less information on a case, this leads to uncertainty and in 
consequence decreased involvement of the affected decision-makers in the discussions 
(Gibson et al., 2005). Hence, knowledge sharing has strong impact on the outcomes of 
the decision-making process, although this phenomenon is only rarely investigated.  
 
 
Advocates and power relationships 
Several studies (Alsultan, 2011; Fijn et al., 1999; Gallego et al., 2009; Gibson et al., 
2005; Janknegt; 2001; Jenkings & Barber, 2004; Motheral et al., 2000; Wirtz et al., 
2005) revealed the existence of an advocate as an important decision criterion. In this 
context an advocate is meant to be the person who supports the drug addition to the 
formulary. This can be a physician who is then taking over the role as a patient advocate 
or some committees even invite external representatives to present their case. Partly this 
is endorsed by a study by Fijn et al. (1999) which highlighted the strong influence of 
hospital pharmacists on decision-making, confirmed by 42% of the committees who 
participated. Alsultan (2011) also confirmed the impact of single members of a hospital 
formulary committee such as influential physicians or pharmacists on the decision-
making process. Considering these studies it seems that influential hospital formulary 
committee members (Gallego et al., 2009) can have significant impact on decision-
making.  
 
One study does not fully support the influence of such criteria (Motheral et al., 2000). 
Here the individual demand for a pharmaceutical drug by a physician or patient only 
came up with a medium importance score. However, Motheral et al. (2000) primarily 
surveyed formulary committee members of health maintenance organizations (HMO) 
which usually deal with more than one hospital. Additionally the respondents were 
mainly pharmacists (three-fourths) and the results were not discussed afterwards which 
only led to the results of the quantitative survey. These study characteristics and the 
focus only on the USA might be the explanation for a different outcome compared to 
other studies many of them conducted in Europe.  
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Except for two studies (Dranove et al., 2003; Gibson et al., 2005), no other study 
explicitly looked at the motivation of decision-makers, interpersonal factors as well as 
power relationships between different hospital formulary decision-makers. One main 
outcome of the Dranove et al. (2003) study, which concentrated on Pharmaceutical & 
Therapeutics Committees of Managed Care Organizations (MCO), has been the insight 
on the importance of working relationships in the respective organizations. The study 
revealed different objectives by decision-makers in the committee depending on whom 
they report to and how their yearly performance goals have been determined. This 
outcome was confirmed by Gibson et al. (2005). Participants in their study doubted a 
true representation of member’s opinions due to the fact that some formulary committee 
members reported directly to other more senior members. Formulary committee 
members were reluctant to discuss against the opinion of their bosses.  
 
Power relationships between individuals are not the only factors driving the motivation 
of hospital formulary committee members. Another result of the Dranove et al. (2003) 
study is the impact of the Pharmaceutical & Therapeutics Committees’ size which can 
negatively affect an adoption decision if the committee is larger. The issue here is 
presumably the difficulty to reach a consensus in a bigger group or in a group with more 
diversity in terms of the represented functions. In contrary, participants in the study by 
Gibson et al. (2005) described a “feeling pressured to conform and reluctant to vote in 
opposition […] or to express dissent […]” (p. 2359). This indicates that groups as such 
do influence decision-making and that once the majority of the group seems to go into 
one direction, it becomes harder for other group members to go into a different direction. 
This dynamic even increase if some group members are more dominant in their roles, for 
example, in terms of their rhetoric capabilities (Gibson et al., 2005) or due to the power 
relationships as mentioned before. A further exploration of these aspects will be done in 
section 2.3.3. 
 
Despite the interesting outcomes of the Dranove et al. (2003) study, the results were not 
further discussed with the respondents, which is derived from the use of a survey 
research method and the targeted survey respondents. It was limited in providing 
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detailed information which is also remarked by the authors of the study. However, due 
to the named reasons the results of the study might only show a small representation of 
the decision-making reality, but they still provide the perspective of the pharmacy 
directors. 
 
In contrast, the research approach by Gibson et al. (2005) was completely different. The 
use of a qualitative case study and interviews as the research method enabled the authors 
to gather in-depth information on the relevance of power relationships in the decision-
making process. Additionally, the mixture of job functions in the conducted interviews 
was much broader and did not only focus on pharmacy directors, but included 
representatives from administration and medical functions. This approach made it 
possible to gather a heterogeneous picture of the different hospital formulary committee 
perspectives on the decision-making process.  
 
 
2.2 Construction of a preliminary hospital formulary decision-
making framework 
The first part of the literature review has shown that hospital formulary decision-making 
starts with the individual preferences of the formulary committee members. Those 
preferences are based on the decision criteria sets which differ individually and which 
are the basis for the subsequent group decision-making process. In this process the 
individual preferences of each member are discussed with the other members of the 
formulary committee. Depending on group decision-making mechanisms discussed in 
detail in the next section, members align their individual preferences which finally lead 
into a consensus group decision (Figure 13).  
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Figure 13: Preliminary hospital formulary decision-making framework. 
 
 
Different aspects of this preliminary hospital formulary decision-making framework 
need to be looked at in detail. For example, there is no clarity on the importance of 
individual formulary committee members for the decision-making process in Germany. 
It has been shown in the literature review that pharmacists most likely have a central 
role, but there is no evidence for Germany. In addition, the impact of other groups, such 
as physicians, general managers or financial administrators is not apparent. There are 
hints that physicians play a bigger role in formulary committees decision-making and 
that there is less impact by general managers or financial administrators, but this has also 
not been shown for the German context.  
 
Current research also lacks information on the transition from the individual decision 
criteria sets to the aligned preferences and the final group decision. Besides efficacy and 
safety of a pharmaceutical drug, the following thematic clusters were identified during 
the systematic review in the previous sections: 
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1. Economic data and costs: this includes health economic evaluations, budget 
impact calculations and acquisition costs. 
2. Type of pharmaceutical drug: differences in the decision criteria subsets in 
dependency of the type of pharmaceutical drug, such as generics or orphan 
drugs. 
3. Administration / Practical criteria: advantages or disadvantages in the 
practical application of a certain drug, considering the local circumstances of the 
hospital. 
4. Emotional criteria and clinical experience: including treatment experience 
from colleagues or other hospitals, decisions taken by other formulary 
committees or anecdotal stories from other hospital formulary committee 
members. 
5. Patient's quality of life: impact of a treatment for the patient's life and the 
respective meaning for the decision-making process. 
6. Relationships to the pharmaceutical industry: indirect impact of relationships 
between members of the formulary committee and the industry. 
7. Decision-making guidelines: influence of guidelines which provide rules and 
recommendations for the decision-making process. 
8. Knowledge sharing: impact of the compiled "evidence" and facts about the 
discussed product and the influence of the pharmacist who usually compiles this 
evidence. 
9. Advocates and power relationships: individuals with a higher impact on the 
decision-making process due to several reasons, such as hierarchical 
dependencies, role of the formulary chair, responsibility for the creation of case 
documentation. 
 
The literature review showed that current research partly identified the applied decision 
criteria but did not assess the relative importance of those. Hence, the preliminary 
hospital formulary decision-making framework also lacks information on the relative 
importance for the different decision criteria.  
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Additionally, decision-making theories or models were not considered and research 
focused only on the practical part of hospital formulary committee decision-making. It 
was necessary to conduct a second systematic literature review on theories and models 
for objective versus subjective decision-making as well as group decision-making. The 
results of this second literature review were used to adapt the preliminary hospital 
formulary decision-making framework. 
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2.3 Group decision-making models and theories 
Figure 14 shows that the first systematic literature review was conducted on healthcare 
and hospital formulary decision-making and that the results were used to design a 
preliminary conceptual framework. The following sections will focus on theories and 
models to improve the conceptual framework.  
 
 
Figure 14: The second systematic literature review. 
 
 
2.3.1 Search strategy 
The second literature review was conducted similarly to the systematic review done in 
the first step. A search via EBSCO with general search terms (described later) was 
conducted on the following databases: Business Source Corporate Plus, Medline and a 
searching via Science Direct with limitation to the following sources: Business, 
Management and Accounting, Decision Sciences, Nursing and Health Professions, 
Psychology, Social Sciences. For the resulting list of 6,879 papers all abstracts were then 
screened for relevance concerning the review's goals. This resulted in a list of 536 papers 
which were partly read and assessed in regards to inclusion and exclusion criteria 
described later. The reference lists of these papers where then used to identify further 
publications pertinent to the review’s goals which had not been identified through the 
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first procedure. Again, their abstracts were screened, doubles eliminated, resulting in a 
total of 67 publications for this part of the literature review. Figure 15 is showing this as 
an overview. 
 
 
Figure 15: Literature review on group decision-making and objective versus subjective decision-
making. 
 
 
EBSCO and Science Direct 
In a first step the search terms used in EBSCO and Science Direct on all abstracts were 
different combinations on "group decision-making" or "objective" and "subjective" and 
"decision-making"  
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Inclusion and exclusion criteria 
Table 4 shows the inclusion and exclusion criteria, which are explained below. 
 
Topic Inclusion criteria Exclusion criteria
Study topic
decision-making of groups including a research focus on 
power relationships, group dynamics, role of individuals, 
knowledge sharing and multi-criteria decision-making, 
rational decision-making
medical research on decision-making, mathematical models 
of decision-making, research on individual decision-making 
without focus on objective/subjective criteria
Timeframe all research since 1990 research before 1990 (exception for seminal texts)
Research type
qualitative and quantitative research in scholarly peer 
reviewed journals, theses, clearly described research 
methodology, literature reviews, books
qualitative and quantitative research in grey literature 
(except theses), unclear study methodology, opinion papers
Language scope English or German all other languages  
 
Table 4: Inclusion and exclusion criteria used in the second literature review. 
 
 
Study topic 
This second literature review considered research on decision-making of groups 
including a research focus on power relationships, group dynamics, role of individuals, 
knowledge sharing and multi-criteria decision-making. The first systematic review 
showed that hospital formulary decision-making is always a group activity, in which 
individuals need to find a consensus on a complex decision scenario. The complexity of 
these scenarios is derived from questions which consist of a variety of different criteria. 
Hence, research on multi-criteria decision-making should be in focus of this review. The 
first systematic review also showed that some individuals in the hospital formularies 
have more influence than others and that available information plays an important role in 
formulary decision-making. In contrast, individual decision-making was mostly 
excluded from the review due to the fact that in hospital drug funding decision-making 
always more than one individual is involved.  
 
Time Frame 
All studies since 1990 were considered in order to have a more recent picture of research 
in this field. The researcher was aware that research on group decision-making has been 
conducted long before 1990. However, the researcher also assumed, if decision-making 
theories or models are still of relevance, they would be referenced in research published 
in the last 24 years. 
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Research type 
In order to look at research with a high quality standard it was decided to only consider 
research published in academic journals and seminal texts. For this reason grey literature 
and pure opinion papers were excluded. If the study methodology did not seem to be 
clear, the research was also not considered for the review. 
 
Language scope 
Due to the language limitations of the researcher the language scope was limited to 
research done in English or German language. 
 
Referenced research papers 
In order to complete the picture of relevant research work, all abstracts of referenced 
research papers of the resulting list of papers were also screened for further indication 
that the respective paper is looking into decision-making of groups including a research 
focus on power relationships, group dynamics, individual roles, knowledge sharing and 
multi-criteria decision-making. If a reference matched these criteria it was fully read and 
inclusion and exclusion criteria were used to determine the relevance of the paper. Due 
to the long history of general decision-making research, the researcher decided to allow 
seminal texts to be included on the review even if they were published before 1990. 
Research was considered to be seminal if it was cited in two or more of the papers 
included in the review. Additionally all citation “branches” and sub-branches of all 
relevant papers have been assessed in the same way.  
 
 
Appendix 2 shows the final list of papers from this second literature review. 
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2.3.2 Objective versus subjective decision-making 
In traditional behavioural decision-making research, emotions and other subjective 
factors are often seen as additional, external factors which influence an objective 
decision-making process, which is often equalized with rational decision-making 
(Loewenstein & Lerner, 2003; Peters, 2006; von Neumann & Morgenstern, 1947). 
Those studies argue that the influence by subjective factors can be indirect, for example, 
by changing the perception of probabilities of decision alternatives. This means, the 
decision-maker (unconsciously) uses subjective factors to change the probability that a 
perceived objective criterion is true. Or it can be direct with increasing emotional 
intensity which results in an increasing impact on the objective decision-making 
(Loewenstein & Lerner, 2003).  One example for high emotional intensity would be the 
case when a doctor treats a relative.  
 
That research is based on the assumption that the cognitive process of decision-making 
does not necessarily need subjective factors, such as emotions, but emotions do exist and 
can influence this process. Likewise, emotion is even seen by some traditional 
behavioural researchers as a factor which potentially falsifies an objective decision-
making process (Sloman, 1996; Kahneman, 2003). This would only be true, if real 
objectivity did exist. More likely is that perceived objectivity is an attempt to provide an 
accurate representation of reality. In this case, all factors, either perceived objective or 
subjective, should be taken into consideration for decision-making. In the author's view, 
this is the only way to safeguard that all possible representations have been evaluated 
and to prevent the exclusion of potential valuable information on reality.  
 
Most of the traditional models of objective or rational decision-making require a 
comprehensive knowledge of all possible alternatives and assume a world which can be 
fully predicted (Simon, 1978). As shown in the first systematic literature review, 
hospital formulary decision-makers almost always have to deal with lack of information 
on a new pharmaceutical drug, even for perceived objective information, such as clinical 
trial data. And they cannot perfectly predict the consequences in case the hospital uses 
the drug. Hence, cases where the decision-maker in the hospital has comprehensive 
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knowledge hardly exist and consequently the traditional models of objective or rational 
decision-making do not apply. Even in an ideal case where comprehensive knowledge 
about a decision task exists, decision-makers might be cognitively limited to process all 
the information leading to an approximation but often not perfect solution. This concept 
is called bounded rationality and is based on seminal work of Herbert Simon (1965). 
 
Further research concentrated on the assumption that the concept of bounded rationality 
is an accurate description of human decision-making processes. Kahnemann and 
Tversky (1974) showed in their research that biases in uncertain decision-making 
situations exist which people try to solve using heuristics. However, in their opinion the 
use of heuristics often leads to suboptimal outcomes, inferior to logical analysis. This 
view was criticized by other researchers  and led to an alternative concept called fast and 
frugal heuristics (Gigerenzer & Todd, 1999) where heuristics are defined as "a strategy 
that ignores part of the information, with the goal of making decisions more quickly, 
frugally and/or accurately..." (Gigerenzer & Gaissmaier, 2011, p.454).  
 
Besides the concepts on the use of heuristics, the unrealistic assumption about complete 
knowledge and perfect predictability has also led to anothermain research stream with a 
different opinion on the quality of subjective factors (Fehr & Gächtner, 2002; Han, 
Lerner & Keltner, 2007; Lerner & Keltner, 2000; Lerner & Tiedens, 2006; Pfister & 
Böhm, 2008; Pillutla & Murnighan; 1996; Zeelenberg, Nelissen, Breugelmans & Pieters, 
2008). Here, subjective factors are not categorized as a distortion to the cognitive and 
objective process, but as an essential part of decision-making.  
 
Research has been conducted in healthcare, especially for physicians or nurses, which 
confirm that subjective criteria such as intuition are a basic and important component of 
decision-making processes (Benner, 1984; Benner, Hooper-Kyriakadis & Stannard, 
2011; King & Appleton, 1997). Intuition is particularly used when the time for decision-
making is short and the task is difficult. In contrast, if the decision-maker has enough 
time and the task is simpler, the use of an analytical process is preferred (Hammond, 
1996, 2000; Pixley, 2004; Zinn, 2008). This is due to the use of assumptions and varying 
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quality of data. Subjective factors help people to reduce uncertainty by reducing a 
decision from a highly complex task to a task with less complexity. This simplification 
can even lead to better outcomes than pure objective decision-making. Research in the 
financial sector concluded that the stock market experts seem to be overwhelmed by the 
quantity of available information which they used for their financial analysis and 
therefore did not perform better than the lay people group (Gigerenzer, 2007). However, 
other recent qualitative studies from the financial sector, such as Fenton-O’Creevy, 
Soane, Nicholson and Willman (2011), confirm that experts use a mixture of perceived 
objective and subjective factors. Most of the studies in the first systematic literature 
review, either quantitative or qualitative research, also showed evidence of this mixture 
of decision-making criteria. 
 
This constant switch between subjective factors and perceived objective factors has been 
formulated into a framework by Hammond (1996, 2000) which he referred to as 
cognitive continuum. He argues that decision-making can oscillate on a continuum 
ranging between intuition and analysis. The cognitive continuum model is one main 
example for a series of models and theories from different behavioural researchers with 
the common idea of human information processing (which includes decision-making) 
based on a dual processing system. System 1 works intuitively and is fast, automatic and 
unconscious, whereas System 2 works analytic and is slower, deliberate and conscious 
(Epstein, 2008; Evans, 2006; Gilovich, Griffin & Kahneman, 2002; Lieberman, 2003; 
Nisbett, Peng, Choi & Norenzayan, 2001; Stanovich & West, 2000; Strack & Deutsch, 
Sun, Slusarz & Terry, 2005; Toates, 2006; 2004; Wilson, 2002). In contrast to 
Hammond and his cognitive continuum model, other dual-processes researchers see the 
two systems in a competitive situation (Dhami & Thomson, 2012). For example, Evans 
& Stanovich (2013) constructed a model where initially all decisions are processed by 
System 1 and System 2 verifies the outcome of the System 1 intuition. If the assessment is 
not satisfactory, System 2 might intervene and change the initial decision-making. This 
view implies an either intuitive or analytic decision-making process which is in contrast 
to the cognitive continuum model and the understanding of how healthcare decision-
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making works with a mixture of objective and perceived subjective criteria (Croskerry, 
2009; Custers, 2013; Norman, Monteiro & Sherbino, 2013).  
 
In addition, Baltussen and Niessen (2006) mentioned a risk of cognitive overload for the 
decision-maker who is required to handle and assess a flood of information about a new 
pharmaceutical drug. Thus, the cognitive continuum model fits well for healthcare 
decision-makers and also provides a rationale for the use of subjective criteria. Due to 
the complexity of healthcare decisions, the analysis side of the cognitive continuum is 
only used in a limited way and many of the decisions are located more on the intuitive 
side. With increasing complexity, for example with high uncertainty of clinical data or a 
high severity of the disease, healthcare decision-makers supposedly increase the use of 
their gut feeling (or intuition) and decrease the use of analysis of perceived objective 
information. 
 
Hammond's cognitive continuum model support of a quasi-rationality using a mixture of 
objective and subjective assessment is positively evaluated in the medical (physicians 
and nurses decision-making) context in recent publications (Cader, Campbell & Watson, 
2004; Croskerry, 2009; Custers, 2013; Norman, Monteiro & Sherbino, 2013; Standing, 
2008). In this context Hammond's model is also preferred to other dual-process theories. 
 
2.3.3 Group decision-making 
Decision-making in a group is a complex process as many individuals collectively form 
a decision in a group environment. This adds additional variables which impact the 
process of decision-making.  
 
Different early studies on group decision-making, much of them conducted in social 
psychology research, have been done focused on the question how individuals come to 
decision preferences and how those individual decision preferences conclude in an 
aggregated group preference (Arrow, 1963; Black, 1958; Lorge & Solomon, 1955; 
Smoke & Zajonc, 1962; Steiner, 1972). Preference in this context means that one option 
is preferred over a set of alternative options. In later stages of group decision-making 
 73 
research, groups were considered as information processing systems and therefore 
looked at how groups use information for their decision-making (Hinsz, Tindale & 
Vollrath, 1997). The key concept behind information processing is social sharedness. 
This means the level of information that is being shared between group members. Even 
more it describes the level of things, such as information, motivations, attitudes, 
preferences, ideas, cognitions or cognitive processes, being shared between members of 
a group (Hinsz et al., 1997). Social sharedness is not only the central concept behind 
information processing in groups, but also a central idea for group decision-making.  
 
Social Decision Scheme Theory, and its successor Social Judgment Scheme Theory, 
belong to the most popular models trying to represent how individual decision 
preferences aggregate into a group preference (Davis, 1973; Stasser, Kerr & Davis, 
1989). This concept will be described in more detail in the next section. 
 
Other theories focus on the explanation of variables which could influence either the 
individual decision preferences or directly the group decision preferences.  Much 
research has focused on the level of information sharing and how this affects group 
decision-making (Gigone & Hastie, 1993, 2013; Hinsz, 1990; Stasser & Titus, 1985, 
1987; Tindale & Sheffey, 2002; Vollrath, Sheppard, Hinsz & Davis, 1989). A related 
topic with a focus on influential power of individuals in group decision-making is 
cognitive centrality (Kameda, Ohtsubo & Takezawa, 1997). Kameda et al. (1997) 
defined “members in terms of the degree of centrality in the sociocognitive network. The 
greater the degree of overlap between the information held by a given member and the 
information held by other members on average, the greater the degree of centrality for 
that member” (Tindale & Kameda, 2000, p. 128). They describe the phenomenon that 
cognitively more central members of a group have a bigger level of influence on 
decision-making.  
 
2.3.3.1 Shared preferences and Social Decision Scheme Theory 
The basic idea of Social Decision Scheme Theory is saying that a group decision is the 
aggregation or combination of the different individual decision preferences of each 
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group member. The result is a single consensus group decision (Davis, 1973; Stasser, 
Kerr & Davis, 1989).  
 
Davis (1973) formally describes a set of mutually exclusive and discrete decision 
alternatives, a = {a1,a2,a3,…an} and n showing the total number of decision 
alternatives. He defines two vectors. One is used to describe the probability p that a 
group member will prefer alternative a, with p = {p1,p2,p3,…pn} and n again showing 
the total number of alternatives. For example, p1 is the probability that a group member 
will prefer a1. The second vector describes the distribution of group member’s 
preferences, with a group size of r and with r = {r1,r2,r3,…rn}. For example, r1 
describes the number of group members who prefer alternative a1. A recent study by 
Ambrus, Greiner and Pathak (2013) based their research on the seminal work of Davis 
(1973). The main result of their study shows that group members with a median opinion 
have the strongest influence on decision-making. This result also confirms the concept 
of cognitive centrality (Kameda et al., 1997) described in more detail later in section 
2.3.3.3. 
 
In order to illustrate this more clearly and to put this into the hospital formulary 
decision-making context, one needs to consider a formulary committee of eight 
members, that is r = 8. In addition the number of decision alternatives is two. a1 is for 
the inclusion of a specific pharmaceutical drug and a2 is against the inclusion of the 
pharmaceutical drug. For example, in case of r = {2,6}, two members are for the 
inclusion and six members are against the inclusion. In addition, p = {0.3,0.7} denotes 
that the probabilities are higher for not including the pharmaceutical drug on the 
formulary list.  
 
One general limitation of the Social Decision Scheme Theory is the prerequisite that the 
decision alternatives need to be discrete. For example, decisions between alternative A 
or alternative B or yes or no decisions. Davis (1996) therefore reformulated the Social 
Decision Scheme model to a Social Judgment Scheme approach which also considers 
continuous decision-making, such as budget decisions. This will not be referred to in 
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detail, because hospital formulary decision-making usually consists of discrete decision 
alternatives (for example, to decide for or against the listing of a pharmaceutical drug – 
yes or no).  
 
Social Decision Scheme Theory is not a model to fully explain all decision processes. 
Davis (1973) already mentions in his paper that his model does not consider “personal 
factors” or “social context”, which is a strong limitation in regards to hospital formulary 
decision-making. As shown in the first part of the literature review, specifically the 
personal factors do play an important role during the decision-making process in 
formulary committees (Dranove et al., 2003; Gibson et al., 2005). It is also questionable 
if a mathematical model, such as the Social Decision Scheme Theory, is an appropriate 
basis for a framework which should explain hospital decision-making. In contrast, Social 
Decision Scheme Theory was meant to predict outcomes of group decision-making. 
According to Wirtz et al. (2005), hospital formulary decisions are often accomplished by 
discussions and consensus and not a math formula which speaks against the applicability 
of this theory. Likewise, the aim of this research is exploratory and aspires to explain the 
decision-making process in hospital formulary committees and thus following a different 
direction. In spite of these limitations, the basic idea of Social Decision Scheme Theory 
can be used for a hospital formulary decision-making framework as it formally explains 
the aggregation of individual preferences which finally form a single consensus group 
decision. 
 
2.3.3.2 Shared knowledge 
In spite of group decision-making research focusing on preferences, like the Social 
Decision Scheme Theory, other research tried to explain group decision-making from a 
different angle. Vinokur and Burnstein (1974) assumed in their Persuasive Arguments 
Theory that for a given issue, always a set of arguments exists. A group decision-making 
process will then be influenced by a sample of this set of arguments. One central 
assumption they made "was the importance of unshared and unique arguments"(Tindale, 
Kameda & Hinsz, 2003, p.15). In their view, shared arguments or information had little 
impact on the decision-making outcomes due to the fact that everyone had that 
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information already. In their opinion unshared arguments or information influence group 
member’s preferences more strongly. 
 
Other seminal research by Stasser and Titus (1985) led to different conclusions. They 
showed that the probability that a group recalls certain information increases with the 
number of group members who know the information. Unshared information is often not 
brought up during group discussions and shared with other group members, whereas 
shared information is more often discussed (Hinsz, 1990; Tindale & Sheffey, 2002; 
Stasser, Taylor & Hanna, 1989; Vollrath et al., 1989). It has also been shown, that group 
members have a tendency of recalling information better if they have not heard this 
information the first time (Larson & Harmon, 2007). This can have the effect that 
members of a group do not have all relevant information to make a comprehensive and 
informed decision (Brodbeck, Kerschreiter, Mojzisch & Schulz-Hardt, 2007; Mesmer-
Magnus & DeChurch, 2009; Stasser & Titus, 1985).  
 
Other factors, such as the individual motivation, also play a substantial role for the 
question if information is shared between group members or not. Toma, Vasiljevic, 
Oberlé and Butera (2013) showed in their study that group members who were assigned 
experts share unique information with others only if the expert’s thinking was 
cooperative. In a competitive situation there is a higher chance that those assigned 
experts withhold information. Assuming that the different members of a hospital 
formulary committee have different motivations and that pharmacists have a focus on 
economic goals whereas physicians have a focus on medical goals, information sharing 
in hospital formulary committees could be suboptimal. 
 
Parks and Cowlin (1996) showed in a study with small groups that a (mock) proof of a 
fact's existence during discussions increases the acceptance of these facts compared to 
other presented information. Hence, the documentation usually prepared and provided 
by the pharmacist (Haslé-Pham et al., 2005; Jenkings & Barber, 2004) could potentially 
have a significant impact on decision-making. 
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Larson, Foster-Fishman and Keys (1994) showed that an increase of group discussion 
time also increased the chances of unshared information to be shared within the 
discussion. On the other hand, less time or time pressure can even emphasize the 
importance of shared information and reduces the willingness of group members to look 
at more decision options (Janis, 1972; Kelly & Karau, 1999). No research on the 
importance of time for the hospital formulary decision-makers has been conducted.  
 
2.3.3.3 Centrality 
Information sharing has been studied well as shown in the last section. Kameda et al. 
(1997) followed the idea that a high level of knowledge sharing from one individual 
group member with other group members lead to more power in the decision-making 
process. They identified two reasons to believe in this idea. First, Stasser, Stewart and 
Wittenbaum (1995) learned in their research that expert individuals in a group have a 
bigger impact on decision-making if their expert role is known to all other group 
members. Secondly, they suggested that a group member will be rather recognized as an 
expert in the group if the perception of the other group members about his or her 
expertise is more established. This is again associated with the presented knowledge 
about information sharing in the above section. Even if an individual has a lot of unique 
information, he or she is not necessarily recognised as the expert of the group. Research 
by Festinger (1964) and Park and Crowlin (1996) have shown that validation of 
information leads to easier acceptance by the group and in consequence to improve the 
individual's status as the expert. For example, if (mock) fact sheets are provided to the 
group members during the discussion which support a specific argument. Conversely, 
shared information is socially validated through the group. For an individual group 
member with a high level of shared information this facilitates to be perceived as an 
expert and thus have more impact on decision-making. Kameda et al. (1997) called this 
cognitive centrality and defined this as the “number of arguments that Member i shares 
with other members” (p. 298). The higher this number is for member i, the higher the 
level of cognitive centrality is for member i. This finding has also been confirmed by 
later research where Wittenbaum and Bowman (2004) found that people rate the task 
capability of others more positively the more shared information they discuss. Kameda 
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et al. (1997) confirmed in their research that cognitive central group members have a 
higher influence on the decision-making process compared to group members who are 
perceived as cognitive peripheral. Cognitive central group members proved to be more 
dominant in the group discussions and resistant to counter-arguments. Even in minority 
situations, when the individual group member represented a minority preference, 
cognitive central group members showed higher influence to the group decision. It was 
easier for them to steer the decision towards their preference compared to cognitive 
peripheral group members. 
 
The explanation of cognitive centrality can be applied to the hospital formulary 
committee context. In the first literature review, Gibson et al. (2005) showed that some 
individuals in formulary committees have a higher influence on decision-making than 
others. In some cases this is due to a hierarchical dependence between different 
members of the committee, but other important factors were also mentioned, such as 
seniority or a good rhetorical capability. Seniority or a higher level in the hospital 
hierarchy automatically means an expert distinction and for cognitive central members it 
is easier to steer decisions (Kameda et al., 1997) which can be suggestive of members 
having a higher rhetorical capability. 
 
2.3.3.4 Subset of arguments 
It was mentioned before that for every decision task, Vinokur and Burnstein (1974) 
assumed that always a set of arguments exists. Kalven, Zeisel, Callahan and Ennis 
(1966) also confirmed in their research on juries that members of the jury already have 
an initial opinion when they hear about the evidence and clearly before they start the 
jury discussion. Group members preliminary build their individual decision preference 
which has a dominant function in all subsequent discussions (Greitemeyer & Schulz-
Hardt, 2003; Faulmüller, Kerschreiter, Mojzisch & Schulz-Hardt, 2010; Stasser & Titus, 
1985). Thus, the subset of arguments of each group member impacts the discussion in 
two ways: First, it aligns the preliminary decision preference of each group member with 
all the additional arguments which are brought up during discussion by other group 
members. Second, the discussion is built upon the subset of arguments and the balance 
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of arguments determines finally which decision preferences will be chosen or changed 
(Stasser & Titus, 1985). In addition, Stasser and Titus (1985) concluded that the 
preliminary decision preferences lead to a selection bias in regards to the information 
which is used in the discussion and shared with the other group members. People with 
specific decision preferences advocate their preference by means of using information to 
defend it. 
 
The last section of this literature review summarized the main concepts and theories of 
decision-making and more specific group decision-making. Knowledge about 
fundamental concepts such as intuition, shared preferences, shared knowledge or 
centrality as well as the importance of objective and subjective decision-making was 
discussed. Much of the research about general objective and subjective decision-making 
or group decision-making was done in laboratory-like experiments (Ambrus et al., 2013; 
Faulmüller et al., 2010; Greitemeyer & Schulz-Hardt, 2003; Larson & Harmon, 2007; 
Toma et al., 2013; Wittenbaum & Bowman, 2004). Despite this methodological 
limitation, much of the research conducted in healthcare and hospital formulary 
decision-making revealed phenomena which can at least partly be explained by the 
general theories and models discussed in the second literature review.  
 
2.4 Refinement of the hospital formulary decision-making 
framework 
 
Figure 13 showed a preliminary hospital decision-making framework which 
incorporated the results of the first literature review. It has been shown that research in 
the specific area of hospital decision-making is focused on practical issues and lacks 
theoretical background. The results of the second literature review complete the hospital 
decision-making framework and add the theoretical component considering ideas and 
theoretical models from behavioural decision-science and psychology research.   
 
One main result from the first literature review showed, that besides perceived objective 
criteria, subjective criteria have a strong impact on decision-making, specifically in 
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cases where the perceived objective criteria is subject to uncertainty. Dual processing 
systems, such as Hammond’s cognitive continuum model (1996, 2000), represent a good 
theoretical basis for decision-making in hospital formularies and help to understand the 
different use of analytic or intuitive decision-making. 
 
According to the Social Decision Scheme Theory (Davis, 1973, 1996), group decision-
making processes function as a combination of all group members’ preferences which 
are aggregated to form a group response. This mechanism can be observed where 
healthcare decision-makers face the challenge of making complex funding decisions, 
often in a group environment. Thus, the general mechanisms of this aggregated function 
should also be applicable for hospital formulary decision-making. However, Davis' 
(1973, 1996) model aimed to predict group decision-making outcomes, but this study 
wants to further explore the group decision-making phenomenon itself. Wrtz et al. 
(2005) showed that decision-making is not only bound to a fixed relative importance of 
decision criteria but is mainly impacted by group discussions and other group decision-
making phenomena, such as influential individuals or information sharing. This is also 
indirectly confirmed by the failure of multi-criteria decision-making tools which are not 
adopted in hospital formulary committees.   
 
Two main theoretical models from behavioural decision-science and psychology 
research will be added to the preliminary hospital decision-making framework: 
1. Dual processing systems: Healthcare decision-makers face the challenge of 
making multi-criteria funding decisions and they use a mixture of analytic and 
intuitive decision-making. Dual processing systems build the basis for a better 
understanding of the interaction of these two different ways of making decisions 
(Epstein, 2008; Evans, 2006; Gilovich et al., 2002; Hammond, 1996, 2000; 
Lieberman, 2003; Nisbett et al., 2001; Strack & Deutsch, 2004; Stanovich & 
West, 2000; Sun et al., 2005; Toates, 2006; Wilson, 2002). 
2. Group decision-making: Most of the time these decisions need to be taken in a 
group environment including the complexity derived from intra-group dynamics. 
For example, this constitutes an increased influence on decision-making due to 
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hierarchical dependencies between group members, dominant acting group 
members or uneven knowledge sharing between group members (Armstrong et 
al., 2008; Kameda et al., 1997).  
 
Those two concepts can help to understand hospital formulary decision making (Figure 
16). In a first step (Figure 16 “step 1”) every decision-maker (usually a member of a 
hospital formulary committee) tries to establish their own preference by using a dual 
processing system. In a second step (Figure 16 “step 2”) this preference will be 
discussed and potentially aligned considering the other members’ preferences to 
conclude in a final decision. Key theoretical group decision-making concepts, such as 
centrality (Kameda et al., 1997) or asymmetric information sharing (Stasser & Titus, 
1985), have influence on the final decision in step two. 
 
  
 
 
Figure 16: Hospital drug funding decision-making framework.
8
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In order to fulfil research objectives RO-1 to RO-6 this research needs to find some 
explanations for the decision-making process in German hospital formularies and the 
applied decision-making criteria. Hence, it is not sufficient to just present and 
describe research outcomes. The analysis must identify the processes and structures 
which finally lead to the empirically visible results.  
This approach is in-line with a Critical Realist research philosophy which is 
explained in detail in section 3.3.  
 
The literature review revealed a lack of use of health economic evaluations although 
hospital formularies seem to have a strong focus on economic measures. Potential 
explanations are a level of mistrust in complex analyses derived from lack of expert 
knowledge of the formulary committee members and mistrust in analyses conducted 
by the industry. In addition, health economic analyses probably do not consider the 
local situation of the hospital. 
 
It was also shown that decisions seem to be made only based on medical or economic 
criteria at least officially. Considering the outcomes of this literature review, it can be 
assumed that hospital formulary committee members also use other criteria than just 
the technical (medical, economic) ones. In cases where ethical arguments are used, 
such as saving the life of a patient, the impact of such other criteria can be 
significant. Presumably members take their decisions “flowing” from an analytical to 
a more intuitive thinking depending on the complexity of the decision-making 
process. If it comes to a cognitive overload due to a considerable amount of 
information, formulary committee members make more use of the intuitive thinking 
and decision-taking. However, formal documentation or guidelines only mention 
technical criteria as justification for decision-making. Formulary committee members 
are reluctant to make the use of perceived subjective criteria official, as they 
probably think that the use of objective criteria is easier to justify. Despite the use of 
subjective decision criteria, any criteria related to the administration of 
pharmaceutical drugs have a low impact on decision-making. Nurses are the 
concerned group for those criteria and physicians and pharmacists do not seem to 
take their concerns serious as a consequence of a superiority thinking (Robinson et 
al., 2010; Thomas, Sexton & Helmreich, 2003; Vazirani, et al., 2005). This is also 
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being reflected in the small number of nurses as members of the hospital formulary 
committee. 
 
Ad-hoc priority setting, without a clear prioritization of decision-making criteria, is 
the normal way of decision-making processes in hospital formularies. Maybe the 
reason for this is the difficulty to quantify the importance of subjective decision-
making criteria and the individuality of decisions. Determination of the relative 
importance of criteria does not make sense in this case as every decision has 
individual and different importance levels. Hospital formulary committee members 
try to identify perceived objective criteria for their decision-making as they might 
feel a simplification of the decision process. 
 
Some individuals in the hospital formulary committee have a certain level of power 
for different reasons and they can influence decision-making. One reason could be 
the fear of some members to jeopardise their relationships with powerful people or 
another reason might be the “blind” acceptance of an expert role. It was also shown 
that external groups, such as patient groups or politicians, can have certain levels of 
power with impact on how decisions are made. This originates from dependencies of 
formulary committee members to be re-elected or due to ethical pressure (in case of 
patient groups). Power derived from hierarchical levels seemed to influence decision-
making in some formulary committees, because members are afraid of the 
consequences in case they do not follow their boss. 
 
The literature review showed that relations between the pharmaceutical industry and 
the committee members influence decision-making. Members appreciate that most of 
the knowledge on pharmaceutical drugs, especially new treatments, comes from the 
manufacturer. On the other hand, members are afraid of being accused of bias in 
their decision-making or bribery or they are just afraid of being misled by statements 
of the manufacturer. Thus relationships with the industry are a very sensitive topic 
and most of the formulary committee members accept, but distrust the influence of 
this relationship on their decision-making (Jenkings & Barber, 2004). 
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Formulary committee members are not satisfied with the preparation time for the 
formulary committee meetings and the amount of provided information. This can 
lead to uncertainty and as a consequence to a decreased active involvement in the 
decision-making process. Maybe the applicants (physicians or pharmacists) do not 
realise this as they are the responsible members to provide the information on a 
pharmaceutical drug. Or they do not want other members to reflect too much on a 
case.  
 
The following table shows potential processes and structures which were identified 
in the literature review: 
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Empirical Potential structures and processes
Lack of use for health economic evaluations 
although hospital formularies seem to have a 
strong focus on economic measures.
Mistrust in complex analyses derived from lack of expert knowledge of 
the formulary committee member and mistrust in analyses conducted 
by the industry.
Health economic analyses probably do not consider the local situation 
of the hospital.
Officially, decisions seem to be made only based 
on medical or economic criteria. But formulary 
committee members admit to use other criteria.
Presumably members take their decisions “flowing” from an analytical 
to a more intuitive thinking depending on the complexity of the 
decision-making process. If it comes to a cognitive overload due to a 
big amount of information, formulary committee members make more 
use of the intuitive thinking and decision-taking. 
Formal documentation or guidelines only mention 
technical criteria as justification for decision-
making.
Formulary committee members are reluctant to make the use of 
perceived subjective criteria official, as they probably think that the 
use of objective criteria is easier to justify.
Small number of nurses as members of the 
hospital formulary committee and administrational 
criteria have low impact on decision-making.
Physicians and pharmacists do not seem to take  concerns of the 
nurses serious as a consequence of a superiority thinking.
Ad-hoc priority setting, without a clear prioritization 
of decision-making criteria is the normal way of 
decision-making processes in hospital 
formularies.
Determination of the relative importance of criteria does not make 
sense as every decision has individual and different importance 
levels. 
Some individuals in the hospital formulary 
committee have a certain level of power for 
different reasons and they can influence decision-
making. 
Some members are afraid to jeopardise their relationships with 
powerful people or they probably accept an expert role without 
questioning it.
External groups, such as patient groups or 
politicians, can have certain levels of power.
Dependencies due to a re-election goal or ethical pressure in case of 
patient groups might lead to power of external groups.
Power derived from hierarchical levels seemed to 
influence decision-making in some formulary 
committees. Members are afraid of the consequences in case they do not follow.
Relations between the pharmaceutical industry and 
the committee members influence decision-
making. Formulary committee members deny an 
influence of this relationship on their decision-
making.
Members appreciate the industry's knowledge on pharmaceutical 
drugs, but members are also afraid of being accused of bias in their 
decision-making or bribery or they are just afraid of being cheated by 
statements of the manufacturer
Formulary committee members are not satisfied 
with the preparation time for the formulary 
committee meetings and the amount of provided 
information.
This can lead to uncertainty and as a consequence to a decreased 
active involvement in the decision-making process.  
 
Table 5: Potential structures and processes identified in the literature review. 
 
 
2.5 Gaps identified in existing literature 
Different aspects of hospital formulary decision-making were not discussed in 
existing literature. For example, there is no clarity on the importance of individual 
formulary committee members for the decision-making process in Germany. It has 
been shown in the literature review that pharmacists most likely have a central role, 
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but there is no evidence for Germany. In addition, the impact of other groups, such as 
physicians, general managers or financial administrators is not apparent. There are 
hints that physicians play a bigger role in formulary committees decision-making and 
that there is less impact by general managers or financial administrators, but this has 
also not been shown for the German context.  Current research also lacks information 
on the transition from the individual decision criteria sets to the aligned preferences 
and the final group decision.  
 
The literature review showed that current research partly identified the applied 
decision criteria but did not assess the relative importance of those. Hence, the 
preliminary hospital formulary decision-making framework also lacks information 
on the relative importance for the different decision criteria.  
 
Additionally, decision-making theories or models were not considered and research 
focused only on the practical part of hospital formulary committee decision-making.  
This is why a second literature review was conducted. However, the conclusions 
derived from this second review and preliminary incorporated into the hospital drug 
funding decision-making framework need to be challenged by this research. 
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3 Research Strategy 
3.1 Introduction and problem definition 
The literature review identified research gaps and showed that hospital formulary 
decision-making is not well understood. This research needs to investigate more 
specifically the role of different functional groups and their impact on decision-
making. Additionally, more insights are required on the importance of different 
objective and subjective decision criteria as well as to understand the theoretical fit 
of Dual processing systems and the mechanisms of group decision-making in the 
context of German hospitals. Owing to the fact that the topic is very sensitive it 
seems to be difficult to get access to involved stakeholders (e.g. physicians, 
pharmacists) and to collect suitable data for research.  
 
Every decision taken in favour of one pharmaceutical drug automatically means a 
limitation to fund another pharmaceutical drug due to limited healthcare budgets. In 
essence the decision-maker also decides to limit treatment to patients of the rejected 
drug, thus bringing the decision-maker into a situation of justifying his decision 
(Niezen et al., 2009; Wirtz et al., 2005). The influential and political nature of this 
has an impact on the willingness of drug funding decision-makers to reveal (all of) 
their real influences. A “hidden agenda” of decision-makers needs to be considered 
when choosing the right research methodology. 
 
This research fills some of the identified research gaps. In the next sections, the 
philosophical position and the basic methodological concepts used for this research 
will be elucidated. Then each activity of the applied research methods will be 
explained and this will also cover topics such as sampling, validity and methods of 
analysis. The final section of the methodology and methods chapter will close with 
comments on ethics. 
 
3.2 Short overview on the overall research design  
The following will provide a short overview and rationale for the overall research 
strategy in order to facilitate a better understanding of the more detailed explanations 
to follow in chapter 4. 
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Based on the results of the literature review, a convergent parallel mixed-methods 
design with a combination of quantitative (survey) and qualitative (expert and market 
research interviews) research methods was chosen. One of the strengths of a 
convergent parallel mixed-methods design is the possibility to combine 
complementary results from quantitative and qualitative research methods (Creswell, 
2003).  
 
According to Creswell (2003), the convergent parallel mixed-methods design has 
four main steps: 
1. Concurrent quantitative and qualitative data collection: Independent from 
each other, the research questions and methods for both parts, quantitative 
and qualitative, are defined. 
2. Separated analysis of the two data strands: Both parts, quantitative and 
qualitative, are analysed separately and results are presented. 
3. Merge the two data sets: Results from both parts, quantitative and qualitative, 
are merged in a combined analysis. Identify, compare and contrast similar or 
different themes and synthesize the results. If required, additional analyses 
are conducted. 
4. Interpret the merged data sets: The outcomes of the merged data sets analysis 
are used to form a better understanding of the research phenomena. It is also 
important to consider and discuss differences or contradictions between the 
two analyses of data sets.  
 
In the parallel-databases variant of the convergent parallel mixed-methods design all 
data sets are analysed separately and only the results of the different analyses are 
then compared. Hence, step three of the above standard process is skipped. Instead, 
both data sets are analysed separately (step two) and the independent quantitative and 
qualitative results are synthesised in the final discussion. This variant is specifically 
useful if both data strands are used in a complementary manner to achieve a better 
understanding of a phenomenon (Creswell, 2003).  
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Figure 17: Overview of the convergent parallel mixed-methods design. 
 
The parallel database variant of the convergent parallel mixed-methods design was 
used for this research and is shown in Figure 17. 
 
3.3 Research philosophy 
This section explains the choice of the research philosophy for this thesis. This is 
important since the research philosophy impacts the whole research project, such as 
the applied research methods or the way the data analysis is conducted (Collis & 
Hussey, 2003). 
 
There are two basic philosophical positions: positivism and constructivism. A 
positivist assumes that an objective reality exists and that a researcher can observe 
this reality. A constructivist believes that the world consists of (subjective) individual 
constructed realities (Guba & Lincoln, 1994). Both basic positions have different 
beliefs in regards to ontology, i.e. the questions of existence and epistemology, i.e. 
the questions of knowledge. In addition, much research work is based on research 
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philosophies somewhere in between the two basic philosophical positions, such as 
post-positivism, critical realism or critical theory. 
 
This research is based on the research philosophy of critical realism. Critical realism 
was developed by Bhaskar (1978) as an alternative to the existing and established 
research philosophies. Bhaskar (1978) criticized the strict separation of positivism 
and constructivism and the resulting difficulties in applying appropriate research 
methods for business management research.  
 
One of the main differences to other research philosophies is a positivist ontology in 
connection with a constructivist epistemology. Critical realism knows three levels of 
reality: the real, the actual and the empirical (McEvoy & Richards, 2006). The real 
describes the underlying structures, objects and mechanisms which generate 
phenomena. This is the “deepest” level of reality and those underlying structures, 
objects and mechanisms are not directly observable. The actual describes the part of 
reality which occurs in the background and might be experienced or not. It is a subset 
of the real and consists of the events which are generated by the (non-observable) 
objects and mechanisms of the real (Zachariadis, Scott & Barrett, 2013). The 
empirical is the subset of the actual which can be experienced and is therefore 
primary target of critical realist’s research. It is the goal of a critical realist to 
experience as much as possible of the empirical domain in order to better understand 
the underlying structures and mechanisms of the real domain.  
 
For this research it is assumed that the hospital formulary decision-making process, 
objectives of decision-makers and power relationships between formulary committee 
members are part of the real domain as they are not directly observable. The 
decision-making behaviour and applied decision-making criteria are part of the 
actual domain because they are a generated or derived from the directly non-
observable objects and mechanisms in the real. Every specific behaviour and 
decision criterion which has been observed by this research is part of the empirical 
domain. The real domain is perceived by different people with different perceptions 
and to identify as many of these perceptions as possible leads to a better view onto 
reality (Perry, Riege & Brown, 1998) as shown in Figure 18. Perry et al. (1998) also 
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describe a perception as “…a window on to reality from which a picture of reality 
can be triangulated with other perceptions” (p.554).  
 
 
 
Figure 18: Different people have different perceptions of the same reality  
(Adapted from Perry et al., 1998). 
 
 
Consequently, observing and analysing individual decision-maker behaviour and 
decision-making criteria preferences will lead to a better understanding of what is 
happening in the real domain. 
 
Another characteristic of critical realist research philosophy is retroduction, which 
describes the way of interpreting and analysing information. As indicated above, 
critical realists assume that the structures and mechanisms of the real domain can 
never be experienced directly, but rather rely on what can be observed in the 
empirical domain. Thus, the information gathered by research can only be a hint of 
how the underlying structures and mechanisms in the real domain function. This 
shift from interpretation of the observable information to a postulate or model of the 
underlying structures and mechanisms of the real domain, which have caused the 
observable information, is called retroduction. A critical realist therefore always asks 
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why something has happened in the empirical domain and what can be the 
mechanism behind that (Olson & Morgan, 2004).  
 
The separation of the three levels of reality also means that interpretations, derived 
from observable information of the empirical domain, are never perfect. This is due 
to the fact that the underlying structures or mechanisms can never be observed 
directly. Only certain events in the actual domain which are caused by such 
structures or mechanisms can be observed in the empirical domain. This also means 
that the empirical domain does not even allow observing all events generated by 
those mechanisms in the actual domain. As a result, these interpretations are always 
good as long as there are no better interpretations. Better interpretations can 
potentially come from additional information gathered in the empirical domain and 
then lead to a correction of the latest interpretation. The idea behind this process is an 
ongoing improved understanding of the real domain and its underlying structures and 
mechanism. Accordingly, this research did not want to show the perfect model of a 
drug funding decision-making process in a hospital formulary, but the goal was to 
enhance the understanding of this process. A better understanding of the process 
provides greater transparency on the complexity of decision making for drug funding 
decisions. This allows stakeholders to reflect on their process and this enables 
potential improvements. 
 
Critical realists support the use of mixed-methods research and for many cases the 
most useful research methods approach is a mixed-methods approach with a 
combination of quantitative and qualitative methods (Olsen, 2002). This is because 
quantitative and qualitative research methods have different strengths and 
weaknesses which can be differently utilized during a research project. Quantitative 
research methods can be used “to develop reliable descriptions and provide accurate 
comparisons” (McEvoy & Richards, 2006, p. 71) whereas qualitative research 
methods have their strength in “illuminating complex concepts and relationships that 
are unlikely to be captured by predetermined response categories or standardised 
quantitative measures” (McEvoy & Richards, 2006, p. 71). Thus, a mixed-methods 
research approach helps to uncover and better understand the objects and 
mechanisms (here: the decision-making, the objectives of decision-makers and 
power relationships between formulary committee members) which lead to decision-
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making. Independent of the applied research method(s), a researcher needs to 
consider that the outcome of any research is subject to fallibility due to the 
incapability of observing the real domain (Zachariadis et al., 2013).  
 
This made a convergent parallel mixed-methods design with a combination of 
quantitative and qualitative research methods the optimal approach for this research 
project. Strengths of the quantitative research methods were utilized to improve the 
understanding of structures of hospital formularies in German hospitals, to collect 
information on the hospital formulary committee members and to achieve a first 
understanding of their potential relationship towards each other. In addition, different 
applied decision-making criteria filtered out of the literature review results were 
tested on their relevance and importance for drug funding decision-making in 
German hospitals. In a parallel step, the strengths of qualitative research methods 
were utilized to deepen the achieved knowledge of the literature review as well as to 
broaden the understanding of specific parts of the overall drug funding decision-
making process. For example, in the quantitative survey part a few questions 
generally tried to clarify the power level of specific hospital formulary committee 
members and the potential impact of this on the final decision-making. Due to the 
limitation of surveys to gather deep knowledge on this complex relationship 
structure, the qualitative interview part was used to improve the understanding on 
this specific subject. Here it was possible to ask why and how questions and to 
challenge answers taken out of the survey part or given directly by interview 
partners.  
 
Before, it was mentioned that using a mixed-methods approach does not only need 
justification in terms of the methodological sense but it also needs support by the 
applied research philosophy. In this case, it was clearly outlined that a mixed-
methods approach makes sense due to the different strengths and weaknesses of 
quantitative and qualitative research methods which were utilized to best address the 
research questions. The overall research goal, to improve the understanding of the 
drug funding decision-making process in German hospital formularies, can best be 
achieved by trying to interpret the observable events in the empirical domain and 
then to design a framework which shows as best as possible the underlying structures 
and mechanisms in the real domain. The aim is not to predict decision outcomes 
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(positivism) or just to understand the individual beliefs of decision-makers 
(constructivism), but the goal was to enhance the understanding of the decision-
making process in order to allow stakeholders to better understand their own process, 
compare it to processes of other hospitals and to identify opportunities for 
improvement. 
 
Despite the advantages of critical realism as the underlying philosophy of this 
research it is important to reflect on potential disadvantages. For example, 
retroduction can lead to different results since underlying structures or mechanisms 
can never be observed directly and the interpretation is dependent on the researcher. 
Hence, it is crucial to be as transparent as possible in the way retroduction is 
conducted. Additionally, if two different generative mechanisms in the real domain 
create a similar event in the (observable) empirical domain, the interpretation of such 
results can lead to false conclusions (Zachariadis et al., 2013). This context 
dependency of events and the potential fallibility in the interpretation of events is 
always part of critical realism. Another example is the use of quantitative and 
qualitative research methods which is generally supported by critical realism. If the 
different methods lead to divergent outcomes, the interpretation of the results can be 
different (Creswell, 2003; Easterby-Smith, et al., 2008).  
The last sections have explained in detail why critical realism as the underlying 
research philosophy is appropriate and that the preliminary framework derived from 
the literature review is part of the critical realist approach. This framework allows a 
tentative examination of the actual and real domains, which is then adjusted 
according to additional or contradictory data from this research. Furthermore, it has 
been shown that a mixed-methods approach in combination with triangulation 
methods had the greatest potential to be a valuable addition to existing research. 
Following a more detailed explanation on mixed-methods design and triangulation, 
the next sections will define the implementation of the research design. 
  
3.4 Mixed methods 
The literature review has shown that healthcare decision-making is dependent on a 
variety of criteria and that it can be very subjective, depending on the individual set 
of decision criteria (Barasa et al., 2014; Eddama & Coast, 2008; Koopmanschap et 
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al., 2010; Niezen et al., 2009). It is likely to be different for the different decision 
levels in a healthcare system. For example, a national decision-maker in a 
governmental health technology assessment (HTA) institution might look very 
closely on health economic cost-effectiveness whereas a hospital pharmacist on a 
local hospital level is likely to primarily consider the impact of the pharmaceutical 
drug on his budget. This research is focusing only on decision-making in hospital 
formularies. Conversely, based on the literature review results it is also reasonable to 
assume that there is a variance of applied decision-making criteria, individual sets of 
decision criteria and individual power dynamics dependent on the respective hospital 
formulary. 
 
The individual sets of decision criteria and the variety of involved stakeholders 
favour a flexible research approach. In order to better understand the decision-
making process it is crucial to look at it from different perspectives because of the 
different decision criteria applied and the different stakeholders involved in the 
process. From the author’s perspective and philosophical point of view (see section 
3.3), only this approach makes it possible to get closer to the underlying objects and 
generative mechanisms which explain the decision-making process. This implicitly 
recommends a convergent parallel mixed-methods design, which enables the 
researcher to gather more than just one perspective on the same phenomena 
(Creswell, 2003; Easterby-Smith, Thorpe & Jackson, 2008). In spite of the 
advantages of a mixed-methods approach, the use of mixed methods is also 
considered controversial due to the risk of contradictory results making it difficult to 
reach a conclusion (Easterby-Smith et al., 2008). The author disagrees regarding the 
negative connotation with contradictory results. In contrary, contradictory results 
make it possible to identify new topics or themes which might have been unseen 
when using only one research method. Additionally, the use of a mixed-methods 
approach enables possibilities to increase validity through data triangulation or 
methodological triangulation (see section 3.5) 
 
A mixed-methods approach can also be a challenge from a research philosophy point 
of view. 
Bryman and Bell (2007) stated that qualitative and quantitative methods are based on 
different epistemological positions, meaning different perspectives on how to acquire 
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knowledge about the phenomena being researched. Therefore the research 
philosophy must fit to the concept of a mixed-methods approach (see section 3.3). 
 
Mixed-methods research is not necessarily the better research approach leading to 
better outcomes and it is subject to the same limitations as mono-method research. If 
it is appropriate to use and done properly, it has the potential for the researcher to 
enable access to difficult research areas, to provide a better understanding of 
phenomena compared to mono-method research and might improve validity when 
triangulation is used (Bryman & Bell, 2007; Creswell, 2003). 
 
This research uses a mixed-methods design for the following reasons: 
1. Complementarity: Mixed-methods can be used to get complimentary 
information on the phenomenon under observation (Creswell, 2003; 
Zachariadis et al., 2013). Different perceptions of the real domain improve 
the understanding of the underlying objects and generative mechanisms.  
2. Compensation: A weakness of one research method can be compensated by 
other research methods (Zachariadis et al., 2013). Critical realists recognize 
the difference in strengths and weaknesses of quantitative and qualitative 
research methods. The use of different methods to compensate this is 
accepted (Zachariadis et al., 2013). 
3. Diversity: Divergent views of one phenomenon can improve the research 
outcomes. Again, different views of the real domain improve the 
understanding of the underlying objects and generative mechanisms 
(Zachariadis et al., 2013). 
 
For this research, especially considering the varying results of former research on 
this topic, a convergent parallel mixed-methods design is appropriate and a valuable 
addition to the mono-methods approaches done in the past as it is a new approach to 
understand hospital formulary decision-making. 
 
3.5 Triangulation 
The decision to use a convergent parallel mixed-methods research design was based 
on two main reasons: the chances of getting better access to the research area and the 
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belief that a combination of different research methods lead to a better understanding 
of the phenomena. For example, it was very difficult to find hospital formulary 
committee members who were willing to participate in an interview. Hence, the use 
of the online survey made it possible to gather more perceptions of the phenomena 
from different people. A third important reason was to take advantage of 
triangulation and hence the possibility of improving validity of the gathered data. 
 
Triangulation means “…using more than one method or source of data in the study 
of social phenomena” (Bryman & Bell, 2007, p.412). Two different types of 
triangulation were important for this research: data triangulation and methodological 
triangulation. Looking for different perspectives of different decision-makers can be 
referred to as data triangulation and using different research methods can be referred 
to as methodological triangulation according to Denzin (1970).  
 
Data triangulation helped to strengthen the validity of data. This was done by asking 
different decision-makers in the hospital formulary (decision-makers with different 
functions and from different hospitals) to provide information on the research topic. 
Thus, different perspectives about the same phenomena were collected. In cases of 
diverse information from different decision-makers, it was possible to identify areas 
of interest which were not covered by the literature review. Those areas were 
considered in more detail in the further process.  
 
Three main goals are formulated for methodological triangulation:  
1. Confirmation: Different methods will be applied to improve the reliability of 
the findings, thus limiting individual bias of each method (McEvoy & 
Richards, 2006). In this research some questions in the quantitative part were 
validated (confirmed) by questions in the qualitative part (e.g. questions on 
the influence level of different formulary committee members).  
2. Completeness: Using different methods will result in a higher level of detail 
as different methods have slightly different perspectives (McEvoy & 
Richards, 2006). Some information on the drug funding decision-making 
process is hardly measurable by quantitative research methods whereas some 
information can be easily collected. This is for example the case with 
relationships between the different hospital formulary members, which could 
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be easier explored by using qualitative research methods, such as expert 
interviews. In contrast, the importance of different decision-making criteria 
could be well captured by quantitative research methods. 
3. Abductive inspiration or retroduction: Using different methods also gains 
a much deeper understanding of the phenomenon and the underlying causal 
mechanisms (McEvoy & Richards, 2006).  
 
Retroduction is the logical key concept for critical realism (McEvoy & Richards, 
2006) as it fits perfectly well to the idea of interpreting observable experience to 
explain the underlying structures and mechanisms of the real domain. In this 
research, a survey and interviews were used to let hospital formulary committee 
members describe parts of their decision behaviour. Those descriptions represent 
events triggered by the generative mechanisms of the real domain. And they can 
only be captured in the empirical domain, which is the observable subset of the 
actual domain (Zachariadis et al., 2013). Using retroduction, those descriptions were 
used to conduct an interpretation of the underlying mechanisms of the real domain 
(here: the decision process, the objectives of decision-makers, the power 
relationships between decision-makers and the decision criteria).  
 
Retroduction is also compatible with the explanatory focus of critical realist research 
work. The confirmation goal of triangulation makes also sense for critical realists as 
they assume one social reality which exists independent of the mind. Therefore 
different observations can be used to challenge each other in regards to the best 
explanation of the structures and mechanisms of the real domain which have caused 
them. Finally, the completeness goal of triangulation is compatible with a critical 
realist research philosophy. Different research methods (quantitative or qualitative) 
can result in different insights on the same reality which can be utilized to improve 
the interpretations of the real domain. Thus, the use of triangulation methods is 
generally supported by critical realism as the underlying philosophy for this research.  
 
This research used quantitative methods (expert survey) and qualitative methods 
(expert interviews, company market research data) to collect information on the same 
phenomena but with a different focus to gain complementary perspectives. 
Quantitative methods were used to collect: 
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 General information on the hospital formulary decision-making process  
 General information on the structure of the formulary committee  
 The different members of the formulary committee  
 Influence of the different committee members on decision-making 
 Applied decision criteria.  
 
In order to deepen those insights and to get in-depth information on formulary 
committee member’s roles, influence and motives as well as the relative importance 
of decision criteria, additional qualitative research methods were used. According to 
the convergent parallel mixed-methods design, both research methods were used in 
parallel (Creswell, 2003).  
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4 Research methods and methodology 
 
 
 
Figure 19: Convergent parallel database variant mixed-methods design. 
 
 
Figure 19 shows the overall research process which consists of eight main activities 
with step 2, 3 and 4 being conducted partly in parallel and independent from each 
other. These activities are described in detail in the following: 
 
4.1 Literature review (step 1) 
The literature review consisted of a three-step systematic review. As a first step, 
hospital formulary decision-making was investigated, followed by a review of 
healthcare decision making. The latter offered a broader view as it included other 
decision making levels. Finally, general decision making was addressed to identify 
basic theories and models relevant for the specific questions of the thesis. 
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In total the results of the literature review built the basis for creating a research 
framework, combining some of the general decision-making models with the specific 
results of hospital formulary committee decision-making (see Figure 16).  
4.2 Hospital online survey (step 2) 
The second step was a web-based survey (see full survey in Appendix 3) using the 
service provider SurveyMonkey (http://de.surveymonkey.com). This survey was 
created to identify the basic structures of hospital formularies (e.g. number of 
participants, frequency of meetings) and to elicit which functions are represented in 
the committee (e.g. physicians, pharmacists, nurses). In addition the survey asked 
respondents to rate the importance of different decision criteria (identified in step 1 
in the literature review) on a Likert scale and to add and rate additional applicable 
criteria. The survey also included questions in regards to the perceived influence of 
different members of the group on the decision process. All questions were 
formulated based on the literature review results with the intention to answer 
research questions RQ-1 to RQ-4, but primarily RQ-1 and RQ-2. This means that the 
survey aimed to add knowledge to the structures of decision-making, such as the 
importance of each group of the hospital formulary committee. Furthermore, the 
survey addressed the use and the importance of decision criteria applied in step one 
of the dual processing system of the hospital formulary decision-making framework 
(Figure 16).  
 
A cover letter (see Appendix 4) introduced the research project and provided the 
required hyperlink to the SurveyMonkey project website. The research rationales as 
well as the research questions were described. This was sent via email to the 
hospitals in the sample addressing the Head of the Hospital Formulary or other 
members of the hospital formulary. In order to improve the response rate, all 
hospitals in the sample were reminded twice to complete the survey. The reminder 
was sent by email after eight and twelve weeks. In many cases the hospitals 
responded by refusing participation due to three main reasons (in the order of most 
received):  
1. Participation not possible because of limited time 
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2. Participation not possible because the hospital generally does not participate 
in surveys 
3. Participation not possible because the area of interest is a confidential, 
hospital internal area 
 
In those cases, hospitals were marked in the overall sampling and no reminders were 
sent. 
Before the survey was fielded, it was piloted with two hospital formulary committee 
members. Those committee members were first asked to fill out the online survey 
and then to have a follow-up discussion. During this follow-up discussion the 
committee members were asked to provide general feedback on different aspects of 
the online survey. For example, they were asked if the wording used in the survey 
was understandable, if questions seem to be relevant to them, if answer alternatives 
were missing, how long they needed to complete the survey and if the required time 
was appropriate and feasible in a normal working environment of a hospital 
formulary committee member. The feedback was mostly positive and only some 
minor adjustments were done. The most significant change was adding the group of 
financial administrators (=accountants in other countries) to the answering options of 
some questions. The required time indicated was around 30 minutes and just at the 
maximum of what seemed to be acceptable for the two committee members.  
 
Online surveys have advantages, such as faster response, attractive formats and fewer 
unanswered questions (Bryman & Bell, 2007, Easterby-Smith et al., 2008). But they 
also can have disadvantages, such as anonymity issues, multiple replies or they are 
restricted to an online population (Bryman & Bell, 2007). By using SurveyMonkey, 
possible anonymity issues were not a problem, because respondents were only 
identified by a unique numerical identifier. This identifier ensured that only one 
questionnaire was submitted from this address, but at the same time the numerical 
identifier did not allow a direct identification of the real name or address. In this way, 
the risk of multiple replies was also reduced.  The restriction to an online population 
was not seen as an issue for this research, since (mostly) all hospitals have access to 
the internet. At least, all hospitals of the sampling frame had an email address. 
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4.3 Survey sampling 
As said before, the survey had the primary goal to identify basic structures of 
hospital formularies in Germany. Hence, the inclusion criteria for the survey were 
very broad. In 2013, Germany had 1,996 hospitals (Statistisches Bundesamt, 2013).  
 
Based on the results of the literature review, pre-discussions with the two hospital 
formulary committee members and the professional experience of the author, the 
following inclusion and exclusion criteria for the survey sampling were determined: 
Criteria Inclusion Exclusion 
Number of beds >= 300 beds < 300 beds 
Type of institution Private, public, ecclesial none 
 
Table 6: Inclusion and exclusion criteria for the survey sampling. 
 
Number of beds 
In Germany, the average hospital had 181 beds (Statistisches Bundesamt, 2013), with 
big university hospitals often having more than 1,000 beds. Table 7 shows a detailed 
breakdown of number of hospital beds in Germany. 
 
Number of beds  
Hospitals with  <  50 beds............   377 
Hospitals with  <  100 beds  .........   256 
Hospitals with  <  150 beds ..........   250 
Hospitals with  <  200 beds ..........   182 
Hospitals with  <  300 beds ..........   273 
Hospitals with  <  400 beds...........   200 
Hospitals with  <  500 beds...........   137 
Hospitals with  <  600 beds...........   92 
Hospitals with  <  800 beds ..........   75 
Hospitals with  >  800 beds...........   94 
Ownership  
Public hospitals...........................   596 
Free/Ecclesial hospitals...............   706 
Private hospitals..........................   694 
Total   1,996 
 
Table 7: Hospital size and ownership structure. 
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For the purpose of this research, the minimum number of hospital beds was 300. If 
hospitals have less than 300 beds the two pilot formulary committee members felt a 
risk of analysing hospitals which are too specialised. Bigger hospitals include these 
specialist functions, but provide a broader basis of additional functions. Having this 
in mind, there would have been a risk of a big variance of different drug funding 
decision-making processes derived only from this special group of very small 
hospitals, which are usually organised differently. For example, one major 
consideration is that small hospitals often do not have a formulary committee. On the 
other hand, the survey should include also very big hospitals. They usually all have a 
hospital formulary committee and the size of a hospital was a potential variable with 
impact on the drug funding decision-making which should be tested. 
 
Type of institution 
The sample was not limited in regards to the type of institution. Three main types of 
institutional ownership exist in Germany: public, private, ecclesial. A hospital can be 
either owned by a city or state, which is called a public hospital or by a company, a 
company group or a financial institution, which is called a private hospital. Finally, 
the church can be owner of a hospital, which is called an ecclesial hospital. Usually 
unrestricted access to all hospital types exists as long as patients are insured by one 
of the many health insurance companies. Such insurance is compulsory. For this 
research, there was no limitation in terms of these different ownership structures. To 
the contrary, there was a potential value in including these different types of 
institutions, since they could be a variable impacting the decision-making. It was 
reasonable to assume that, in regards to drug funding, a hospital with private 
ownership might have different goals compared to a hospital with an ecclesial 
ownership. Privately owned hospitals are owned by private investors with the 
profitability goals. Additionally they are often listed at the stock exchange which 
increases the pressure on their return on investment. Hence, those hospitals 
potentially have a strong economic focus due to their ownership status. 
 
The sample was created through self-selected non-probability sampling as the main 
purpose was exploration (Saunders, Lewis & Thornhill, 2009). This means that 
hospitals were selected from a complete list of all German hospitals (Rombach 
Druck- und Verlagshaus GmbH & Co. KG: Deutsches Krankenhaus Adressbuch 
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(DKA) 2012) who fulfilled the inclusion criteria for the study. The DKA is a publicly 
available, paid address book of all hospitals including information on the number of 
beds and the type of institution. It is updated every year. For the survey the DKA 
2012 was used. The sampling frame for the survey included 598 hospitals which 
were contacted and asked via email to participate in the survey. 
 
4.4 Expert interviews (step 3) 
The expert interviews were semi-structured and based on the outcomes of the 
literature review.  They followed three main goals of which the first and second ones 
were more explanatory and the third was more exploratory: 
1. To gain a deeper understanding of the use of decision criteria and their 
relative importance.  
2. To gain a deeper understanding of the influence of different formulary 
committee members and the respective impact on the final decision-making. 
This addressed the group decision-making process in step two of the hospital 
decision-making framework (Figure 16).  
3. To identify additional topics or issues which have not been considered as a 
result of the literature review and which are relevant for the research 
objectives RO-1 to RO-6. 
 
Depending on the specific research goals a structured, semi-structured or 
unstructured interview type is favourable. Because of the mix of explanatory and 
exploratory goals the semi-structured interview was considered to be the most 
appropriate (Saunders et al., 2009). In contrast to pure quantitative research methods, 
such as a survey, semi-structured interviews are also capable of describing and 
explaining complex, social phenomena (Sayer, 2000). Thus, they have a central role 
for critical realist research on decision-making, because of their ability to describe 
and explain the multifaceted generative mechanisms of the real domain (Zachariadis 
et al., 2013).  
 
All questions were put into an interview guide, which was used to steer the interview 
but provided enough flexibility in terms of the more explorative information 
(Bryman & Bell, 2007). Especially in cases, where new themes or topics which were 
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relevant for the research objectives occurred, the interviewer tried to explore those 
specific issues. 
The interview guide was then tested in two pilot interviews and the respondents of 
these two pilot interviews were asked questions about: 
 the structure of the interview,  
 the comprehensibility of the questions,  
 the detail level of the questions and  
 the length of the interview. 
 
According to the pilot interviewees, only physicians and pharmacists really have the 
power to influence drug funding decisions. In contrast, the literature review showed 
that other groups, such as general managers of hospitals or financial administrators 
can influence decision-making. Thus, challenging questions to verify this expert 
opinion were added to the expert interview guide. Except for this change the 
feedback was positive and no additional adaptations to the interview guide were 
recommended. There were only concerns about the length of the interview. The 
original interview length was something between 45 minutes and one hour. Both 
pilot interviewees raised the concern that this will be too long and that it would be 
difficult to get respondents for the interviews without payment. Based on this 
feedback the interview guide was streamlined and some questions regarding the 
structure of the formulary committee, which were also part of the online survey, were 
removed. The final interview length was then estimated to be between 30 and 40 
minutes. This change was seen as acceptable from the two pilot interviewees. 
 
The general interview structure and the content of the separate sections are shown in 
following (the complete interview guide can be found in Appendix 5): 
 
Introduction 
The research project was shortly described as well as the general process of the 
expert interviews.  
Decision-making process 
This part included questions and discussions on the decision-making process, the 
type of decision-making, time related issues around decision-making and the 
transparency of the process. 
Decision-making criteria 
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The following part included questions and discussions on the applied decision-
making criteria. The focus on this part was the use of subjective decision criteria, 
such as experience or gut feeling. Other questions were related to difficult decision 
situations or the reason why different decision criteria are used. 
Group decision-making 
Following this, questions and discussions primarily focused on the topic of decision-
making in interaction with other formulary committee members. The influence of 
formulary committee member’s opinions on the decision-making behaviour of the 
interviewee as well as the level of influence and power of specific hospital formulary 
committee members were discussed here. 
External influence and closing 
The interview closed with questions on possible external factors which influence the 
decision-making behaviour of the formulary committee.   
 
As discussed earlier, this interview guide had the aim of providing a framework for 
each interview and did not limit the possibilities of the interviewer to freely explore 
interesting themes or topics. Usually some questions of the interview guide were 
used to open the discussion. Following this, the interview often developed into a 
discussion where the interviewer followed up on answers or asked specific questions 
which investigated the answer of the interviewee. If the specific discussion seemed to 
be finished, the interviewer returned to the interview guide and used another of the 
interview guide questions. 
 
The initial contact with all interview participants was done by email. For this purpose 
a cover letter was developed which shortly introduced the author and the research 
project. The research goals were explained and a bigger section referred to 
confidentiality in order to reassure confidence in the project. If there was a positive 
answer on the participation, one telephone call was conducted in advance to enable 
the potential participant to clarify questions which were not addressed by the cover 
letter. For example, some interviewees wanted a verbal confirmation about the 
anonymity of the interviews. This pre-call was also used by the author to talk shortly 
about the way the interviewee was selected, as this was in all cases someone from the 
professional network of the author. Specifically in cases where the author did not 
know the interview partner personally, this pre-call discussion about the referring 
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contact was helpful to build up trust (Polit & Beck, 2004). Besides the possibility of 
asking organisational questions, the main purpose of this pre-call was the 
arrangement of a potential date and time for the interview. 
 
Most of the interviews were conducted by telephone. One pilot interview was done 
in person at the hospital. Since literature generally recommends conducting non-
standardised interviews face-to-face (Bryman & Bell, 2007; Saunders et al., 2009), 
the reasons for doing this by telephone are explained in the following. The main 
reason why telephone interviews were chosen was based on the recommendation of 
both pilot interviewees. They argued that a physician or a hospital pharmacist has 
limited time and as such a telephone interview would be easier to conduct then face-
to-face interviews. 
Another point was the perceived anonymity of a telephone call. They felt more 
comfortable answering questions about a sensitive topic like decision-making if 
asked on the telephone.  
 
Considerable planning flexibility was requested by the respondents. Both 
pharmacists and physicians had challenges to determine a fixed interview time due to 
their hospital duties and patient emergency cases which of course had priority. For 
example, four interviews were cancelled on one day and rescheduled. One interview 
was postponed three times on short-notice due to emergency cases. Having in mind 
that the interviewees were spread across Germany, this made it operationally 
impossible to conduct most of the interviews face-to-face. 
 
4.5 Interviewee sampling 
The sampling was a non-probability, heterogeneous approach, done by screening of 
existing professional networks, followed by the use of the snowball-technique to find 
additional experts. Experts here mean hospital employees with medical, economic or 
other special knowledge about the topic of listing of drugs to the hospital formulary. 
In addition they should be active or former members of a hospital formulary 
committee. This sampling approach is appropriate to use if access to the area of 
interest is difficult to achieve or the identification of the right cases is difficult 
(Babbie, 2008; Saunders et al., 2009). Experts from public professional networks, 
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such as Xing (http://www.xing.de) or LinkedIn (http://www.linkedin.com), were 
asked for their interest in participation or if they knew someone else who potentially 
could be interested. Considering the low level of response to this request, it was clear 
that access to those experts is challenging. Thus, the professional network of the 
author was used to identify interested interview partners. If interview partners were 
identified, they were asked if they knew additional experts who could be interested.   
After discussions with the two pilot interviewees, three main groups of respondents 
were identified, who seemed to have the greatest potential of providing valuable 
input to this research: 
1. Medium non-private (public or ecclesial) hospitals with 300-800 beds, due to 
their potential variety of functional departments and thus their variety of 
members in the hospital formulary. 
2. Large non-private (public or ecclesial) hospitals with more than 800 beds, 
including university hospitals and their potential focus on scientific goals. 
3. Private hospitals with more than 300 beds, due to a potential stronger focus 
on economic measures. 
 
According to studies about hospital formulary committees (Armstrong et al., 2008; 
Späth et al., 2003) two sub-groups with potentially different interests are important to 
answer the research questions: pharmacists and physicians. This was also confirmed 
by the preliminary analysis of the online survey, where pharmacists and physicians 
were the only groups with impact on decision-making and the feedback from the 
pilot interviewees. The minimum requirements were that all participants should be 
involved in drug funding decision-making in formulary committees. This concluded 
in a sample of six experts, two different functions in each of the three main groups of 
hospitals (medium non-private, large non-private, private).  
 
Owing to the central role of pharmacists in the hospital formulary and that physicians 
have the highest representation in the hospital formulary, the initial sample was 
extended to one additional expert per main group, either pharmacist or physician. 
Thus, the final sample for the expert interviews consisted of nine experts which are 
shown in the following table: 
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Interview Respondent 
Code 
Function Chair Hospital 
size  
(approx. 
number of 
beds) 
Type of 
institution 
(ownership) 
Main 
group  
1 B1 Physician No 580 Ecclesial Medium 
non-private 
2 B2 Pharmacist  Yes 1,700 Public Large non-
private 
3 B3 Pharmacist  Yes 570 Private Private 
4 B4 Pharmacist  Yes 1,100 Public Large non-
private 
5 B5 Pharmacist Yes 1,400 Public Large non-
private 
6 B6 Pharmacist  Yes 380 Ecclesial Medium 
non-private 
7 B7 Pharmacist  No 1,100 Public Large non-
private 
8 B8 Physician No 1,400 Public Large non-
private 
9 B9 Pharmacist  Yes 990 Ecclesial Large non-
private 
 
Table 8: Expert interview sample. 
 
 
 
The table also shows that one physician for a private hospital is missing and it was 
not possible to get one additional interviewee from a private hospital (neither 
physician, nor pharmacist). The researcher then decided to add another interviewee 
from a public hospital who is not the chair of the hospital formulary committee.  
 
4.6 Market research interviews (step 4) 
In addition to the expert interviews, the researcher was able to achieve access to an 
additional source of information. Market research interviews on a company drug 
product, conducted with 32 pharmacists, physicians and nurses for a pharmaceutical 
company during two months in 2013, covered the hospital formulary decision-
making process. 
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The researcher was allowed to use the interview raw data and to extract the specific 
information on the researcher’s questions regarding hospital formulary decision-
making. 
This fitted well into the mixed methods approach and added additional perspectives 
to the difficult-to-gather information on hospital formulary decision-making. 
 
Physicians and nurses were separately interviewed in small groups in a studio of the 
market research company. Every physician and every nurse worked in a different 
hospital. Two group interviews with nurses and four group interviews with 
physicians were conducted. Pharmacists, often chairs of a hospital formulary 
committee and therefore in an exposed position, were interviewed in single 
interviews. Two interviews were done by telephone and six in a studio of the market 
research company. Every pharmacist worked in a different hospital. 
 
The following table summarizes the participant structure of the market research 
interviews conducted in a studio and by telephone. Information on the size or the 
ownership of the hospital was not given: 
Role City 1 City 2 City 3 City 4 Sum Type 
Physicians 4 4 4 4 16 Group 
Nurses 4 - 4 - 8 Group 
Pharmacists - 2 2 2 6 Single 
Pharmacists 1 1 - - 2 Single/Tel. 
Sum 9 7 10 6 32  
 
Table 9: Participant structure (Market research studio interviews). 
 
 
 
The transcribed data did not include code names and respondent’s answers were just 
indented. Hence, the researcher assigned code names to allow identification of the 
different functional groups in the analysis. The following code names were used 
(Table 10): 
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Interview Respondent 
Code 
Type of interview 
1 PG1 Physician Group Interview 1 
2 PG2 Physician Group Interview 2 
3 PG3 Physician Group Interview 3 
4 PG4 Physician Group Interview 4 
5 NG1 Nurse Group Interview 1 
6 NG2 Nurse Group Interview 2 
7 P1 Pharmacist Interview 1 
8 P2 Pharmacist Interview 2 
9 P3 Pharmacist Interview 3 
10 P4 Pharmacist Interview 4 
11 P5 Pharmacist Interview 5 
12 P6 Pharmacist Interview 6 
13 P7 Pharmacist Interview 7 
14 P8 Pharmacist Interview 8 
 
Table 10: Code names for company market research interviews. 
 
 
The market research interviews were conducted with the aim to gain information on 
the procurement process of a specific pharmaceutical product and the general process 
of decision-making in hospital formulary committees. Thus, the market research 
inclusion criteria were determined to consider those two aims and the participants 
were selected narrower than the inclusion criteria envisioned for the expert 
interviews of this research. However, the researcher considered that this limitation 
does not reduce the value of the given information but with the objective of being 
transparent, all inclusion criteria will be shown in Table 11. 
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Physicians Nurses Pharmacists 
Head physician, in total 
30% should be members 
of the formulary 
committee 
 Head pharmacist and 
member of the hospital 
formulary committee for 
at least two years 
Balanced mix of operating 
theatre, intensive care and 
emergency care 
Balanced mix of operating 
theatre, anaesthesia and 
intensive care 
 
Decision-maker for 
product x 
Experienced users of 
product x 
Procurement and supply of 
product x 
> ten applications of 
product x per year 
> ten applications of 
product x per year 
> five supplies of product 
x in the last six months  
Six anaesthetists with 
focus on heart surgeries 
  
 
Table 11: Inclusion criteria for market research interviews. 
 
 
There are limitations with this data. The market research interviews had broad 
objectives and hospital formulary decision-making was a specific topic for part of the 
interviews. Hence, the data is less detailed compared to the expert interview data. 
The market research interviewer wanted to better understand the decision-making 
process, but did not try to identify the underlying mechanisms. Hence, the data is not 
as rich in regards to information as the expert interview data, but provides supportive 
information. 
 
In addition, it is not clear which type of hospitals (size or ownership) the respondents 
were located at.  
 
4.7 Transcript strategy 
In order to analyse the expert interviews, the interviews were recorded on a digital 
recording device and then all data was transcribed. The following main transcript 
rules of Kuckartz, Dresing, Rädiker and Stefer (2010) were applied: 
 
1. The interviews were transcribed literally and were not summarized.  
2. Language and punctuation was slightly flattened to adapt to written German. 
For example, “This won’t help” would be transcribed as “This will not help” 
or in German: “Er hatte noch so‘n Buch genannt“ would be transcribed as “Er 
hatte noch so ein Buch genannt“. 
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3. Longer breaks (approximately breaks longer than 3 seconds) were marked 
with (…). 
4. Vocalisations like „mhm“ or „aha“ were not transcribed. Vocalisations like 
laughing or sighing were noted down in brackets. 
5. The input of the interviewer was displayed as “I” whereas the input of the 
interview respondent was displayed as “B”. The number of the interview was 
added behind the “B”. For example, for interview number 5, the input of the 
interview respondent was displayed as “B5”. 
6. Each change between interviewer and interview respondent was shown in a 
new paragraph. 
 
As indicated before, the interview data from the market research project was already 
transcribed when the author received it.  
 
A sample transcript of the expert interviews can be found in Appendix 6. 
 
 
4.8 Validity and reliability 
Validity deals with the question if the data which is captured and used for analysis is 
representative of what one wants to look at (Bryman & Bell, 2007; Collis & Hussey, 
2003).  
Quantitative researchers use different definitions for validity than qualitative 
researchers. In quantitative research, validity has three main categories: design 
validity, measurement validity and inferential validity (Zachariadis et al., 2013). 
Reliability describes the possibility of someone else being able to repeat this research 
and getting similar results (Bryman & Bell, 2007; Collis & Hussey, 2003). Validity 
and reliability are the main concepts for quantitative research. Qualitative researchers 
use different aspects for validity and reliability, such as trustworthiness, authenticity 
and credibility in order to increase the quality of a research study (Creswell & Miller, 
2000; Golafshani, 2003; Porter, 2007).  
In a convergent parallel mixed-methods design, which is the applied method for this 
thesis, validity should be considered separately for the quantitative data and the 
qualitative data (Creswell, 2003).  
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4.8.1 Validity and reliability of the (quantitative) online survey 
Face validity is the minimum level of measurement validity for a quantitative 
research project. It can be achieved if experts with experience in a specific topic 
confirm the appropriateness of the research approach and the data sources (Bryman 
& Bell, 2007). As described in chapter 4, the online survey was tested with two 
experienced hospital formulary committee members in order to achieve face validity. 
In addition, a healthcare professional with more than 20 years of experience, who is a 
Sales Director at a pharmaceutical company and who is responsible for drug funding 
negotiations with hospitals had been asked to assess the online survey (and also the 
interview guide for the expert interviews). He reviewed both and confirmed that 
those measures are appropriate to answer research questions RQ1-RQ4 and research 
objectives RO1-RO6. Therefore face validity has been achieved.    
 
Pure quantitative research often tries to achieve generalisability or design validity 
(Bryman & Bell, 2006; Zachariadis et al., 2013). In critical realist research this is 
problematic (Johnston & Smith, 2010; Zachariadis et al., 2013). Empirical events are 
observable traces of events in the actual domain which are derived from mechanisms 
in a specific context. External validity then assumes that similar relationships 
between events in the empirical domain can appear under completely different 
circumstances. From a critical realist view this is not impossible, but cannot be 
concluded from the observed empirical events. Similar events in the empirical 
domain can occur with similar or completely different generative mechanisms in the 
real domain. Hence, there is no causal relation between two similar events in the 
empirical domain and two similar generative mechanisms in the real domain 
(Zachariadis et al., 2013) 
 
Reliability is a concept which is not applicable from a critical realist perspective. 
Owing to the critical realist assumption that every perception is fallible, different 
research could come up with different results. However, also these results are fallible 
and thus it is desirable from a critical realist perspective to collect as many 
perceptions as possible in order to continuously improve the understanding of the 
generative mechanisms of a phenomenon. 
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4.8.2 Trustworthiness, authenticity and credibility for the 
(qualitative) interviews 
Qualitative researchers have also measurements to prove credibility of their findings. 
Trustworthiness, authenticity and credibility should help to determine if findings of a 
qualitative study are “accurate from the standpoint of the researcher, the participant, 
or the readers of an account” (Creswell, 2003). Multiple methods can be used to 
ensure the quality of findings and it is recommended to use multiple approaches 
(Creswell, 2003). In this thesis the following methods were applied: triangulation, 
rich description, reflexivity and comprehensive data presentation: 
 
Triangulation 
The main concept applied is data triangulation as described in detail in the sections 
before. Using different sources of data, helped to increase the validity of this 
research. Thus, the sample selection for the expert interviews was crucial. Hospital 
formulary committee members with different perspectives and goals, such as 
pharmacists and physicians, were selected for the interviews. In addition, 
representatives from a variety of different hospital types (private, public, ecclesial) 
and sizes (380 beds –1,700 beds) were asked during the expert interviews to gain 
perspectives from as many different sources as possible. The data from the market 
research project additionally added different perspectives to allow triangulation. As a 
result, using these different sources to create the themes, led to an increased validity 
(Creswell, 2003). 
 
Rich description 
Results from the thematic analysis were presented with a rich description of the 
setting and the circumstances. Additionally, different perspectives were provided 
which created a more realistic picture of the findings (Creswell, 2003). 
 
Reflexivity (researcher’s bias) 
During the data analysis, the researcher provided additional explanations, how the 
interpretation of findings was influenced by the researcher’s background. Due to the 
fact that the author is a healthcare professional, reflexivity is crucial for credible 
research (Creswell, 2003). 
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Comprehensive data presentation 
Data was presented in a comprehensive way. This means that besides the regular 
themes, also discrepant information, which ran contrary to the regular themes, was 
exposed and discussed. For the reason that all perceptions are fallible, it is essential 
for the discussion to provide all evidence without any filters. Presenting more than 
just one perspective makes the findings more valid (Creswell, 2003). 
 
 
4.9 Time horizon 
This research is a cross-sectional study, as it is showing the process for drug funding 
decision-making (in Germany) at a specific time (Babbie, 2013). The research phase 
was conducted over a twelve months period. Hence, a cross-sectional analysis is a 
valid assessment for a point in time. This research does not focus on showing 
changes over time, which would be a longitudinal study design (Babbie, 2013). 
Practical experience also shows that changes in drug decision-making are not 
changing greatly in short time periods and often changes are over a longer term 
driven slowly by large changes in governmental policy. 
 
The expert interviews showed a variety of perceptions about the same phenomena. 
This is not only in line with the critical realist research design and data triangulation, 
but also one primary goal of cross-sectional research (Bryman & Bell, 2007). 
 
4.10  Data analysis 
4.10.1 Quantitative data analysis (step 5) 
An applied convergent parallel mixed methods design requires the separate analysis 
of the quantitative and qualitative data (Creswell, 2003). The researcher decided to 
focus on descriptive statistics for the analysis of the quantitative survey data for two 
reasons:  
Firstly, in critical realism, quantitative methods can be viewed as mainly descriptive 
due to their methodological inability to uncover the generative mechanisms of the 
real domain and to sufficiently explain complex social mechanisms, such as the 
decision-making process or the power relationships between formulary committee 
members (Sayer, 2000; Zachariadis et al., 2013).  
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Secondly, low willingness to participate in research on this sensible topic and to 
share insights on the internal process of hospital formulary decision-making reduced 
the statistical power of the survey data. Hence, the quantitative survey data is a 
limited, but still a valuable source of information to support the explanation of the 
underlying mechanisms in the real domain. It can help to identify structures (e.g. the 
structure of hospital formularies in German hospitals) and indicate the importance of 
applied decision-making criteria (Zachariadis et al., 2013). However, as standalone 
data it only becomes valuable in combination with other data sources, such as the 
qualitative expert interview data and the qualitative data from the market research 
study.  
 
4.10.2 Qualitative data analysis (step 6 and 7) 
For the reason that the expert interviews and the market research data derived from 
different data gathering steps, both data sets were first analysed separately. After that 
and according to the convergent parallel database variant of a mixed-methods design, 
both qualitative data sets, as well as the quantitative data set, were compared and 
discussed in the final discussion chapter.  
 
One qualitative data set was transcribed and the company market research data was 
already transcribed at the time of reception. Both were (separately) analysed with 
thematic network analysis (Attride-Stirling, 2001), a specific approach to conduct 
and structure a thematic analysis (Braun & Clarke, 2006; Miles & Huberman, 1994). 
The goals were to identify relevant topics or issues according to the research 
questions RQ1-RQ4 and the research objectives RO1-RO6. It was necessary to 
decide between an inductive thematic analysis which develops the themes purely 
from the interview data or a theoretical thematic analysis which works more 
deductively and uses questions and themes derived from the literature review for the 
coding procedure (Braun & Clarke, 2006). Because of the inability to observe objects 
and generative mechanisms in the real domain and the resulting risk of fallibility it 
did not make sense to use a pure inductive or a pure deductive approach. Hence, this 
research deductively used pre-developed themes from the literature review and the 
specific research questions, but during the coding procedure additional (new) themes 
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were allowed. Using this approach, the conclusions on the real domain from other 
research were considered and added to the perceptions from this research. 
 
Thematic network analysis consists of six main steps (Attride-Stirling, 2001) which 
were followed during the analysis: 
1. Code material: Codes represent the basic content of selected data, which are 
interesting for the phenomenon under research and which show potential 
themes (Attride-Stirling, 2001; Braun & Clarke, 2006). In this step, all 
transcripts were read and data clusters were built. First codes were generated 
to describe those data clusters. Eleven codes were derived from the literature 
review and the preliminary decision-making framework and two additional 
ones were identified during the coding process. 
2. Identify themes: In the next step, codes which described an overarching 
theme were cumulated into one group. Following this, the themes were 
refined to achieve a balance between being specific to avoid repetitions and 
being broad enough to compile different text segments which share a similar 
idea. For example, the coding procedure of the expert interviews led to 134 
different themes. 
3. Construct thematic networks: The themes defined in step two were re-named 
as basic themes and those which shared larger issues were clustered into 
organizing themes. Following this, different organizing themes which share a 
“claim, proposition, argument or assumption” (Attride-Stirling, 2001, p.393) 
were again clustered into global themes. The claim, proposition, argument or 
assumption was used as the name of the global theme which represents the 
“ideas mentioned at the lower level” (Attride-Stirling, 2001, p.393) orientated 
on the basic themes. This step was finished with the graphical “web-like” 
(Attride-Stirling, 2001, p.393) representation of the global, organizing and 
basic themes. 
4. Describe and explore thematic networks: This is a first step of the analysis 
and it includes the description of the thematic network as well as an 
exploration to identify patterns. The network was used as a guide to go 
through the original transcripts and to analyse the underlying ideas supported 
by the respective text segments. 
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5. Summarize thematic networks: Once the description and exploration of a 
thematic network was finished, the underlying patterns and ideas were 
summarized.       
6. Interpret patterns: This step combines the outcomes of the thematic network 
analysis with the research questions. Underlying pattern and ideas which 
were identified during step four and five were discussed in relation to the 
research questions RQ-1 to RQ-4. 
 
4.11 Discussion and conclusions (step 8) 
The final step of this research incorporated all data (literature review, the online 
survey, the expert interviews and the market research interviews) into a concluding 
analysis using data triangulation and methodological triangulation. This helped to 
confirm, adapt and extend the hospital formulary decision-making framework which 
was introduced in the literature review chapter. Retroduction was used to interpret 
the observable information from the empirical domain, captured with quantitative 
and qualitative research methods, with the aim to create propositions about the 
underlying structures and mechanisms of the real domain, such as the way step 1 and 
step 2 in the hospital drug funding decision-making framework (Figure 16) function.  
 
4.12 Ethics 
This section refers to the ethical considerations which accompanied this research. It 
follows the rules of the ethical code book of the University of Gloucestershire 
(University of Gloucestershire, 2008). Research ethics describe the way the 
researcher should behave in relation to the rights of the subjects of the research 
project or other people affected by the research (Saunders et al., 2009). Ethical issues 
can arise throughout the whole research process (Creswell, 2003). Accordingly, the 
researcher needs to address and discuss them. Four main areas of ethical principles 
are important to consider (Diener & Crandall, 1978): 
 
1. Harm to participants and privacy: It is the researcher’s responsibility to 
ensure that the collected data and the research does not harm or jeopardize the 
participants (Bryman & Bell, 2007, Creswell, 2003). A research project in a 
sensitive context like drug funding requires a high level of confidentiality. 
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Many hospital formulary committee members would not like to talk openly 
about their choice of decision criteria (Wirtz et al., 2005). Hence, it is the 
researcher’s responsibility to protect and respect participant’s privacy 
(Creswell, 2003). For example, the data presented in this thesis does not 
mention any hospital names to make it impossible for external people to trace 
back the information sources. 
 
All collected raw data from the expert interviews was safely stored on a 
password protected hard drive. Only the author had access to this hard drive. 
For the analysis, the data was only used in an anonymous way from the 
beginning. The different participants were coded without real names. For 
example, participant number one was coded with “B1”. This code was then 
used throughout the thesis. 
All raw data from the online survey was stored on the same hard drive. The 
online survey was already made anonymous during the data collection. 
Therefore it was not possible to connect one answer from the online survey to 
a specific person or hospital. As mentioned before, there was a possibility for 
the participants to receive a preliminary analysis of the online survey data as 
a reward for participation. In this case the participants needed to provide an 
email address. Although this email address could be any email address, this 
basically connects the answers of the online survey to one specific person. 
Thus, it was required to also save this raw data on a password protected drive.  
 
All raw data from the market research project was stored on the same hard 
drive. This data was already made anonymous when the author received the 
electronic files. Participants were coded without real names, similar to what 
has been done for the expert interviews. In addition, the author signed an 
agreement with the market research company, declaring that the author will 
only use the interview data for analysis connected to this thesis and that he 
will not try to decode the raw data to identify any of the participants.  
 
With this process, the author is the only one who could connect answers, 
either from the expert interviews or the online survey, with a concrete person. 
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All raw data will be deleted with a software tool which makes it impossible to 
recover, as soon as the thesis is fully accepted by the University.  
 
2. Informed consent: It is the researcher’s responsibility to be fully transparent 
towards the participants in terms of the purpose of the research, the 
participant’s role and its possible consequences (Sarantakos, 2005) and to 
allow participants to refuse participation (Creswell, 2003). The participants 
should not be deceived and they should be aware about their participation in a 
research study (Creswell, 2003). Participants were always informed about the 
research purpose in advance of data collection.  
 
The expert interviews which were part of this research involved participation 
of adult human experts. In advance of every expert interview, a cover letter 
with a description of the research project including a section on 
confidentiality has been sent to the participants. In addition, the author had a 
telephone call in advance of every expert interview to give the participant the 
possibility to ask additional questions. Lastly, right before every interview 
was conducted, the author again explained the purpose of this research, that 
the interview data will be transcribed and analysed for this purpose and asked 
the participant to confirm his consent with doing this interview. The 
interviews were only started if the participant clearly confirmed his/her 
consent which happened in all interviews. The author knows one of the 
participants personally. He has no relationships with any of the other 
interview partners. None of the interview partners were paid for doing the 
interviews, but there was an offer to all participants to receive some exclusive 
preliminary analysis from the online survey. Participants were required to 
provide an email address if they wanted to receive this data. 
 
Regarding the data from the market research project, the participants were 
already aware that their answers would be transcribed and analysed by the 
pharmaceutical company for market research purposes. The participants were 
also paid for their interviews and the interview transcript data was provided 
without any names to the author. Two written agreements were set up to 
clarify the use of the market research data for this thesis: one, between the 
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author and the market research company, which allows the author to use the 
interview transcripts for analysis in the context of this thesis and another one, 
between the author and the pharmaceutical company, which also allows the 
author to use the interview transcripts for analysis in the context of this thesis. 
Both agreements also regulated the appropriate use of the data and the 
anonymity of all participants. 
 
Regarding the data of the online survey, the email which was sent out to all 
hospitals in the sample, also described the research project and the use of the 
data for this thesis. With the participation in the online survey, people 
automatically agreed with the use of the data for this research. Participants of 
the online survey were not paid. 
 
4.13 Limitations 
It was already mentioned that face-to-face interviews were operationally less viable 
due to the geographic spread of the interviewees and also not recommended by the 
pilot interviewees due to concerns of losing interviewee’s willingness to provide in-
depth information on the decision-making process. Telephone interviews facilitate 
the collection of such sensitive data because they allow the interviewees to feel more 
comfortable because of the perceived anonymity (Hopper, 1992). In addition, there is 
little evidence that telephone interviews produce a lower quality data than face-to-
face interviews (Novick, 2008).  However, the focus on the pure interview wording 
without the consideration of any non-verbal factors, such as gesture and facial 
expression, can be seen as a limitation for this research (Fontana & Frey, 2005). 
Hence, for this research this can be seen as limitation although it is a minor issue. 
Generative mechanisms are identified by the researcher’s ability to link the data from 
the empirical domain to structures in the real domain which is independent of non-
verbal clues (Zachariadis et al., 2013). Another limiting aspect is the general 
interviewer bias (Saunders et al., 2009). An interviewer has an impact on the 
interview process, for example, the interviewer can ask questions using different 
accentuation, tone, gesture and mimic which could have an impact on interviewees 
and their responses. By using semi-structured interviews and an interview guide to 
minimize the bias, this risk was limited (Saunders et al., 2009). 
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Interviews were conducted in German language because this was the mother-tongue 
of all participants, but for the analysis, the (German) transcripts were translated into 
English. This resulted in quotes which were sometimes a bit convoluted. It was 
decided to translate as close as possible to the original German wording in order not 
to lose any language specific information.  
 
One potential limitation of this study is based on a result of this research. As 
described more in detail in section 6.4.1, some discussions happen already outside of 
the hospital formulary committee meeting which potentially impacts the decision-
making process. For example, this happens when a small group of people come to an 
agreement in advance based on these pre-meeting discussions. However, this is not 
always the case and the impact of these pre-discussions is also not fully clear.  
 
Lastly, all collected data is based on the different perceptions of people involved in 
the decision-making process and basically fallible. Triangulation should help to 
increase the chances of getting a more accurate representation of the generative 
mechanisms of the real, but also triangulation itself is fallible because it is based on 
assumptions and finally relies on the individual interpretation of the researcher. 
 
4.14 Summary 
This chapter presented the research strategy and research methodology utilized for 
this thesis. 
 
In the beginning, the main outcomes of the literature review were repeated and the 
knowledge gaps in existing literature were discussed in order to conclude with the 
research questions and research objectives. General concepts, such as mixed-methods 
research and triangulation were explained since they are basis for the applied 
research design. The research philosophy needs to match with the applied methods 
and methodologies. Critical realism fits with mixed-methods research as well as with 
triangulation and was elucidated before the concrete research design was discussed in 
detail. The different steps of this research, such as the online-survey, expert 
interviews or the market research interviews were described including the utilized 
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sampling approach. This chapter finished with some remarks on ethics and possible 
limitations of the adopted research design. 
 
The next chapter will describe the data analysis and discuss the results of the 
analysis. 
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5 Hospital survey data analysis 
5.1 Introduction 
The hospital survey data analysis represents step five in the research design (Figure 
20). According to the convergent parallel database mixed-methods design (Creswell, 
2003), the survey data is analysed separately in the first step and is then combined 
with the qualitative data in a second step to identify the mechanisms of the actual 
and the real domain. 
 
 
 
Figure 20: Hospital survey data analysis. 
 
 
The hospital survey was conducted to answer primarily RQ-1 and RQ-2 but also to 
provide explanatory ideas on RQ-3 and RQ-4. 
 
In total, 584 hospitals which fulfilled the inclusion criterion of more than 300 beds 
were asked to participate in the online survey. Out of these 584 hospitals, 47 filled 
out the online survey corresponding to an 8% response rate. Twelve surveys were 
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only partially filled out. Thus, they were not considered for the final analysis which 
included 35 completed questionnaires (response rate of 6%). The explanation for the 
low response rate of the online survey can most likely be found in the actual or real 
domain and thus will be topic of later chapters. However, one assumption is that 
formulary committee members are reluctant to share insights into the processes and 
structures of the committee because they do not want this to be assessed or changed. 
5.2 Participant structure 
Two-thirds (66%) of the hospitals have more than 800 beds. One-third (33%) have 
300-800 beds. Hence, the participant structure is balanced, but the topic seems to be 
more interesting for bigger hospitals especially considering the higher number of 
smaller hospitals (94 hospitals with > 800 beds versus 504 hospitals with 300-800 
beds, see Table 7). A different explanation could be the limited resources of smaller 
hospitals and therefore less time to participate in an online survey. The survey 
request was sent by email to the head of the hospital formulary or alternatively to an 
active member of the hospital formulary. 83% of the valid responses came from 
pharmacists, 14% from physicians and 3% from the general manager of the hospital 
(Figure 21). This distribution is not surprising since a pharmacist is most of the time 
the head of the hospital formulary (see results later). 
 
  
Figure 21: Participant structure. 
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5.3 Knowledge sharing 
According to the survey results, only 49% of the hospitals have written guidelines for 
the decision-making process of the hospital formulary (Figure 22). 34% of the 
hospitals do not have any, neither written nor verbal, guidelines which regulate this 
process.  
Considering the content of existing guidelines, 80% of the written guidelines name 
criteria which should be applied in the formulary listing decision-making process. 
However, only half of these guidelines define the relative importance of decision-
making criteria.  
 
 
Figure 22: Guidelines and decision-making criteria. 
 
 
In most of the cases (54%), budget impact is mentioned as the most important 
criterion (Figure 23). Other important criteria mentioned are: clinical study data, 
price of the pharmaceutical drug and existing alternatives. In addition to those 
objective criteria, also subjective decision criteria are mentioned, such as 
recommendation by pharmacists or physicians or the experience in the hospital with 
the specific pharmaceutical drug. 
 
The existence of written guidelines which name decision-making criteria does not 
necessarily mean that hospital formulary members also make use of these criteria. 
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However, this result shows that hospital formulary decision-making is complex and 
uses a variety of criteria, objective as well as subjective criteria.  
Decision 
Criterion Budget impact
Clinical trials 
data Price
Existing 
alternatives
Recommendation 
by pharmacist
Clinical 
experience in 
the hospital
Number of 
indications
Types/Easiness 
of administration
Recommendation 
by head 
physician Supply reliability
Number of 
mentions 19 16 15 12 11 11 10 9 9 7  
Figure 23: Decision criteria mentioned in the guidelines. 
 
5.4 Structure of German hospital formularies 
Information about hospital formulary committees in Germany is scarce and the only 
study which was identified in the literature review was published in 1997 (Thürmann 
et al., 1997) and revealed a median number of twelve members of a hospital 
formulary committee. This research showed that most of the committees consist of 
more than twelve members (for 28.57% of the respondents this was always true). 
Very seldom hospital formulary committees have three to five members. This result 
might be influenced by the higher participation of the group of bigger hospitals 
(>800 beds) who make up about 66% of all participants. It also showed that the 
number of participants fluctuates (Table 12). 
 
Never true Rarely true Often true Mostly true Always true
3-5 members 77,14% 8,57% 14,29% 0,00% 0,00%
6-8 members 42,86% 20,00% 14,29% 8,57% 14,29%
9-12 members 31,43% 28,57% 11,43% 17,14% 11,43%
more than 12 members 25,71% 17,14% 8,57% 20,00% 28,57%  
Table 12: Size of the hospital formulary committee. 
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The survey showed that in most of the cases hospital formulary committees are led 
by a pharmacist. This is often, mostly or always true for 74% of the respondents 
(Figure 24). Often, the head physician is taking the lead for the hospital formulary 
committee. This is often, mostly or always true for 28% of the respondents. The 
results show clearly that the General Manager is usually not in the lead of the 
formulary committee (94%). 
 
Number of mentions never true rarely true often true mostly true always true
Pharmacist 7 2 2 6 18
Head physician 20 5 4 1 5
General manager 33 1 1 0 0  
Figure 24: Head of the formulary. 
 
 
The preferred way of coming to decisions is, according to the survey data, on a 
consensus basis (Figure 25). Hospital formulary committees also use a simple 
majority for decision-making.    
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Figure 25: The applied decision-making rule. 
 
 
5.5 Documentation package 
Members of the hospital formulary committee usually receive a documentation 
package before the meetings which contains information about the respective 
pharmaceutical drugs. According to the survey, only 11% of the hospital formularies 
do not provide such a package. In addition, the provided information is used by most 
of the participants for their decision-making. Only 13% of the respondents said that 
they rarely use the information. The content of the documentation package varies 
between hospital formularies. Mostly basic data, such as clinical trials data or the 
price of existing alternatives, is given to inform the member's decision-making. 
 
The survey showed that the documentation package is compiled by the pharmacist 
and in rare cases also by a physician (Figure 26). 
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Figure 26: Who compiles the documentation package? 
 
 
61% of the respondents stated that information material of the pharmaceutical 
manufacturer is considered for the documentation package. In 84% of the cases, 
clinical trials data is mentioned in the documentation package which confirms the 
importance of such data and the results of the literature review. Economic data is also 
top-ranked with price (71%), budget impact (55%) and health economic evaluations 
(52%). The high number of mentions for health economic evaluations is unexpected 
due to the results of the literature review showing a low acceptance of those 
evaluations. Overall the results show the high priority for economic data in the 
documentation package (Figure 27).  
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Decision 
Criterion
Clinical trials 
data Price
Information 
material from 
manufacturer
Existing 
alternatives
Budget 
impact
Number of 
indications
Health 
economic 
evaluations
Types and 
easiness of 
administration
Experience 
in the 
hospital
Recommendation 
by head 
physician
Number of 
mentions 26 22 19 17 17 16 16 12 9 8
 
Figure 27: Decision criteria in the documentation package. 
 
 
5.6 Decision-makers and other decision-making aspects 
Despite the high response rate by hospital pharmacists in comparison to physicians, 
the results for the question of impact level are balanced. For the question of 
pharmaceutical drug listing decision-making, the respondents indicate a similar 
impact level for pharmacists and physicians. Managing directors or financial 
administrators (here: Controlling) do not have significant level of impact (Figure 28). 
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Figure 28: Decision-makers with higher influence. 
 
 
Regarding transparency, the respondents of the survey indicated that the cooperation 
(e.g. clinical trials) between members of the hospital formulary and a pharmaceutical 
manufacturer is seldom communicated. 43% of the respondents stated that this 
happens rarely or never (Figure 29). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of mentions never rarely often mostly always 
Transparency 
regarding pharma 
cooperation 
7 8 4 10 6
 
Figure 29: Transparency regarding committee members and pharmaceutical manufacturers' 
cooperation. 
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There are a relatively high number of economic decision-making criteria mentioned 
in the documentation packages of hospital formularies. Together with the difficult 
economic situation of many German hospitals this suggests that the financial 
situation of the hospital could be a discussion point in hospital formulary meetings. 
This is confirmed by the survey data which show that the financial situation is a 
discussion topic for 97% of the respondents. 52% of the respondents even stated that 
this topic is most of the time (23%) or always (29%) brought up in the formulary 
discussions (Figure 30). 
 
 
 
 
 
Number of mentions never rarely often mostly always 
Financial situation 
discussed during 
committee meetings
1 10 6 8 10
 
 
Figure 30: Is the financial situation a topic in the hospital formulary discussions? 
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5.7 Decision-making criteria for drug funding cases 
77% of the respondents (n=27) said that they use different decision-making criteria 
for different types of pharmaceutical drugs. In contrast 23% (n=8) always use the 
same criteria to decide on drug funding, independent of the therapeutic class of the 
drug (Figure 31). 
 
 
 
 
Number of mentions never rarely often mostly always 
Use of different decision-
making criteria dependent 
on the drug type 
1 10 7 9 8
 
 
Figure 31: Impact of the therapeutic class of a drug on the applied decision-making criteria. 
 
 
Considering only the respondents who use different decision-making criteria for 
different therapeutic classes of drugs, they use different decision-making criteria 
most often in the class of monoclonal antibodies. In order to get a better 
understanding of the relative importance of decision criteria and how they are used 
depending on different type of drugs, the participants were asked to rank 20 different 
criteria according to their importance. It was not possible to assign a rank twice to 
avoid indifferent answers and thus participants were forced to compare different 
criteria. In case participants do not make use of a criterion at all, it was possible to 
classify this criterion or these criteria as non-applicable. Results are shown in Figures 
32-34. The maximum rank, the minimum rank and the median is shown in the 
graphs.   
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For smaller (n=8 with valid responses) and bigger (n=14 with valid responses) 
hospitals considering the therapeutic class of monoclonal antibodies/ 
immunomodulators, the clinical trials data is the most important criterion. The 
bandwidth for the ranking values is also very narrow which means that all hospitals 
see this criterion similarly important. However, on the following ranks there is a 
clear difference between the smaller und the bigger hospitals. When bigger hospitals 
focus on budget impact as an economic criterion and also have a high rank for the 
price of a drug, smaller hospitals assess the importance of hospital experience much 
higher. Nonetheless, the importance of budget impact in all hospitals seems to be 
controversial as the bandwidth of ranking values is very broad.  Besides objective 
decision-making criteria, perceived subjective criteria, such as the hospital 
experience and the recommendation by a head physician, can be found in the list of 
most important criteria. Smaller hospitals put a higher weight on the severity of 
disease which is not mentioned for the bigger hospital group in the top ten criteria. 
Instead, bigger hospitals focus more on criteria which influence the economic aspects 
of a drug, such as number of indications or existing alternatives. 
  
 
 
 
 
Figure 32: Decision criteria for monoclonal antibodies/ immunomodulators (hospitals with < > 800 beds)
1
3
9
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Medical devices are evaluated differently to monoclonal antibodies/ immune 
modulators. Clinical trials data, although in total ranked very high, seems to be less 
important for medical devices than for the group of monoclonal antibodies/ immune 
modulators. This can be seen in the very broad bandwidth of ranking values for 
clinical trials data.   
 
In general, the importance of economic criteria is higher for the group of medical 
devices. Budget impact and price are both mentioned in the group of the top six 
criteria for all hospitals (n=12 with valid responses). Besides this economic focus, 
decision-makers see a bigger importance also for the physician's experience with a 
medical device, independently of the hospital size. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 33: Ranking of decision criteria for medical devices (hospitals with < > 800 beds)
1
4
1
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Pharmaceutical drugs to treat orphan diseases often do not have the same level of 
clinical trials data compared to regular drugs. Hence, the decision-making criteria for 
this drug class were listed in the survey without the possibility to select clinical trials 
data. Consequently, the hospital experience received a high ranking value as a quasi-
substitute for missing clinical trials data. In contrast to all other types of 
pharmaceutical drugs, the severity of disease has the strongest impact on decision-
making.  
Other subjective decision criteria, such as the clinical experience or the 
recommendation by the head physician are ranked in the top five important criteria.  
 
Orphan drugs are often expensive which is also reflected in the high ranking values 
for budget impact and price. For health economic evaluations the result is 
differentiated. Smaller hospitals (n=11 with valid responses) assess the importance 
very high, whereas bigger hospitals (n=20 with valid responses) rank health 
economic evaluations only on the 10th rank.  
 
It is important to mention that the pilot interviewees indicated that pharmaceutical 
drugs to treat orphan diseases are mostly not listed by the hospital formulary 
committee but ordered on a case by case basis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 34: Ranking of decision criteria for orphan drugs (hospitals with < > 800 beds)
1
4
3
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5.8 Summary 
This chapter summarized the most important outcomes of the quantitative analysis of 
the survey data. The survey aimed to primarily answer RQ-1 and RQ-2, meaning to 
answer which criteria in funding decisions for pharmaceutical drugs in hospital 
formulary committees are applied and what their relative importance is. 
Hospital formulary committees apply different criteria for different classes of 
pharmaceutical drugs. The most important criterion for most types of drugs is data 
from clinical trials. In cases where this data is not available, for example with orphan 
drugs, decision-makers try to use a substitute criterion, such as hospital experience. 
Independently of the type of drug, economic criteria, such as budget impact or price 
are of high importance. In some cases the survey showed a bigger importance of 
health economic evaluations. This result is surprising due to the literature review 
results suggesting a minor impact of health economic evaluations in hospital 
formulary committee decision-making. The following, qualitative parts of this thesis 
further explored the reasons for these results. 
In addition to this, the survey revealed ideas on how to answer RQ-3 and RQ-4. It 
showed that pharmacists and physicians have the highest influence on the decision-
making process of the hospital formulary and that pharmacists usually have the role 
of the committee chair. The reasons for this high influence were further elucidated in 
the expert interviews. It was also indicated that many hospital formulary committees 
have no guidelines which regulate the decision-making on drug listings. In cases 
where guidelines exist they do not mention details, such as the relative importance, 
on decision-making criteria. 
The central role of pharmacists is also emphasised by the responsibility of many 
pharmacists to prepare the documentation package for each drug listing case. Most 
formulary committees prepare documentation packages and members use them for 
informed decision-making. The survey revealed a perceived low transparency in 
hospital formulary committees in regards to the cooperation between members of the 
committee and the pharmaceutical industry.  
 
These perceptions from the empirical domain were used in the discussion part which 
merged the quantitative and qualitative analyses to identify the underlying structures 
of the real domain.
145 
6 Expert interview data analysis 
6.1 Introduction 
The expert interview data analysis represents step six in the research design (Figure 
35). According to the convergent parallel database mixed-methods design (Creswell, 
2003), the expert interview data is analysed separately in the first step and is then 
combined with the hospital survey data and the company market research data in a 
second step. 
 
 
 
Figure 35: Expert interview data analysis. 
 
 
The expert interview data was conducted to answer primarily RQ-3 and RQ-4 but 
also to provide more in-depth information on RQ-1 and RQ-2. 
 
The analysis of the expert interview transcripts was based on the structure of the 
thematic networks approach (Attride-Stirling, 2001). The following eleven codes 
were derived from the literature review and the preliminary decision-making 
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framework. They were used in the first step of the analysis in order to slice up the 
interview transcripts into text segments: 
 
1. Group (Tindale, Kameda & Hinsz, 2003): This code contains text passages 
which describe the decision-making process in regards to the hospital 
formulary committee members and their relationship to each other. It refers to 
comments on how the group influences the individual member. According to 
the literature review, the group has a strong influence on the individual 
member’s decision-making behaviour. It is the second step in the hospital 
formulary committee decision-making framework (Figure 16) shaping the 
final decision of each member of the group. 
 
2. Individual (Davis, 1973; Stasser, Kerr & Davis, 1989): This code contains 
text passages which describe the decision-making process in regards to the 
individual hospital formulary committee member. It refers to comments on 
what is important for the individual member and how the individual member 
comes to his or her decision. This is the first step of the full decision-making 
process shown in the hospital formulary committee decision-making 
framework (Figure 16). 
 
3. Centrality (Kameda, Ohtsubo & Takezawa, 1997): This code refers to all 
text which describes how much influence individual members have in the 
group. It also looks at hints which help to understand why respective 
individuals have more influence than others. 
 
4. Dependencies (Dranove et al., 2003; Gibson et al., 2005): According to the 
literature review, power relationships between group members can influence 
decision-making. This code describes all text passages referring to 
dependencies and how they change decision-making behaviour. 
 
5. Information sharing (Gigone & Hastie, 1993, 2013; Stasser & Titus, 1985, 
1987): A key result of the literature review was the relevance of knowledge 
or information sharing between different group members. This code shows all 
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comments in regards to the level of information sharing and the impact it has 
on the individual and group decision-making behaviour. 
 
6. Objective information (Jenkings & Barber, 2004; Vuorenkoski, Toivianinen 
& Hemminki, 2003, 2008): This code contains text passages which describe 
the importance and formulary committee member use of perceived objective 
information.  
 
7. Subjective information (Wirtz et al., 2005):  This code contains text 
passages which describe the importance and formulary committee member 
use of perceived subjective information. 
 
8. Structure (Thürmann, Harder & Steioff, 1997): In order to better understand 
the group dynamics and the relationships between the respective group 
members, it is necessary to understand the structure of a hospital formulary 
committee. This code contains all text which provides more details on this 
question. 
 
9. Process (Martin et al., 2003): Text passages which describe the process of 
decision-making as well as special circumstances leading to exceptional 
decisions were collected under this code. 
 
10. Transparency (Fijn et al., 1999; Plet et al., 2013): This code contains text 
passages which describe the interviewer’s understanding of transparency and 
how this is reflected in the behaviour of the hospital formulary committee 
members.  
 
11. External impact (Dranove et al., 2003; Jenkings & Barber, 2004; Späth et 
al., 2003): The hospital formulary committee is relatively closed to any 
external influence. However, single members are not and they have contact to 
potential external influencers such as patients or the pharmaceutical industry. 
Additionally, the hospital (and also the formulary committee) is not isolated 
and part of the highly regulated health system of the country. This code 
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provides all comments which refer to any external impact source and how it 
impacts decision-making. 
 
In order not to limit this research and to allow explorative information, the initial list 
of codes was not closed. During the coding phase, two additional codes were added: 
 
12. Type of drug: One important topic from the expert interviews was the 
distinction made during the decision-making process which was dependent on 
the type of drug. Hence, a separate code was used to make the additional 
topics around differentiation also clear in the analysis. 
 
13. Role: During the coding phase it also became obvious that each member’s 
understanding of their role (as a physician, pharmacists or something else) 
impacted their decision-making behaviour. Thus, an additional code was 
required to capture important details on this aspect. 
 
Following the coding phase, the text segments were re-read to identify and refine 
themes which represent the second step of building thematic networks. Table 13 
shows the sample result of this procedure related to the code “subjective 
information”. The identified items for all 13 codes amounted to 134 basic themes. 
 
Code (1st step) Themes (2nd step) --> Basic Themes
Members try to avoid difficult final decisions
Own clinical trial involvement has strong influence
Subjective criteria are difficult to use as a justification for a decision
High patient empathy in combination with low budget impact means an easier listing decision 
Strong emotional arguments absorb objective criteria
Argumentation needs to be convincing
Stronger characters convince more easily
The way of communicating an opinion is vital
Expert opinion alone is not sufficient for a positive decision
Expert opinion becomes more important if other data does not allow differentiation
Expert opinion is of high value
Less available data increases the importance of practical experience
Practical experience must fit to the clinical trials data in order to be accepted
Subject areas are protected
Subjective information
 
Table 13: Themes identified for the code “subjective information”. 
 
 
The identified basic themes were clustered into groups of similar issues. Based on 
these issues, an organizing theme was created which contains the different basic 
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themes. Again, this is shown exemplary for the organising theme “Value of 
expertise” in Table 14. 
 
Themes (2nd step) --> Basic Themes Organising Themes (3rd step)
Expertise of different functions is valued, accepted and protected
The role perception influences the member's expectations
Important decisions decrease trust in expert's opinion
Individual experience alone is not sufficient to convince
Practical experience becomes more important if other data does not allow differentiation
For important decisions members prepare additional information
Value of expertise
 
Table 14: Basic themes identified for the organising theme “Value of expertise”. 
 
 
 
From the basic and the organizing themes, the main propositions, issues and 
arguments were taken to deduce a global theme which is the core component of one 
thematic network (Attride-Stirling, 2001). The last step in this analysis stage is the 
verification of the identified thematic networks. Hence, the basic themes and the 
underlying text segments were again read and checked if the text segments support 
the basic, organizing and global themes as well as the themes reflect the propositions, 
issues and arguments of the text segments. One final thematic network with all 
organising and basic themes is shown in Table 15. 
  
 
 
 
Themes (2nd step) --> Basic Themes Organising Themes (3rd step) Global Themes 
Pharmacists have the strongest impact on decision-making
Pharmacists have a central role in preparation of the documentation
Physicians have pre-discussions with the pharmacist to estimate chances of success
Physicians and pharmacists also align outside of the committee
Expertise of different functions is valued, accepted and protected
The role perception influences the member's expectations
Important decisions decrease trust in expert's opinion
Individual experience alone is not sufficient to convince
Practical experience becomes more important if other data does not allow differentiation
For important decisions members prepare additional information
Importance of department leads to more central role
The chair of the committee is of diverse importance
Some medical departments are more involved in the committees than others
Group consensus can mean a consensus between the two most powerful members
Direct hierarchical dependencies have less impact on decision-making
Difficult decision situations require an individual for final advice
Members should participate in order to increase transparency
Physicians and pharmacists are the decision-makers, but practical 
experience has impact on decision-making independent of functional 
roles
Role of the function
Value of expertise
Key decision-makers
 
Table 15: Thematic network with all organising and basic themes. 
 
 
 
 
1
5
0
 
151 
This was done for all 134 basic themes. After all verification and refinement steps 
and elimination of double themes, five thematic networks with 16 organising themes 
were defined and will now be discussed in detail. Table 16 shows the overview of all 
thematic networks. 
 
Global Themes Organising Themes (3rd step)
Key decision-makers
Value of expertise
Role of the function
Role of the individual
Impact of communication
Pre-meeting decision-making
External impact by the industry
Importance of cross-sectional treatment
Reputation of the hospital
Justification
Role of subjective criteria
Information sharing
Budget impact
Real costs
Importance of economic criteria
Type of drugs
Physicians and pharmacists are the decision-makers, but 
practical experience has impact on decision-making 
independent of functional roles
The personality of the individual committee member has 
strong impact on the group decision-making behaviour
External factors have a significant impact on the formulary 
committee decision-making
Subjective criteria impact decision-making but the open use 
is limited due to perceived difficulties in justification
Despite the strong importance of budget impact, economic 
criteria rarely lead to rejection
 
Table 16: Five thematic networks with all 16 organising themes. 
 
Figure 36 summarises the process of building the thematic networks: 
Figure 36: Process of building thematic networks.
152 
6.2 Physicians and pharmacists are the decision-makers, but 
practical experience has impact on decision-making 
independent of functional roles 
This thematic network comprises of three organising themes and 17 basic themes 
(Figure 37). It describes the strong influence of physicians and pharmacists on the 
decision-making process of the hospital formulary committee group. Besides the 
functional role of a formulary committee member, experience with a pharmaceutical 
drug (either own experience or experience from another member) can impact 
decision building. In this context, this thematic network also describes the 
relationship between the two most important roles in a hospital formulary committee. 
 
 
Organising Themes Basic Themes
Pharmacists have the strongest impact on decision-making
Pharmacists have a central role in preparation of the documentation
Physicians have pre-discussions with the pharmacist to estimate chances of success
Physicians and pharmacists also align outside of the committee
Expertise of different functions is valued, accepted and protected
The role perception influences the member's expectations
Important decisions decrease trust in expert's opinion
Single experience alone is not sufficient to convince
Practical experience becomes more important if other data does not allow differentiation
For important decisions members prepare additional information
Importance of department leads to more central role
The importance of the chair of the committee varies
Some medical departments are more involved in the committees than others
Group consensus can mean a consensus between the two most powerful members
Direct hierarchical dependencies have less impact on decision-making
Difficult decision situations require an individual for final advice
Members should participate in order to increase transparency
Key decision-makers
Value of expertise
Role of the function
 
Figure 37: Thematic network describing the dominance of physicians and pharmacists. 
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6.2.1 Key decision-makers 
Pharmacists have the strongest impact on decision-making. Despite the important 
role of physicians, pharmacists have the advantage of a broader total view on all 
decisions. Usually they are heavily involved in the agenda preparation, preparation of 
case documentation and they can decide for which topic they would like to prepare 
additional data.  
B3 (pharmacist): But I believe the one who facilitates and prepares the 
meetings, this is the one with the greatest influence. It is as simple as that. 
 
B8 (physician): Basically in the committee meeting, someone has the best 
chances to prevail, if this person is best prepared. That is always the case. 
Usually the pharmacists are best prepared. 
 
Even physicians utilise pharmacists to prepare documentation for their listing 
applications. On the one hand, physicians do realize the strong position of 
pharmacists and they regret this, but on the other hand some physicians seem to 
accept their role and let pharmacists take over the control.  
B3 (pharmacist): I wish specific groups would have more interest in the 
formulary listing, for example the physicians. But they often prefer to sit back 
and say: this is done by my pharmacist. 
 
B9 (pharmacist): The meetings of the committee are accompanied by 
presentations […]. The content is mainly prepared by the pharmacists, partly 
from the respective medical department. I would have said this is done by the 
head physician, but the head physician is rarely doing this on his own, maybe 
in 20% of the cases. In 80% of the cases this is done by the pharmacist. 
 
Physicians are seen as the experts for medical questions, but they also need to 
convince other physicians. Pharmacists usually have a standalone position in the 
committee. They combine medical and economic knowledge and for some topics 
they are the only ones with subject specific knowledge, such as logistics of 
pharmaceuticals or pharmacoeconomics. Even in hospitals where the pharmacists do 
not have the formally powerful function as the chair of the committee, they have 
indirect power due to their involvement in preparation of meetings or the close 
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alignment with the chair. The committee meeting facilitation and negotiation is also 
done by the pharmacist, independent of whether he or she is the chair or not. 
B2 (pharmacist): Most influence has the chair of the committee. This is one of 
our head physicians… and the director of the committee, because he steers 
the meetings well, right. And…I will say it like this…I am the director…in 
principle I prepare and steer this as best as I can.  
 
B4 (pharmacist): With his style to facilitate the committee meeting, it is clear 
that the chair has impact and we have impact on the chair, because we [the 
chair and the pharmacist] align very closely and additionally we have, from 
my perspective, a substantial direct impact in the committee meeting.  
 
B9 (pharmacist): The chair of the meeting is usually restricted to the welcome 
and introduction of participants and to hand over the negotiation lead to the 
pharmacists. 
 
Sometimes the pharmacists even have the possibility to decide without any formal 
approval by the committee. Those situations might be specific and not the normal 
case, but they are examples for the autonomy of the pharmacist’s role. Another 
example is the possibility for pharmacists to decide on the manufacturer without 
committee approvals in case of generic drugs or drugs who are perceived to be 
generic. 
B2 (pharmacist): If we…I do not know, receive a special request [for a 
pharmaceutical drug] twenty times, then I can probably decide without any 
formal agreement by the committee. 
 
B2 (pharmacist): And it happens sometime, that we take drugs on the list 
without any formal agreement. 
 
B8 (physician): Right now we have the opinion that the standard [DRUG 
TYPE], independent which brand, is relatively uniform or similar. This 
means, that the pharmacist selects based on economic grounds. 
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Pharmacists do not make use of their influence for all decisions. They carefully 
weigh up the opportunities and risks to interfere. In the event of important decisions, 
such as decisions with high budget impact, pharmacists are more active than in other 
situations.  
B4 (pharmacist): Well, for very important decisions we partly interfere 
and…prepare data, in order to simply have objective data available for the 
committee meeting. 
 
And pharmacists do not have the last word for all questions in the committee. They 
acknowledge the differing perspectives from physicians and often do not interfere in 
those questions considered highly sensitive. Pharmacists have a key role in decision-
making for those decisions with very similar pharmaceutical drugs, drugs with a high 
budget impact and in cases of existing alternatives. Other cases, such as decisions 
about new and innovative drugs or drugs for specific therapeutic areas, are heavily 
influenced by the physician’s opinion.  
B3 (pharmacist): There are situations where the financial issues by the 
pharmacy are ignored and people say: we need this for specific medical 
reasons. And this is what I accept then. 
 
B7 (pharmacist): The pressure, the pressure…well we could call it the 
pressure from a department or from, from a specific…physician. But 
that…that must be massive pressure then, ok. […] As a pharmacist I would 
not interfere with the depth of cardiologic therapy or we prefer not to do this 
here. And if one physician decides to, I do not know, take [PRODUCT X] but 
not [PRODUCT Y], then, then I cannot do very much. 
 
B7 (pharmacist): If a specific department, such as cardiology, decides to list 
three or four drugs, and they make a big effort, get studies and then they 
discuss, this leads to a real discussion in the committee. I mean, well, there 
they naturally…the department naturally has a significant impact. 
 
In spite of these specific situations where physicians have the potential last word in 
the decision-making process, physicians are cautious about the formulary committee 
meeting and the influencing power of pharmacists. Because of this, they have pre-
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discussions with the pharmacist to estimate their chances of success. This pre-
meeting alignment shows that physicians take the role of the pharmacist very serious, 
since they are afraid to hear about the pharmacist’s objection against their proposal 
during the committee meeting and in front of their medical colleagues. 
B1 (physician): If I want to introduce a new drug the first thing I do is to call 
the pharmacist, ask him about his opinion about this drug, the pros and cons, 
also about the manufacturer, pricing, price negotiation. This means, if we go 
to the hospital formulary, I have already coordinated with the pharmacist. 
 
B5 (pharmacist): Then they [the physicians] ask in advance, if that, if this 
really makes sense. This has already happened, that they have asked very 
carefully in advance, if this works or not. 
 
6.2.2 Value of expertise 
Subject matter experts and members with experience in using a specific 
pharmaceutical drug are generally well accepted. If the member is accepted as an 
expert for this therapeutic area, other committee member’s trust in his opinion and 
practical experience achieved in the hospital has a good reputation with impact on 
decision-making. However, there can be doubt about the expert opinion if it is in 
conflict with existing perceived objective data, such as data from clinical trials. 
Despite the trust in the expert’s opinion this implies a predominance of specific 
perceived objective data and confirms the dominant position of clinical trials data. 
B1 (physician): In the first place I trust the presentation or the statements of 
the respective department which tries to list a specific pharmaceutical drug. 
 
B6 (pharmacist): If the pharmaceutical drug is used mainly in the Intensive 
Care Unit, the respective lead physician has a key say in talking about this 
[…]. 
 
B6 (pharmacist): Actually he must present plausible…from his department 
clinical experience. Clinical trials data and the other data need to match 
somehow. 
 
157 
B7 (pharmacist): On the opposite this implies that the experience you have 
done in your own hospital, this means the practical application, this is quite 
an important criterion for the decision. 
 
The level of importance of a decision (in regards to costs or budget impact) might 
also be a reason for hospital formulary members not to trust the opinion of an expert. 
For example, in cases where the pharmaceutical drug is very expensive, committee 
members do not trust the presented data alone but rather try to prepare their own data 
or the committee might decide to simply restrict usage with a dual control (e.g. 
approval from a second physician required). This does not mean that formulary 
committee members have less trust in the experts, but they are more cautious since 
the potential damage for the hospital can be higher. 
B4 (pharmacist): Well, for very important decisions we partly interfere 
and…prepare data, in order to simply have objective data available for the 
committee meeting. 
 
B9 (pharmacist): Then the price…does not prohibit the use of a drug, like it is 
possible in the outpatient sector, but it leads to…a dual control before 
approval. 
 
Non-pharmacists or non-physicians seem to play a secondary role in the decision-
making process of a hospital formulary committee. The committee asks subject 
matter experts about their opinion and their recommendation, but the decision-
making itself is only done by physicians and pharmacists. For example, nurses are 
being asked about the advantages and disadvantages of drug handling or dosage 
issues. If the respective drug is not appropriately covered by the hospital 
reimbursement system, financial administrators are being asked about possibilities to 
solve this issue and to get adequate funding for the drug. Often, non-pharmacist or 
non-physician functions are not part of the regular committee or they have a special 
membership status. In strategic cases, where the use of the drug is loss-making, but 
from the hospital perspective makes sense due to reputation gain, the medical 
director and general manager are the decision-makers. 
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B1 (physician): No, I have commented on it in the questionnaire, because the 
financial administrator definitely provides impact or his recommendation, but 
he does not decide.  
 
B1 (physician): And there is the financial administrator, who says, we have 
this or that possibility to get reimbursement. If there is no special allocation, 
this would stress our budget significantly. 
 
B2 (pharmacist): If a department is established in a sector and they would 
like to treat some patients, although the drug is not covered by hospital 
reimbursement with the health insurances, in this case one must discuss this 
with the general manager and the medical director, how important it is to 
enable this treatment for the department […]. 
 
B4 (pharmacist): Nursing services can generally participate as…with 
observation status, means without voting rights.   
 
In the formulary committee, members protect their subject areas. This means that 
they easily accept other member’s opinions only for the topics which do not belong 
to their respective functional area. Physicians have trust in physician’s opinions if the 
topics relate to medical topics, such as efficacy or safety. The economical or logistics 
expertise is assigned to the pharmacist. The competence around the application of the 
pharmaceutical drug is assigned to nurses. Hence, if a physician proposes a change of 
a pharmaceutical drug this is automatically associated with medical reasons. If the 
pharmacist proposes the same change, other (medical) members associate this with 
economic reasons.  
B1 (physician): […] because I trust on the vote of the respective department 
which applies for the listing of a pharmaceutical drug. If a pharmacist 
proposes a change for a drug, I see this differently. There I question myself, 
if…I better take an example. If product A can be purchased cheaper from a 
different company, the presence of company A or B plays a role for me.  
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B1 (physician): Especially from the pharmacy on the one hand. Clearly they 
have the responsibility to present the price, the supplier issues of company X 
for example, which we do not know and cannot estimate. 
 
Despite the high value of the colleague’s opinion an expert opinion alone does not 
seem to be sufficient in order to achieve a listing of the pharmaceutical drug. This 
again shows that a perceived subjective criterion, such as practical experience or 
expertise does not convince other formulary members if there are no additional 
criteria to support.  
B3 (pharmacist): Hmm […], actually only the recommendation of a colleague 
is not sufficient for a listing.  
 
B5 (pharmacist): The listing, I believe, will not be done based on a single 
experience. I think I can say this pretty clearly […]. But finally, without good 
clinical trials data one would not put this drug on the list.  
 
B7 (pharmacist): There is no evidence and the physician made good 
experience with it – this is something we would block! 
 
The expert opinion is seen as an addition to other data, specifically in cases where 
the perceived objective data does not allow clear decisions or at least makes it hard to 
differentiate between alternatives.  In addition, the expert opinion becomes 
increasingly important if there is lack of other data. For example, this is often the 
case with new innovative pharmaceutical drugs where only a few clinical trials exist. 
B6 (pharmacist): And then it happens that with new drugs there is lack of 
experience because they have not been on the market for very long. And…but 
he has experience that in special cases the new drug has a higher efficacy. 
And based on this the discussion was held. 
 
6.2.3 Role of the function 
In section 2.1.8 the impact of the individual role of a physician or pharmacist has 
already been discussed. In addition to that, the perceived importance of a full 
department can also have influence on the decision-making impact.  Some 
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departments, such as cardiology or oncology seem to have more weight in the 
decision-making process due to their strategic and economic importance for the 
hospital.  
B5 (pharmacist): […] I mean, if one is sort of really important and earns a lot 
of money for the hospital, then it is not completely absurd to claim a certain 
level of weight in the decision-making. 
 
B7 (pharmacist): […] as a pharmacist I would not interfere with the depth of 
cardiology therapy or we prefer not to do this here. And if one physician 
decides to, I do not know, take [PRODUCT X] but not [PRODUCT Y], then, 
then I cannot do very much. 
 
B7 (pharmacist): If a specific department, such as cardiology, decides to list 
three or four drugs, and they make a big effort, get studies and then they 
discuss, this leads to a real discussion in the committee. I mean, well, there 
they naturally…the department naturally has a significant impact. 
 
The role of a department is also important in regards to the involvement in the 
hospital formulary discussions. Some departments are more focused on the use of 
pharmaceutical drugs than others. Hence, their efforts in the committee discussions 
are bigger than the efforts of other departments.     
B3 (pharmacist): If I look at one hospital, I have here 13 different 
departments, and of those 13 different departments only I as a pharmacist 
and 2 or 3 who really discuss, who have really dealt with the case, those are 
the…internists, who work a lot with drugs, and there are the anaesthetists, 
who work a lot with drugs, and possibly also the pain therapists. But all 
others are not very interested. […] I said already I have 13 hospitals – this is 
a problem in all hospitals. Those who work a lot with drugs, they are very 
knowledgeable and the others, well, well… [laughs].  
 
Nevertheless, participation in the hospital formulary committee meetings is very 
important in order to guarantee transparent communication. The different functions, 
such as physicians, pharmacists, nurses or financial administrators have the 
responsibility to inform their respective departments and colleagues about decisions 
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which have been taken in the committee, specifically about the reasons behind 
decisions. Notwithstanding the individual member’s involvement in the use of 
pharmaceutical drugs and the resulting level of effort in the discussions, every role 
has a representative function and serves as an information source for non-committee 
members. 
B4 (pharmacist): […] who participates in committee meetings should also 
inform his or her department. Well, we take meeting minutes, even very 
detailed meeting minutes, nevertheless there are always argumentative 
nuances, which you need to report back from the live meeting. 
 
The chair of a committee formally has a higher importance than other members of 
the committee. But the impact of this higher importance of the committee chair is 
inconclusive. As a consequence of his position, he has a central role in the committee 
as a facilitator and moderator. Difficult decision situations require an individual for 
final advice. 
In those cases where no majority vote is possible, the chair has a clear responsibility 
to take a decision. Noticeably he has a very important role in such a situation. 
Nonetheless, often the importance seems to be only on paper due to other members 
who utilise their influence on the chair.   
B3 (pharmacist): But I believe the one who facilitates and prepares the 
meetings, this is the one with the greatest influence. It is as simple as that. 
 
B4 (pharmacist): With his style to facilitate the committee meeting, it is clear 
that the chair has impact and we have impact on the chair, because we align 
very closely and additionally we have, from my perspective, a substantial 
direct impact in the committee meeting.  
 
B4 (pharmacist): […] for the theoretical case of equality of votes, the vote of 
the chair would be decisive. 
 
B9 (pharmacist): The chair of the meeting is usually restricted to the welcome 
and introduction of participants and to hand over the negotiation lead to the 
pharmacists. 
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The different importance of different functional roles might lead to concentrated 
power. Taking decisions becomes easier but the risk of having biased decision-
making swayed by small groups or individual members is higher. For example, close 
relationships between the powerful function of the pharmacist and the committee 
chair can lead to decision-making situations where no other function dares to take an 
opposite position.  
B2 (pharmacist): Most influence has the chair of the committee. This is one of 
our head physicians… and the director of the committee, because he steers 
the meetings well, right. And…I will say it like this…I am the director…in 
principle I prepare and steer this as best as I can. And if the chair then says: 
“Well, we decide this now!” then this is consensus, right.  
 
B4 (pharmacist): With his style to facilitate the committee meeting, it is clear 
that the chair has impact and we have impact on the chair, because we align 
very closely and additionally we have, from my perspective, a substantial 
direct impact in the committee meeting.  
 
Direct hierarchical dependencies do not seem to have influence on hospital formulary 
decision-making. Most of the members of the committee are on the same or a similar 
seniority level in the hierarchy. Only the medical director and the general manager 
can be more senior than other members of the committee. In case of the general 
manager, the members of the committee respect his position, but they also recognise 
a lack in medical competency, since usually he has a business management 
background. In case of the medical director, functional competency beats hierarchy. 
If another member has the highest competency level he or she is able to prevail 
against the medical director. Likewise, members sometimes seem to use the 
hierarchy in order to push their application for drug listing if they lack a convincing 
argument. In this case, they try to end a discussion with the hint that the listing is a 
wish of their boss. 
B1 (physician): Formally, the general manager is boss of everyone, who 
works in the committee. But he is a businessman. Thus, he has no medical 
competency. 
 
163 
B3 (pharmacist): No, this [the decision-making] should happen on a 
competency level. And there it happens that a physician prevails against his 
boss. 
 
B4 (pharmacist): The, the routine work in the committee is delegated to 
senior physicians and not very often, but sometimes, there is this argument, if 
there is no other argument: Yes, my boss wants it this way! 
 
B5 (pharmacist): Somehow they must be seen as separate. Well, I do not 
believe that this has any influence. In a hospital you will always find 
strategically more important departments than others, but this has nothing 
directly to do with hierarchies […]. 
 
B9 (pharmacist): This does not depend on the position! [...] the medical 
director prevails not because he is the medical director, but probably 
because his arguments are better. 
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6.3 The personality of the individual committee member has 
strong impact on the group decision-making behaviour 
This thematic network comprises of two organising themes and eight basic themes 
(Figure 38). It describes how the character of individuals in the committee has 
influence on the decision-making process. In addition, this thematic network 
broaches the issue of communication and how the way the formulary committee 
members communicate decisions impacts other member’s opinions.  
 
 
Organising Themes Basic Themes
The individual personality influences other committee members
The individual ability to communicate influences the impact on the group
Stronger characters convince more easily
Strong emotional arguments can change decision-making
Presentations are short and thus presenters can place their important messages
Argumentation needs to be convincing
The way of communicating an opinion is vital
Information advantages support the power of argumentation
Impact of communication
Role of the individual
 
Figure 38: Thematic network describing the impact of personality and communication. 
 
6.3.1 Role of the individual 
Formulary committee members have a significant influence on the committee 
decision-making process if they are perceived as strong personalities by other 
committee members. The perceived strength of personality derives from several 
criteria, which combined make this member a leader with an impact on decision-
making. Value of expertise is one of the criteria which were discussed in section 
2.1.8. In spite of being a subject matter expert the member needs good 
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communication skills to persuade other members of this expert role. Good meeting 
preparation which leads to information advantages compared to other committee 
members also strengthens the member’s ability to convince the committee. Partly the 
position, for example being the chair of the committee, plays a role but is not 
sufficient as a criterion alone. Finally, a member needs to show leadership values, 
such as determination to complete the picture of a strong personality. 
B1 (physician): There was a little bit of an uproar, but finally this has been 
implemented.  In this case there was a command of the medical director 
necessary to put the people…a little bit under pressure. 
 
B9 (pharmacist): The pharmacists are usually best prepared. This is why they 
are so convincing. The power of pharmacists in the committee is not 
dependent on their position, sometimes this is good, sometimes this is bad, 
but this dependent on their…good knowledge about the topic of negotiation. 
This is one criterion. 
 
B9 (pharmacist): The second criterion is the personality. A weak pharmacist 
prevails not as easy as a strong pharmacist. But also a weak head physician 
can prevail not as good as a strong head physician […]. In a discussion the 
strong personalities prevail and those people who have information 
advantages which they can clever use in the discussion. 
 
6.3.2 Impact of communication 
Communication has a key role in the decision-making of the hospital formulary 
committee. On the one hand it is the way how members communicate and on the 
other hand it is the way how members select the content of their communication. For 
example, even if an opinion is correct in terms of the technical perspective, this 
opinion needs to be “sold” to other members of the group. The reason is that many 
questions are very specific to the respective function and experts need to explain 
their opinion in a way that other members with less expertise also understand the 
rationale. Otherwise they would not be convinced despite the high acceptance of and 
trust in the role of the expert. As such, the way the formulary committee members 
communicate their opinion is vital. The presented data is often not sufficient and 
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members need to convince their colleagues in regards to the necessity of adding the 
respective drug. Thus, it is not only the perceived objective or subjective information 
about a drug, but it is also the ability of an individual member to transfer convincing 
messages which supports a listing. This can be done with good rhetorical capabilities 
and clever communication. 
B1 (physician): Well…usually there is a trial listing for a drug, if the head 
physician defends the case intensively, if he really needs it. 
 
B6 (pharmacist): Perhaps all of the mentioned reasons were not solid enough 
and he was not able to convince people […].And then it depends, how 
someone is able to present this in a convincing way. 
 
B6 (pharmacist): Thus, it also depends how well-grounded the arguments are 
communicated and how well-grounded…how well-grounded those arguments 
are. 
 
Interviewer: Well, the position counts less, but it is rather the personality of 
the individual, right? 
B9 (pharmacist): The personality and the power of his argumentation. This is 
fair to say. 
Interviewer: Does rhetoric play a role? 
B9 (pharmacist): For sure! 
 
Besides the way how to communicate it is decisive how members build up their 
argumentation and what kind of arguments they select to support their case. Some 
members prepare their own case presentations and thus have a chance to filter the 
presented information to best support their argumentation. Due to the limited time for 
the presentation in the committee, not all information can be showed. This also 
means that the presenter usually has the best knowledge about his or her 
pharmaceutical drug which derives into an information advantage compared to other 
committee members. 
B9 (pharmacist): Thus, he has compiled the publications in a way that his 
opinion is supported. This is the same way we do it. 
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B9 (pharmacist): The applicant of the drug listing prepares a small dossier, 
two pages, not a big folder with all possible studies, but two pages with the 
most important attributes of the drug. 
 
Another example to show the significance of the way to communicate is the use of 
strong emotional arguments, such as the life of a patient. Combining these arguments 
with the argumentation makes it harder for other members to contradict. 
B3 (pharmacist): Somebody said…somebody just said [during the 
discussion]: Well, this is enough! We talk about patient’s lives and this is 
what we need! Full stop! This is independent of the costs.
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6.4 External factors have a significant impact on the 
formulary committee decision-making 
This thematic network comprises of four organising themes and 21 basic themes 
(Figure 39). It describes the impact of external factors on the hospital formulary 
decision-making. Two main areas are important: factors within the hospital, but 
outside of the hospital formulary and factors external to the hospital, such as the 
pharmaceutical industry, regulations or the patient perception of the hospital. 
 
 
 
Organising Themes Basic Themes
Consensus decisions are preferred
Members try to ally with others before the meetings
Many decisions are not fully discussed during the committee meetings
Critical points of the discussion might not be shared with the group
Pre-committee alignment is used as a strategic method
Members expect to have difficult discussions before the committee meeting
Members do have an opinion before they go into the meeting
Members believe they decide independently
External impact by the industry has a negative connotation
Business relationships with the pharmaceutical industry influence decision-making
Pharmaceutical industry has more impact with new and innovative drugs
External impact of the pharmaceutical industry is strong on the listing application
Own clinical trial involvement has strong influence
The hospital must take cross-sectional responsibility towards patients
Continuation of patient treatment is crucial
Health insurances have no direct impact on decision-making
Health insurances have strong indirect influence on decision-making
Relationships to the outpatient physicians are considered for decision-making
Positive reputation is a strong argument against costs
Some treatments are crucial for the representation of the hospital expertise
Importance of cross-sectional treatment
Reputation of the hospital
Pre-meeting decision-making
External impact by the industry
 
Figure 39: Thematic network describing how external factors impact decision-making. 
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6.4.1 Pre-meeting decision-making 
Members have an opinion about specific topics before they go into the hospital 
formulary committee meeting. As already discussed above, they usually receive an 
agenda and some kind of documentation in advance which they review and prepare 
themselves for those topics in which they have an interest. The individual pre-
meeting opinion is then challenged during the meeting with arguments of other group 
members, but it marks the reference point for each member.  
B1 (physician): The topics for the bi-annual committee meeting are known to 
everyone in advance, they will be communicated by the pharmacist who 
organises everything and who is also the chair. 
 
Interviewer: But you have already an opinion, yes or no, for the specific drug, 
before you go into the meeting? Or is this wrong? 
B5 (pharmacist): Exactly, most probably you will have an idea, mhm. 
Someone would have reviewed the studies and found out; if one believes that 
there is a benefit, and a place where the usage is justified with us. 
 
Interestingly, a lot of the potential group discussion is already done in advance to the 
committee meetings. Members expect to have very difficult or controversial 
discussions with colleagues before the meeting. For some, it has a strategic 
component to ally with other influential members before the actual meeting starts. 
This increases the chances to successfully argue ones case and to convince others, 
specifically if the case is supported by influential members. However, if critical 
discussions are conducted before the actual formulary committee meeting, cases are 
not appropriately considered during the committee meeting. Members of the 
committee get a biased, positive picture of the case, since critical points might not be 
shared with the group. In addition, this pre-meeting arrangement also leads to a 
strong supporter alliance for the respective case which makes it difficult to challenge 
for other committee members.  
B1 (physician): If I want to introduce a new drug the first thing I do is to call 
the pharmacist, ask him about his opinion about this drug, the pros and cons, 
also about the manufacturer, pricing, price negotiation. This means, if we go 
to the hospital formulary, I have already coordinated with the pharmacist. 
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B1 (physician): If I want to introduce a drug in my department, I expect 
colleagues to accept my proposal, unless they have a really big counter-
argument, but then I would expect to hear this in advance. 
 
B5 (pharmacist): Then they [the physicians] ask in advance, if that, if this 
really makes sense. This has already happened, that they have asked very 
carefully in advance, if this works or not. 
 
This pre-meeting alignment is useful for the committee members in regards to their 
preference of deciding on a consensus basis. Hospital formulary committee members 
prefer to take decisions without being too aggressive against other member’s 
opinions. Hence, pharmaceutical drugs are seldom fully rejected. It is more likely 
that committee members decide to allow a test run, apply restrictive criteria to its use 
and often postpone a difficult decision. With this approach they also have the 
opportunity to create and gather more data for a drug to take a better informed 
decision at a later date. 
B5 (pharmacist): Well, a rejection is very seldom. But that someone says, 
somehow we cannot…we are not really convinced, yet, actually we would like 
to see more data, more…very often just more treated patients […]. Sometimes 
someone just says, we postpone the application for half a year and wait how 
the data looks like. This happens. 
 
B6 (pharmacist): Then in most cases we came to the conclusion, if the budget 
was really impacted, then we said: we observe this for another three or four 
months […]. But it was not the case that we said, well that…that the 
committee has forbidden something. 
 
B9 (pharmacist): A department would like to have this and we think it does 
not make sense. Then we try to block this. Or we say we could have a try. 
Having a try means, this is what I said already before, just see, if the drug 
finds its area of application.  
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6.4.2 External impact by the industry 
Although hospital formulary committee members believe that they take independent 
decisions, when asked in more detail, many acknowledge a significant influence by 
external factors, such as the pharmaceutical industry. Especially for new 
pharmaceutical drugs, the industry provides the majority of the published 
information and in this way has the opportunity to have an indirect impact on 
formulary committee decision-making. In addition, committee members recognise 
the efforts of the industry to influence committee members to promote their products. 
B1 (physician): I believe that in the initial phase, the introduction of a new 
substance, the pharmaceutical industry has a big influence, inevitably. 
 
B3 (pharmacist): It depends, how often the drug gets promoted, how often the 
frequency of the sales force visits is and the more often the drug is pushed the 
easier it is in the heads, we should not fool ourselves. This is the case. […] I 
believe the…pharmaceutical industry has influence on the listing applications 
but if the applications get approved, there they actually have no influence. 
 
Interviewer: How strong would you see the influence of the pharmaceutical 
industry on the committee’s decision-making? 
B6 (pharmacist): Yes, definitely, definitely significant, I need to say and in 
fact…this is not meant in a bad way, but it is primarily a fact that a lot of 
well-prepared information comes from the pharmaceutical industry. 
 
In general, this is a sensitive topic where external impact by the industry has a 
negative connotation. This negative connotation might even lead to a very negative 
impression of the application, since the assumption of external influence decreases 
the trust in the expert’s opinion of an application. Committee members refuse a 
direct impact of the pharmaceutical industry on their decision-making and they 
assume that listing applications may be affected but not the listing decisions. They 
have an ambivalent opinion about external relationships and the potential influence 
on decision-making. On the one hand, members see the external relationships 
positively, for example in cases where industry asks committee members about their 
expert opinion. On the other hand they do not want any external influence on their 
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decision-making and like to keep their independence. In addition, they seem to be 
afraid of the impact this could make to their justification towards the public. 
Interviewer: How would you describe the influence of the pharmaceutical 
industry on your decision-making? Does this exist? If yes, how can it be best 
described? 
B5 (pharmacist): … well, ultimately I would think, that this is […] I would 
say this [any impact] is impossible. But now you are asking me and not the 
applicant. 
 
B8 (physician): Well, I am saying this pretty clear, because if I – I refer this 
to me personally – if I have the suspicion that an application […] yes, is 
directly initiated by the pharmaceutical industry […] this would be a negative 
criterion. 
 
B8 (physician): I mean, if someone is NOT in the public in seminars or as a 
consultant for a company, then this person is probably wrong at our hospital, 
saying this very explicitly. This is hard to understand by the public, but this is 
logical. If I have experts, then those experts also work somewhere else.  
 
If members are involved in clinical trials they have a special bond to the respective 
pharmaceutical drug. Clinical trial participation is good for the physician’s reputation 
and it is even better for his reputation if the trial is successful. Hence, the physician 
has a personal interest in positive data for the respective pharmaceutical drug. For 
this reason, the participation in a clinical trial can make a member a very strong 
advocate for this drug in the formulary committee.   
B7 (pharmacist): Well, especially those…those who were involved in the 
development or participated in big clinical trials, those people insist heavily 
on their drugs. 
 
B7 (pharmacist): You have head physicians, who participated long ago in a 
[COMPANY] [PRODUCT] study and they want their [PRODUCT], there is 
nothing else, they do not care about current clinical trials. 
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6.4.3 Importance of cross-sectional treatment 
All of the interviewed hospital formulary committee members agreed that health 
insurances have no direct impact on decision-making. However, for certain questions 
they do have indirect impact. This can be the case for pharmaceutical drugs which 
are used for treatments initiated in the hospital and which are continued afterwards in 
the outpatient sector (cross-sectional treatment). As a result of reimbursement 
regulations, health insurances have a good level of pharmaceutical drug control in the 
outpatient sector. This has even increased with a law implemented in 2011 
(Arzneimittelneuordnungsgesetz = AMNOG) and regulates an evaluation process for 
new pharmaceutical drugs in parallel to their market start. The evaluation process 
takes six months and a negative outcome can have significant impact on the 
outpatient reimbursement. This impact can be so significant, that the outpatient 
physician might refuse to prescribe the drug.  
However, hospital formulary committee members have a strong interest to make 
continuation of drug treatment possible for two main reasons. Firstly, treatment only 
makes sense, if the patient can continue with it after the hospital stay. Secondly, 
hospitals have an interest in good relationships with the outpatient physicians in their 
domain as they are dependent on the willingness of outpatient physicians to allocate 
patients to the hospital.  
B2 (pharmacist): There we have decided as the formulary committee to delete 
this drug from the list to prevent any issues with outpatient physicians, ok. 
They would have run into problems with the health insurances. If it is not 
reimbursable, the patients need to pay out of their own pockets and this 
would have been…mmh…just a little bit difficult […] 
 
B3 (pharmacist): I hear more and more often: we cannot prescribe this, 
because the outpatient colleagues with their budgets, they would change this 
anyways. And this is actually too bad.  
 
B4 (pharmacist): Indirectly this actually plays a role: what can be prescribed 
in the outpatient setting? Well, we try to avoid having drugs on the list which 
cannot be prescribed in the outpatient setting. 
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B5 (pharmacist): […] someone cannot see the hospital fully isolated at this 
point […] but I believe as long as someone talks about treatment 
continuation, it becomes difficult, if someone is not considering how much the 
treatment costs. 
 
6.4.4 Reputation of the hospital 
The importance of costs, prices and reimbursement issues of a pharmaceutical drug 
was discussed earlier in section 2.1.8, but one external factor strongly mitigates 
against these cost issues: the reputation of the hospital. When hospital formulary 
committees think about a certain drug listing they consider if this new drug can be 
used for new and innovative treatment. Even in cases where the reimbursement of 
the drug leads to a negative financial outcome, the decision might turn positive, if the 
drug allows a treatment which increases the reputation of the hospital.  
B1 (physician): If a physician can argue why a therapy, which is not 
appropriately reimbursed and thus loss-making, makes sense because of the 
department reputation, in order to create awareness for the special expertise 
of this department, then the vote of the head physicians is surely important for 
the general manager. 
 
Another example of this external factor is the hospital reputation with the patient. If a 
competitor hospital offers a more innovative therapy or a more convenient therapy 
for the patient this is a disadvantage for the hospital. This is why committee members 
for their drug listing decision-making also consider what is offered in other 
competitor hospitals. 
B9 (pharmacist): […] with the neighbouring hospital you have these 
competitor thoughts: “They now offer this treatment method. This is why we 
also need to have that!” […] If the patient says: “There you can take a pill 
and there you get an injection with a needle…” There you would not like to 
be the hospital with the needle. Such an argument also plays a role. 
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6.5 Subjective criteria impact decision-making but the open 
use is limited due to perceived difficulties in 
justification 
This thematic network comprises three organising themes and 14 basic themes 
(Figure 40). It describes the impact of subjective criteria on the decision-making 
process of the hospital formulary committee group as well as issues related to the use 
of subjective criteria and justification of decisions. In addition this thematic network 
refers to the implications of information sharing between the formulary committee 
members.  
 
 
Organising Themes Basic Themes
It is easier to justify decisions based on objective criteria
The documentation of decisions is very limited in reflecting the main discussion points
In regards to applied decision criteria, transparency is limited
Transparency means to report all conflicts of interest
Transparency is needed to avoid being accused of bribery
Transparency means to have process clarity
Gut feel decisions are accepted if pure objective decision-making is difficult
Assessing the importance of subjective criteria is difficult
High patient empathy in combination with low budget impact means an easier listing decision 
Quality of subjective criteria is measured with objective criteria match
Documentation provides only filtered information
Information sharing is key for willingness and ability to discuss
Preliminary discussions preclude members to get all information
Preparation prior to the meetings allows informed decision-making
Justification
Role of subjective criteria
Information sharing
 
Figure 40: Thematic network: the role of and issues with subjective decision-making criteria. 
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6.5.1 Justification 
Transparency is an important topic for the members of the hospital formulary 
although the understanding of the meaning can be different for each member. 
Hospital formulary committee members feel that a certain level of transparency is 
necessary to protect them from being accused of any form of corruption. It is also 
important as decisions have an impact on a limited budget where decisions can 
potentially lead to limitations of treatment to other departments or patients and it is 
their responsibility to explain why a specific drug is justified. However, this level of 
transparency can be achieved in different ways and members have different focal 
points. The basic understanding of transparency includes the documentation of the 
decision-making process or the reporting of any business relationships between 
formulary committee members and the pharmaceutical industry.  
B1 (physician): Because decisions of the hospital formulary committee are 
budget relevant [...] this is an expensive decision which possibly limits the 
resources for other things, at least temporarily. 
 
B3 (pharmacist): [...] and that everybody discloses their relationships...or the 
pros and cons and not till then a mutual decision is taken for or against a 
listing. And this is transparency for me. [...] that you are not doing a listing 
just to please a certain sales force representative and that we are not corrupt, 
neither on the physician's side nor on the pharmaceutical side. 
 
B4 (pharmacist): On the one hand we would like to have clarity on the 
processes here; this means how the decision-making works, this is a basic 
principle. We would like to have legal certainty. This also means, well, how 
should I express this, defence against corruption accusation or prevention of 
being accused of corruption. (...) Yes, I believe, those are the relevant 
criteria. 
 
Members find it easier to justify their decisions with objective criteria instead of 
mention any perceived subjective criteria. Hence, the documentation only 
concentrates on the final decision and is either describing the decision-making 
process or the decision of the committee only. The documentation of decisions is 
very limited in reflecting the main discussion points related to the decision and it 
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does not specify any decision criteria. Furthermore, the documentation is limited to 
perceived objective information, such as medical, safety or economic criteria. Due to 
the perceived issues with justification, the formal process can even block the actual 
decisive subjective criteria and make members think of ways to justify based on 
other, more accepted perceived objective criteria. 
B4 (pharmacist): We are doing this on purpose and do not specify the 
decision criteria. It...That means, it is, of course it is mentioned that decisions 
should be taken based on medical, pharmaceutical and economic criteria. 
This of course is clear. 
 
B5 (pharmacist): [...] probably because we are doing this [process] very 
strictly, probably they [any subjective criteria] are not presented openly. I 
would not exclude that people make their experiences [with the drug] but 
would not name it this way, just because it is not allowed here.  
 
B6 (pharmacist): Well, only the decision was documented but not the 
discussion leading to the decision. 
 
B7 (pharmacist): There is no need to publish all discussion points, but in any 
case the decision. [...] You cannot explain to everyone why you have chosen a 
specific cardiologic drug. [...] This is why the hospital formulary committee 
exist. Well, in principle this is like a parliament. 
 
6.5.2 Role of subjective criteria 
The impact of perceived subjective criteria on the decision-making process is 
difficult to describe for the members of the hospital formulary committee. There is 
awareness that these criteria potentially have influence on the member's opinion, but 
it is difficult for members to estimate the importance compared to other criteria. In 
case the available objective criteria fail to help making an easy decision, committee 
members accept the potential use of perceived subjective criteria, such as gut feelings 
or practical experience.  
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B1 (physician): If it is just a small difference in price, I would decide based 
on my gut feeling always for the company, which is more present in my area. 
Decisions based on gut feeling do exist. 
 
B4 (pharmacist): Of course it plays a role if somebody has experience with 
the drug, which you can use for decision-making. But it is really difficult for 
me to rate the importance quantitatively.  
 
Although, hospital formulary committee members generally accept the existence and 
impact of perceived subjective criteria, they have concerns in using them for an 
official justification. Even in cases where subjective criteria, such as practical 
experience, are recognised, members try to make a connection to existing perceived 
objective information. For example, this is the case when practical experience results 
may not match clinical trials data in order to be valid. 
B4 (pharmacist): […] and I need to make a decision, then gut feeling and 
similar things have an impact. This is true. But it depends on how you 
translate gut feeling: If I translate this with “irrational decision” – this is 
something we cannot accept, of course. 
 
B5 (pharmacist): Well, such subjective criteria do not exist here. Nobody 
could understand such criteria. 
 
B5 (pharmacist): But, if the physician is more willing to apply for funding if 
he made good experience, this is something I would not exclude. This is 
human, probably. But this way you cannot justify your decision here. This 
would be difficult. 
 
B6 (pharmacist): Actually he must present plausible…from his department 
clinical experience. Clinical trials data and the other data need to match 
somehow. 
 
Higher empathy with patients due to the severity of their disease or because they are 
children can lead to easier discussions. In these cases, members tend to accept more 
easily perceived non-objective information. In some cases, discussions are 
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interrupted by very strong emotional arguments. Members try to convince other 
members with reference to the moral and ethical goal to save patients’ lives. 
B1 (physician): But with oncology patients, if the oncologist argues 
intensively that he needs his product A or B, you would rather agree without 
discussing too much. 
 
B3 (pharmacist): Somebody said…somebody just said: Well, this is enough! 
We talk about patient’s lives and this is what we need! Full stop! This is 
independent of the costs. 
 
B7 (pharmacist): For the paediatricians you have sometimes slightly 
emotional decisions, and there, there nobody interferes. You have low costs 
and then everybody thinks, alright, we can provide this, and then everybody 
smiles and approves. 
 
6.5.3 Information sharing 
Information sharing is a key factor in the decision-making process of a hospital 
formulary committee as it determines the willingness and ability of committee 
members to have a serious discussion. If members do not have all information to 
make a decision, the perceived expert level of other members with more knowledge 
creates a barrier for the discussion.  
 
However, the majority of hospital formulary committee members might miss key 
information as many colleagues have pre-discussions, during which critical and 
difficult aspects of the decision task are already addressed. Members also align their 
opinion already upfront if possible. In those cases, other committee members get a 
biased presentation of the decision and probably do not realize that key information 
is missing.  
B1 (physician): If I have an important counter-argument against a specific 
drug which a department head would like to introduce, then I would call him 
in advance and ask him, why exactly this drug, why not the alternative? [...] If 
I want to introduce a new drug the first thing I do is to call the pharmacist, 
ask him about his opinion about this drug, the pros and cons, also about the 
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manufacturer, pricing, price negotiation. This means, if we go to the hospital 
formulary, I have already coordinated with the pharmacist. 
 
B5 (pharmacist): Then they [the physicians] ask in advance, if that, if this 
really makes sense. This has already happened, that they have asked very 
carefully in advance, if this works or not. 
 
In addition, the information provided in advance to the meetings is already biased as 
the content of the documentation depends on the willingness of the person who is 
responsible to share information with other members of the committee. This 
willingness is dependent on the applicant's individual goals and as the applicant 
wants a positive decision, the provided documentation is favourable to the case. 
Furthermore, the content of the documentation is limited by the amount of time 
members have for the preparation of the documentation and then also the time for 
discussions in the committee. 
B9 (pharmacist): [...] we try to form our opinion and we then try to present 
this opinion. This is... this is done the same way by the others [...] Thus, he 
has compiled the publications in a way that his opinion is supported. This is 
the same way we do it. 
 
B9 (pharmacist): The applicant of the drug listing prepares a small dossier, 
two pages, not a big folder with all possible studies, but two pages with the 
most important attributes of the drug. 
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6.6 Despite the strong importance of budget impact, 
economic criteria rarely lead to rejection 
This thematic network comprises of four organising themes and 20 basic themes 
(Figure 41). It describes the role of economic criteria and specifically the important 
role of budget impact in the decision-making process of the hospital formulary 
committee group. Despite the importance of budget impact, economic evaluations 
have no significant impact. This is due to their universal implementation and thus 
they often lack a hospital specific focus. Another important aspect of this thematic 
network is the difference in decision-making in regards to the type of the 
pharmaceutical drug. The applied decision criteria are dependent on what type of 
drug is under consideration. 
 
Organising Themes Basic Themes
Level of budget impact influences the willingness for compromise
High budget impact limits flexibility for other departments
Very high budget impact can limit the funding decision
Big difference in overall costs are handled more formally
Impact on the department increases member's willingness to get involved in the discussion
Costs of switching to a new drug is relevant
Safety of a drug means patients safety and cost savings
Total costs include drug costs and process costs
Clinical trials data often do not properly reflect the hospital population
Importance of economic criteria is too big
Economic evaluation has not a big impact
Economic criteria do not lead to a total rejection
Importance of economic criteria increase in case the committee sees similiarity for two drugs
Members differentiate between different types of drugs
If drugs are used in more than one department, members increase their discussion efforts
Decisions on very new drugs are often preliminary
Members trust the opinion of experts in cases of therapy area specific drugs
Orphan drugs are usually not listed
Specific drugs are challenged less than others
Importance of economical criteria
Budget impact
Real costs
Type of drugs
 
Figure 41: Thematic network describing the importance of several economic criteria. 
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6.6.1 Budget impact 
Budget impact plays a central role in the decision-making process. One main reason 
for this importance is the potential limitation for the different departments of a 
hospital. That is, a high budget impact for a specific drug used in one department 
limits the possibilities of other departments due to the decreased total budget. In 
consequence this means that members are more willing to compromise if the budget 
impact is lower. Hence, members supporting a request for funding for a high budget 
impact will often need to justify this as this complicates the listing decision. For 
example, a restricted listing might require certain senior physicians who need to sign-
off every use of the drug. Or the drug will only be listed for a sub population with the 
highest efficacy. 
B1 (physician): Because decisions of the hospital formulary committee are 
budget relevant [...] this is an expensive decision which possibly limits the 
resources for other things, at least temporarily. 
 
B5 (pharmacist): The single departments have global budgets and they are of 
course interested to meet their budget goals or even to free up money to use it 
somewhere else to invest. Or to put it into the opposite: If the money is spend 
for...mostly expensive pharmaceutical drugs, it is missed somewhere else. 
 
B5 (pharmacist): [...] you look at the total costs of the current therapy and 
compare this with the costs of the new therapy. And if there is a big 
discrepancy, then the additional benefit needs to be significantly higher. Or 
you would, this also happens, list the drug only for a small portion of the 
patients. 
 
B9 (pharmacist): Or it [the drug] is listed and in principle known for regular 
usage but very expensive, a second person should approve. [...] but a head 
physician needs to sign-off each usage. 
 
The impact of a pharmaceutical drug on the budget also influences the efforts of 
members to participate in the discussion. For low budget impact drugs, members 
might even accept a drug without any discussions or questions, since they feel that 
the effort is not worth any action. In addition, budget impact influences the 
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willingness to accept other usually strong data, such as efficacy data from clinical 
trials. If a drug shows efficacy superiority in comparison to the current drug, but its 
costs are significant higher, then the requirement for the presented evidence would be 
higher than it would be in case of a small difference in total costs.  
B4 (pharmacist): Let’s say, if the ophthalmologist asks for a tear substitute, 
this does not really matter. […] If it is about changing Heparins, which 
affects the whole hospital, then of course we put a high effort into collecting 
all facts. 
 
B7 (pharmacist): For the paediatricians you have sometimes slightly 
emotional decisions, and there, there nobody interferes. You have low costs 
and then everybody thinks, alright, we can provide this, and then everybody 
smiles and approves. 
 
B7 (pharmacist): The reason is that those drugs are not expensive. You would 
not invest more energy if you talk about 3,000 EUR yearly costs […]. 
6.6.2 Real costs 
Hospital formulary committees consider the total costs that the introduction of a drug 
will make rather than just considering the acquisition costs. Cost assessments 
appreciate that safety of a drug is relevant for savings due to increased patient safety 
and less adverse events, unexpected hospitalisations and other resource implications 
which otherwise would need to be dealt with in the hospital. Besides the drug costs, 
the calculations include process costs and also costs for switching from one drug to 
another. A major challenge for committee members is that clinical trials often do not 
fully reflect the patient population characteristic for the hospital. This might lead to 
imprecise assumptions regarding the specific hospital costs. 
B2 (pharmacist): Yes, yes, but this does not help us at all. These studies are 
actually, there are so many exclusion criteria and they are done with, let's 
say, relatively healthy, younger patients, right. If someone...half of our 
patients are older, let's say, and they also have all different kinds of co-
morbidities, right. 
 
184 
B6 (pharmacist): [...] and then we save time in the surgery preparation and 
then of course we can...we can support our staff. 
 
Interviewer: Should the importance of economic data [...] from your 
perspective be higher than today? 
B7 (pharmacist): [...] that this is not yet the case, the reason for this is that 
those data, well let's say, first needs to be collected or that the data is 
different in every hospital. This is why every hospital needs to find its own 
data. 
 
B7 (pharmacist): What kind of process costs are behind this? And this is what 
we need to consider in our price negotiations, because you cannot change 
everything for...for 1,500 EUR, if everybody is involved and then you save 
1,500 EUR and you have all this effort to change everything. 
6.6.3 Importance of economic criteria 
The feeling of hospital formulary committee members is that the impact of economic 
criteria has increased and that its level of importance to decision-making should not 
be higher. This concern has been mentioned by both physicians and pharmacists. 
Especially in situations where the committee members have difficulties in 
differentiating two drugs, the importance of economic criteria increases. 
B3 (pharmacist): Actually today, people consider the money too much. [...] It 
should not be more important than this. 
 
B4 (pharmacist): In the meantime we have the hard-core money-saver on the 
medical side, and we need to stop here, money is important, but it is not 
everything. The quality...should play the biggest role. 
 
B8 (physician): Right now we have the opinion that the standard [DRUG 
TYPE], independent which brand, is relatively uniform or similar. This 
means, that the pharmacist selects based on economic grounds. 
 
One interesting outcome is that even big concerns about economic criteria usually do 
not lead to a total rejection of listing a pharmaceutical drug. Members are reluctant in 
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issuing final negative decisions and rather allow a trial period in which additional 
data should be generated. For hospital formulary committee members the 
postponement has the advantage that they are no losers in these discussions. The 
applicant can try the pharmaceutical drug and use it with patients on a case-by-case 
basis, but the drug is not on the list, yet.  
B1 (physician): One wants to gather personal experience if the drug is 
convincing but the clinical trials data not sufficient, the head physician gets 
the chance to place single orders or a restricted volume to make his 
experience. And then he is allowed, as discussed before, to report back about 
his experience. 
 
B4 (pharmacist): For orphan diseases the products will usually not be listed, 
but they will be ordered on special request. And here we are more flexible, I 
would say…allowing the physician to gather experience. 
 
B8 (physician): On the other hand I have the advantage to have additional 
cases over the year which helps to gather experience, and very often these 
are special drugs, very often these are oncology drugs. 
 
In spite of the high significance of economic criteria in general, economic evaluation 
as a more specific decision-making criterion is of low importance. The biggest 
obstacles for a higher acceptance of economic evaluations are preparation time, skills 
of the formulary committee members and the lack of hospital specific evaluations. 
Economic evaluations can be complex and without dedicated experts it takes often 
much too long to fully assess an economic evaluation. In addition, physicians often 
lack the basic knowledge and understanding of the economic evaluation concepts 
resulting in low interest. Besides time and skills, economic evaluations are not well 
accepted because they do not show numbers which are comparable to the individual 
hospital situation. Thus, the outcomes of an economic evaluation are worthless for 
the decision-making process. 
B6 (pharmacist): [...] Then the efforts to explain the calculations are too 
high. Ideally would be if participants would have more knowledge [on health 
economics], how this works, then this would be much easier. 
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Interviewer: How do you estimate the impact of, let's say in general health 
economic evaluations [...]? 
B7 (pharmacist): Actually I do not consider this. I...have currently not very 
much time to work on this in detail. [...] And...I do not really know, frankly 
speaking, where I would need such a general pharmacoeconomic...health 
economic study for my specific portfolio. 
6.6.4 Type of drugs 
Different types of pharmaceutical drugs are evaluated differently. Members of the 
hospital formulary use different decision-making criteria dependent on the type of 
drugs. This becomes very clear in case of drugs for the treatment of rare diseases 
(orphan drugs). These drugs are usually not put on the formulary list due to their 
irregularity of use. Physicians need to order those drugs always on specific request.  
B4 (pharmacist): For orphan diseases the products will usually not be listed, 
but they will be ordered on special request.  
 
B7 (pharmacist): If it is really an orphan drug, it will not be added to the list, 
that is…that will be ordered in those rare cases with approval and eventually 
cost commitment and so on. You would not find this in the list. 
 
In cases of drugs specific to a therapeutic area, members trust the opinion of the 
concerned department and the respective subject matter expert. Members also make a 
differentiation in regards to the therapeutic area: oncology drugs, although often 
expensive, and paediatric drugs seem to be less challenged than others. However, if 
drugs are used in more than just a single department, the concerned members put 
more efforts in the discussion about the listing.  
B1 (physician): On the other hand you are in a different situation with 
oncology patients compared to patients who require a new hip, where drug A 
and drug B are quite comparable.  
 
B3 (pharmacist): Normally it is the same criteria with…maybe with slightly 
different focus. Let’s say, for oncology drugs the tolerance or the patient 
outcomes have…a bigger weight than probably for a cardiovascular drug or 
so. 
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B4 (pharmacist): If it is about changing Heparins, which affects the whole 
hospital, then of course we put a high effort into collecting all facts. 
 
B4 (pharmacist): And then I would like to add: It really depends on what you 
are talking about. If you discuss antibiotics, the microbiologists has the 
highest influence, if you talk about cardiovascular drugs, it is the cardiologist 
and so on. This is dependent on the functional focus. 
 
B7 (pharmacist): If some paediatricians state that this is better, than, than 
this would normally be approved, yes, than…nobody discusses this, because, 
because no one would like to become acquainted with this. Those are special 
things. 
 
There is also a differentiation between drugs with existing active substances and new 
and innovative drugs. For new drugs there is usually a lack of available data or the 
available data is limited. Members accept this by taking decisions on new, innovative 
drugs on a preliminary basis. This way, the applicants of the drug listing application 
get a chance to try a new drug and make practical experience regarding efficacy, 
safety, but also costs. Following this trial period, they need to report back to the 
group who then take a final decision. Another preliminary decision might postpone 
the whole discussion to a later time point, also having in mind that the chances for 
more available data are then higher.   
B4 (pharmacist): If the situation is really unclear, I am a little bit reluctant. 
Then you could probably say we take the decision now to have a trial on this 
drug for half a year or a year. This would most probably go into this 
direction. 
 
B5 (pharmacist): Especially for new drugs there is a lack for big patient 
studies, which are not initiated until the marketing authorization is there. 
When this happens you also have bigger studies with much more patients. 
Sometimes someone just says, we postpone the application for half a year and 
wait how the data looks like. This happens. 
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B7 (pharmacist): You always give people the opportunity to make their 
experience or to have trial or whatsoever. 
 
B9 (pharmacist): We just do this and have a trial. And then at the end we 
have a result, after half a year or when we meet again, if this was ordered at 
all. 
 
6.7 Summary 
This chapter summarised the findings of the qualitative expert interview analysis. 
The analysis identified five thematic networks about the decision-making process of 
hospital formulary committees. 
 
The first thematic network describes the strong influence of physicians and 
pharmacists on the decision-making process of the hospital formulary committee 
group and that the experience with a pharmaceutical drug can impact other members’ 
decision building. Especially the dominant role of the pharmacists is also topic in 
other thematic networks. Pharmacists usually prepare most of the information which 
is used in the hospital formulary committee discussions. Hence, depending on the 
pharmacists’ willingness and ability to communicate issues, other committee 
members receive more or less information (thematic network four). In addition, 
pharmacists are often approached already before formulary committee meetings by 
physicians who want to have pre-alignment which adds additional power to the 
pharmacists (thematic network three).  
 
Following this, the second thematic network describes how the character of 
individuals in the committee has influence on the decision-making process and how 
the way the formulary committee members communicate decisions impacts other 
member’s opinions. A member who has more information than other members 
regarding a case can make better arguments which overlaps with the issue of biased 
information sharing (thematic network four). It is also decisive how processes of the 
formulary committee impact the influence level of certain members. Due to a limited 
time to present a case during the committee meetings, the member who prepares the 
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case information selects the most favourable argument. This issue is also addressed 
in thematic network four. 
 
The impact of external factors on the hospital formulary decision-making is the focus 
of the third thematic network. Two main areas are important: the factors inside the 
hospital, but outside of the hospital formulary and factors outside of the hospital, 
such as the pharmaceutical industry, regulations or the patient perception of the 
hospital. A key topic is a discrepancy between the big importance of relationships to 
the pharmaceutical industry and the perceived low impact on decision-making. 
Formulary committee members confirm different aspects which underline the 
importance of those relationships but they also deny any bias on their decision-
making. 
 
Then, the impact of subjective criteria on the decision-making process of the hospital 
formulary committee group is described in the fourth thematic network. This 
network includes a description of committee member’s issues in regards to the use of 
subjective criteria and justification of their decisions. Official documentation of 
formulary committee decisions does not provide hints for the acceptance or usage of 
subjective criteria but committee members make regularly use of them. This network 
also refers to the implications of information sharing between the formulary 
committee members. Thus it overlaps with thematic network one, two and three.  
 
The last thematic network describes the role of economic criteria and specifically the 
important role of budget impact in the decision-making process of the hospital 
formulary committee group. Despite the importance of budget impact, economic 
evaluations have no significant impact and often are not hospital specific enough. 
Another important aspect of this thematic network is the difference in decision-
making in regards to the type of the pharmaceutical drug. The applied decision 
criteria are dependent on what type of drug is under consideration. This thematic 
network, like thematic network one, emphasises the importance of pharmacists with 
the focus on economic measures. However, it also confirms the acceptance of 
subjective criteria, as described in thematic network four, because rejections are 
seldom made only based on the economic criteria.  
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7 Company market research data analysis 
7.1 Introduction 
The company market research data analysis represents step seven in the research 
design (Figure 42).  
 
 
 
Figure 42: Company market research data analysis. 
 
 
 
The company market research data represents an additional data source which was 
not specifically conducted for this thesis. All interviews for this market research were 
conducted by a pharmaceutical company in order to better understand hospital 
formulary committee decision-making for a specific pharmaceutical drug of the 
company.  
 
The analysis of the company market research interview transcripts was based on the 
structure of the thematic networks approach (Attride-Stirling, 2001) as described 
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already for the expert interview data analysis in chapter 6. The same eleven codes 
from the literature review were used in the first step of the analysis in order to slice 
up the interview transcripts into text segments: 
Group, Individual, Centrality, Dependencies, Information sharing, Objective 
information, Subjective information, Structure, Process, Transparency, External 
impact. 
 
In order not to limit this research and to allow explorative information, the initial list 
of codes was not closed. However, during the coding phase, no additional codes 
derived from the interview transcripts. 
 
Following the coding phase, the text segments were re-read to identify and refine 
topics which represent the second step of building thematic networks. This was done 
for all codes which resulted in twelve different basic themes (Table 17). 
 
Code (1st step) Themes (2nd step) --> Basic Themes
Centrality Nurses have no direct impact on the decision-making process
Centrality Pharmacists and physicians are the decision-makers
Centrality, Subjective information, Type of drug Expert opinions and experience are accepted as valuable input
Centrality, Group Selected key people have pre-meeting discussions
Centrality Pharmacists have a gatekeeper function
Centrality, Type of drug In case of generic drugs the decision is taken by the pharmacist
Group The formulary committee is used to legitimise pre-meeting decisions
Group Concerned departments have a higher decision-making weight
External impact Pharmacists have pre-discussions with the pharmaceutical industry
Objective information Cost considerations are dominant in the decision-making process
Objective information, Subjective information Cost concerns do not only consider the price of a drug
Information sharing The committee members often receive filtered information  
Table 17: Twelve different basic themes. 
 
 
 
All thematic networks with organising, basic and global themes are shown in Table 
18. 
  
 
 
 
Basic Themes Organising Themes (3rd step) Global Themes 
Nurses have no direct impact on the decision-making process
Pharmacists and physicians are the decision-makers
Pharmacists have a gatekeeper function
In case of generic drugs the decision is taken by the pharmacist
Expert opinions and experience are accepted as valuable input
Concerned departments have a higher decision-making weight
Selected key people have pre-meeting discussions
The committee members often receive filtered information
The formulary committee is used to legitimise pre-meeting decisions
Pharmacists have pre-discussions with the pharmaceutical industry
Cost considerations are dominant in the decision-making process
Cost concerns do not only consider the price of a drug
Key decision-makers
Pre-meeting decision-making
Value of expertise
Importance of economic criteria
Despite an accepted value of practical 
experience, the pharmacists have the 
highest impact on decision-making in 
the formulary committee 
Pre-meeting alignment leads to 
decision-making outside of the 
formulary committee and reduces the 
committee to a legitimisation role
Costs are the dominant criterion for 
specific pharmaceutical drug groups  
Table 18: Global themes to formulate a proposition for the organising and basic themes. 
 
 
 
1
9
2
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7.2 Despite an accepted value of practical experience, the 
pharmacists have the highest impact on decision-
making in the formulary committee 
This thematic network comprises of two organising themes and six basic themes 
(Figure 43). It describes the key role of pharmacists as the decision-makers with the 
highest impact on the hospital formulary committee decision-making. In addition, 
this thematic network also refers to the importance of practical experience and the 
value of expertise for the members of the committee.  
 
 
 
Organising Themes Basic Themes
Nurses have no direct impact on the decision-making process
Pharmacists and physicians are the decision-makers
Pharmacists have a gatekeeper function
In case of generic drugs the decision is taken by the pharmacist
Expert opinions and experience are accepted as valuable input
Concerned departments have a higher decision-making weight
Key decision-makers
Value of expertise
 
Figure 43: Thematic network describing the high impact position of pharmacists. 
 
 
7.2.1 Key decision-makers 
Pharmacists and physicians are the key decision-makers in a hospital formulary 
committee. Despite the central role of nurses in regards to the operational usage of 
pharmaceutical drugs, the decision-making process role is of minor importance. If 
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nurses want to address any concerns about a drug they need to discuss this with one 
of the direct decision-makers, such as physicians or pharmacists.  Especially 
pharmacists have a very prominent position since they often take responsibility as a 
gatekeeper. Thus, pharmacists can significantly influence the decision-making 
process of the hospital formulary with their possibility to allow or block an 
application for drug listing.  
P4 (pharmacist): In the hospital formulary committee you have physicians, 
then pharmacists, accordingly the general management. Those are the 
decision-makers in the hospital. 
 
NG1.1 (nurses): I believe that nurses have the weakest voice in the decision-
making process. In the end we have the “executive” but the actual decision is 
taken by the physicians and pharmacists. 
 
NG1.2 (nurses): In our hospital it is mainly the pharmacist, with 99%. 
 
NG1.3 (nurses): In our hospital it is mainly the head physician. […] I need to 
pass him, the head physician. I would need to get his attention and then tell 
him the advantages and disadvantages. He is then the one to decide if we will 
try it. He is the one to pass it on to the pharmacist and says that we will give 
it a try or not. 
 
Interviewer: You see yourself more in the operational role? 
NG1.1 (nurses): I can talk a lot. But is somebody interested? 
 
NG2.1 (nurses): You can say it if you have seen or heard something. But if 
somebody is listening, that is the question. You need to have very strong 
arguments that the pharmacy contemplates. 
 
In case of generic drugs or very similar drugs the decision power lies with the 
pharmacist. Those cases are often not even discussed in the hospital formulary 
committee meeting and can be fully decided by the pharmacist. 
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P2 (pharmacist): If it is a comparable drug. […] Then it would not 
necessarily be required to go via the hospital formulary committee, but can 
be decided by the pharmacy. 
 
P7 (pharmacist): If it is comparable to the current drug. […] then it is not a 
topic for the hospital formulary committee. It is then one of my basic tasks to 
assess, what kind of product it is. Is it really comparable? And then to contact 
the manufacturer to talk about prices. 
 
7.2.2 Value of expertise 
Hospital formulary committee members accept the opinions of experts and 
experience is seen as a valuable input for an informed decision-making. 
Consequently this also means that concerned departments with the experience have 
more weight in the decision-making process. On the contrary, departments which are 
not directly concerned and thus do not directly represent expert opinions, have less 
weight. 
P1 (pharmacist): I would talk to my [SPECIALIST], how they assess the drug. 
Before I propose a listing, I would talk to the opinion leaders or people who 
use the drug already; with them I would sit at one table and discuss the case. 
 
P2 (pharmacist): We always ask the users of the drug first, if they see any 
problems, if we change the drug. […] In addition we have a [SPECIALIST] 
in the committee. This does not have everyone. His opinion is of great 
importance. Those are the opinion leaders. 
 
P5 (pharmacist): Then you have a decision. This does not need to be 
unanimously, but it needs to be by the majority. Of course, the urologist 
would not be in a decisive role. He raises his arm or not [in a discussion 
about an anti-coagulant drug]. 
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7.3 Pre-meeting alignment leads to decision-making 
outside of the formulary committee and reduces the 
committee to a legitimisation role 
This thematic network comprises of one organising theme and four basic themes 
(Figure 44). It describes a possible second way of decision-making outside the 
hospital formulary committee meetings and its impact on the decision-making 
process of the committee. The pre-meeting discussions do not only include 
discussions between (internal) members of the hospital but also external 
stakeholders, such as the pharmaceutical industry. 
 
 
 
Organising Themes Basic Themes
Selected key people have pre-meeting discussions
The committee members often receive filtered information
The formulary committee is used to legitimise pre-meeting decisions
Pharmacists have pre-discussions with the pharmaceutical industry
Pre-meeting decision-making
 
Figure 44: Thematic network describing the influence of pre-meeting discussions. 
 
 
7.3.1 Pre-meeting decision-making 
A certain level of discussions happen outside of the hospital formulary committee 
meetings between selected members who want to either clarify difficult decisions 
upfront or who want to align with others to increase chances to have a successful 
application. This way, other committee members might be in a situation where they 
do not receive all available data for an informed decision-making. For example, 
physicians might talk to the pharmacist in advance or the pharmacists have already 
pre-discussions with the pharmaceutical industry about pricing. Additionally, the 
members who present their application have the opportunity to prepare their 
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messages in the best possible way for a positive outcome. Due to the limitation of the 
presented data for each case, members of the committee only get a snapshot of the 
case, where the content is compiled by the applicant. 
P3 (pharmacist): All that information is then used in the committee meeting. 
Or even in advance.  
 
Interviewer: Does it happen that in those pre-discussions you already talk to 
the manufacturers, eventually already talk about prices? 
P4 (pharmacist): Yes, of course. […]Everybody prepares themselves, on the 
physician’s side, as well as on the pharmacist’s side. There it sometimes 
happens that, depending on the urgency, you have discussions or telephone 
calls in advance to the meeting. This means you have certain agreements. 
You discuss, what is really important! 
 
P6 (pharmacist): The applicants present their case in 10-12 sentences, what is 
essential for them and in addition the most important references. That is 
sufficient for a decision. 
 
The formulary committee is also used to legitimise those pre-meeting decisions. In 
these cases members coordinate with others, already take a decision and then put an 
application into the hospital formulary committee process in order to get an official 
approval.  
P3 (pharmacist): This means, one would like to achieve a consensus. 
However, this does not need to be during a committee meeting. This can be 
prepared also in advance to the meeting, but then needs to be officially 
approved in the meeting, since you would like to have your decision 
legitimised. 
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7.4 Costs are the dominant criterion for specific 
pharmaceutical drug groups 
This thematic network comprises of one organising themes and two basic themes 
(Figure 45). It describes the dominant role of cost considerations on the decision-
making behaviour of hospital formulary committee members.  
 
  
 
Organising Themes Basic Themes
Cost considerations are dominant in the decision-making process
Cost concerns do not only consider the price of a drug
Importance of economic criteria
 
Figure 45: Thematic network about the dominant role of costs. 
 
 
7.4.1 Importance of economic criteria 
The importance of economic criteria is very high for the hospital formulary 
committee decision-making process. Even in cases where the alternative drug has 
advantages compared to the current drug, the cost criterion has a significant impact 
on the decision-making discussion. The price of a pharmaceutical drug is important 
but the cost discussions of the committee members can be broader, more 
comprehensive considering also process costs. 
NG2.1 (nurses): Most of the time, the cost factor is the main criterion. 
 
P4 (pharmacist): Nowadays it is always important to focus on the available 
data; data in the sense of costs. What does it all cost? […] Data in regards to 
the frequency of use, so that you can include the importance level and the 
cost factor into your calculations. Is it for a broad spectrum or is it a very 
narrow indication. 
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PG2.1 (physicians): It needs to be massively better, or cheaper. But if it is 
more expensive, then it needs to be massively better. 
 
PG2.2 (physicians): Finally, the killing argument is always the cost factor. 
This is where it always ends up, unfortunately. I can only agree. Even if it is 
massively better and more expensive, a lot of argumentation effort would be 
needed. The pressure on costs is so strong.  
  
PG3.1 (physicians): It is not uncommon that drugs are changed due to better 
handling which finally leads to an improved workflow to decrease costs, even 
if the price of the drug is higher. 
 
7.5 Summary 
This chapter summarises the findings of the qualitative company market research 
interview analysis. In general, the company market research data generated far less 
themes than the expert interview data analysis. The reason for this was the original 
purpose of the company market research which was different to the goals of this 
research. A description of the hospital formulary decision-making process was only a 
small part of the company market research interviews. Hence, the depth of the 
captured interview information was less detailed and only eleven basic themes could 
be extracted. Out of these eleven themes, three thematic networks about the decision-
making process of hospital formulary committees were identified.  
 
The first thematic network describes the key role of pharmacists as the decision-
makers with the highest impact on the hospital formulary committee decision-
making. In addition, this thematic network also refers to the importance of practical 
experience and the value of expertise for the members of the committee. Most of the 
outcomes of this thematic network were not new but confirmed findings from the 
expert interview data analysis. One exception was information regarding the role of 
nurses in the hospital formulary committee. This was already topic in the literature 
(Martin et al., 2003; Plet et al., 2013) but not much insight could be extracted from 
the expert interviews. In contrast, the company market research data analysis 
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confirmed a small impact of nurses on hospital formulary committee decision-
making despite their direct role in providing pharmaceutical drugs to patients.  
 
Following this, the second thematic network reveals a possible second way of 
decision-making outside the hospital formulary committee meetings and its impact 
on the decision-making process of the committee. The pre-meeting discussions do 
not only include discussions between (internal) members of the hospital but also 
external stakeholders, such as the pharmaceutical industry. 
 
Cost considerations and their dominant role on the decision-making behaviour of 
hospital formulary committee members are described in the last thematic network 
and confirmed findings from the expert interview data. 
 
Despite the low level of detail of the interview data, it is a valuable add-on to the 
overall analysis. The company market research interviews were conducted with very 
different functional roles (physicians, pharmacists and nurses) and thus covered 
additional groups who were not considered for the expert interviews. It added some 
new insights on the role of nurses and also showed some dissatisfaction with the 
current situation from the nurses’ perspective. This added additional perceptions to 
the data analysis and facilitated the identification of underlying generative 
mechanisms which will be discussed in the next sections. 
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8 Discussion 
8.1 Introduction 
The literature review showed, that besides perceived objective criteria, subjective 
criteria have a strong impact on hospital formulary committee decision-making, 
specifically in cases where the perceived objective criteria is subject to uncertainty. 
Dual processing systems, such as Hammond’s cognitive continuum model (1996, 
2000), represent a good theoretical basis for decision-making in hospital formularies 
and help to understand the different use of analytic or intuitive decision-making. But 
hospital formulary committee decision-making is more complex combining 
individual decision-making and group decision-making. According to the Social 
Decision Scheme Theory (Davis, 1973, 1996), group decision-making processes 
function as a combination of all group members’ preferences which are aggregated to 
form a group response. In addition, a study by Wirtz et al. (2005) showed that 
decision-making is not only bound to a fixed relative importance of decision criteria 
but is mainly impacted by group discussions and other group decision-making 
phenomena, such as influential individuals or information sharing. Based on these 
results, a hospital formulary committee decision-making framework was constructed 
to visualise the complexity of the process (Figure 46). 
 
 
Figure 46: Hospital formulary committee decision-making framework. 
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This chapter represents step eight in the research design (Figure 47). According to 
the convergent parallel database mixed-methods design (Creswell, 2003), the results 
of the quantitative analysis (step five) and the qualitative analyses (step six and 
seven) were compared and discussed for final conclusions. Generative mechanisms 
were identified to allow the evaluation of potential practical implications. The 
outcomes of the three data analyses (survey, expert interviews and company market 
research interviews) were basis for the identification of underlying mechanisms. 
These mechanisms and conclusions were used to specify and extend the preliminary 
hospital formulary committee decision-making framework and to formulate 
implications for stakeholders. 
 
Figure 47: Comparison and discussion of the combined results. 
 
 
In the course of these conclusions the research questions RQ-1 to RQ-4 will be 
answered and discussed. 
 
203 
8.2 The balance between intuitive and analytic decision-
making 
This section mainly answers research questions RQ-1 and RQ2:  
RQ-1. What are the criteria in funding decisions for pharmaceutical drugs in 
hospital formulary committees? 
RQ-2. What is the relative importance of each of those criteria in funding 
decisions for pharmaceutical drugs in hospital formulary committees? 
 
The literature review demonstrated that the cognitive continuum model (Hammond, 
1996, 2000) fits well as a theoretical basis for healthcare decision-making. It 
describes the decision-making of individuals as an oscillation on a continuum 
ranging between intuition and analysis.  
The results of the quantitative analysis showed that formulary committee members 
use a mix of perceived objective and subjective criteria for their decision-making. 
Nonetheless, the survey did not ask questions to explore if and how members of the 
committee actually decide based on a cognitive continuum type of model. This is 
different for the qualitative analyses which confirm that members of the committee 
balance the weighting of the different decision criteria dependent on surrounding 
conditions. The results show a clear preference for perceived objective criteria and 
data from clinical trials is the most important criterion for all decision tasks. It is also 
visible in the qualitative analyses results that the preference for perceived objective 
data derives from the impression of members of the committee that decisions are 
easier to justify. For example, this can be seen in the way the documentation of 
formulary committee decisions is done. Perceived subjective criteria are not 
documented, even though members of the committee apply them for their decision-
making. This outcome is supported by the findings of other studies which showed 
that written decisions as part of drug funding decision documentation are mostly 
justified with scientific or economic reasons independent how many other perceived 
subjective criteria have been adopted (Dean et al., 2013). 
In addition, the qualitative analyses also revealed that perceived subjective criteria is 
challenged if it shows different conclusions than the available perceived objective 
criteria.  
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All data analyses showed that in some cases practical experience as a decision-
making criterion becomes more important. This phenomenon of the empirical/actual 
domain is based on committee members’ increasing willingness to accept subjective 
data if uncertainty increases. In the real domain there is an uncertainty mechanism 
which opens hospital formulary committee members to accept subjective data, even 
if they usually have a clear preference for perceived objective data. 
All data analyses also showed for the empirical/actual domain that perceived 
objective data, if available, create more trust than practical experience. In some cases 
this was argued with less risk of bias and a higher scientific rigor. The phenomena in 
the empirical/actual domain demonstrate that perceived objective criteria are 
favoured even though they are not always available. One explanation is the decision-
making mechanism in the real domain based on the scientific background of most 
members of the formulary committee and the resulting importance of perceived 
objective data. This leads to the observed preference of objective criteria and the 
reluctance of committee members to mention practical experience in the official 
justification.   
The empirical/actual domain also indicated a big difficulty for committee members 
to quantify the importance of subjective data for the decision-making process. Thus, 
the mechanism in the real domain is that decision-makers make use of subjective 
criteria but this happens more intuitively and implicit.  
One outcome visible in the empirical/actual domain which was mentioned in the 
expert interviews and which weakened the acceptance of perceived objective data 
was a lower willingness to discuss an application for an oncology drug or a drug used 
for children. For the real domain, this shows that an increase in empathy can 
positively influence the acceptance of subjective criteria which is described more in 
detail in section 8.2.3. 
 
8.2.1 Economic data and costs 
Within the literature, health economic evaluations, and specifically cost-effectiveness 
analyses (CEA), are used seldom in decision-making at the hospital level (Gallego et 
al., 2009; Williams & Bryan, 2007).  In most cases the results of the quantitative 
analysis confirmed this assumption with one exception for orphan drugs were health 
economic evaluations had a high importance ranking. This result for orphan drugs 
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cannot be fully explained since the qualitative data analysis revealed a very 
consistent low importance of health economic evaluations in hospital formulary 
decision-making. One possible explanation could be a confusion of the meaning of 
health economic evaluations with other economic measures. All three data analyses 
showed a high importance of economic measures evidenced in the empirical/actual 
domain. Budget impact and costs were identified as dominant decision-making 
criteria especially for pharmacists. This represents a cost orientation of the 
pharmacists and assumes that hospitals have put economic topics on high priority. 
The mechanism behind this is the financial pressure on hospitals which is reflected in 
the formulary committee's decision-making. Results of the qualitative analyses 
demonstrated that members of the committee are more willing to discuss if the 
budget impact is higher and thus they might face restrictions on their own financial 
flexibility. This result from the empirical/actual domain supports the assumption that 
committee members defend their departments. The mechanism behind this behaviour 
is the limit on the total budget and a potential restriction for one department if 
another department causes higher costs. It also revealed grounded in the real domain 
that physicians and pharmacists are afraid of losing importance and power compared 
to other departments. Budget impact as a criterion is more pronounced in this study 
than in other research. There might be various reasons for this outcome. The 
relatively high importance of budget impact as a criterion might reflect an increased 
financial pressure on German hospitals in recent years compared to earlier studies or 
other countries. Differences might also be derived from the way this research was 
conducted. Many earlier studies on decision-making criteria used a survey-only 
methodology to evaluate the importance of decision-making criteria. Physicians or 
pharmacists were probably more reluctant to rank budget impact higher in a survey 
without a possibility to further explain this as it was possible in the expert interviews.  
 
Despite this strong influence on hospital formulary committee decision-making, 
economic criteria usually do not lead to rejection of a drug listing which was one 
important result of the qualitative analyses. It is more likely that the committee 
decides to allow a drug on a temporary basis. In the real domain this relates to a 
power mechanism. This means that formulary committee members are afraid of 
voting against a drug, proposed by a (powerful) colleague, and potential 
consequences if there are no clear facts which support a rejection. A vote against a 
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drug request from another member might lead to a negative opinion from this 
member on their next own application.      
 
Literature showed that one of the issues around the data provided to hospital 
formulary committees is the lack of local adaptation. Very often the data is used in a 
general way instead of adapting to the local hospital situation which makes it very 
difficult for the decision-makers of a formulary committee (Späth et al., 2003; 
Williams & Bryan, 2007; Walkom et al., 2006). Clinical trial populations often do 
not match with the patient population of the respective hospital. The qualitative 
analyses endorsed this assumption. For the real domain this means that hospitals are 
not interested in general costs, but they are only interested in costs relevant for the 
specific hospital situation. 
 
When hospital formulary committees consider the cost of a drug, they usually do not 
only refer to the price. They rather consider total costs including drug costs and 
process costs. Hence, the costs of switching to a new drug are important as well as 
costs associated with side effects of a drug.   
 
8.2.2 Type of pharmaceutical drug 
The literature was only vague in regards to the question if the type of a 
pharmaceutical drug influences the decision-making process in hospitals. Only two 
studies (Gallego et al., 2009; Motheral et al., 2000) looked more closely at this 
question and came to the conclusion that formulary committee members consider 
different aspects in the decision-making process if the drug is used for treatment of a 
severe disease and no comparable alternatives are available.  
The quantitative results of the survey analysis demonstrated that 51% of the 
respondents use different decision-making criteria for different types of 
pharmaceutical drugs. Detailed results from the quantitative analysis for different 
classes of drugs emphasised the use of different criteria for different types of drugs. 
For orphan drugs, members of the committee apply different criteria due to the lack 
of clinical trials data and most of the time a high price. However, orphan drugs are 
usually handled outside the hospital formulary committee listings because they are 
not used on a regular basis. Physicians can order them on special request and the 
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qualitative analyses results confirmed that physicians have the highest impact on 
orphan drug decision-making.  
 
Newly developed drugs are treated differently compared to already established drugs. 
The reason for that is the lack of available data and the resulting uncertainty. 
Hospital formulary committee members take decisions on those drugs very often on 
a preliminary basis to allow experience gathering for other members. 
 
8.2.3 Emotional criteria and clinical experience 
The literature review confirmed the use of perceived subjective criteria such as ethics 
or clinical experience in decision-making of hospital formulary committees (Wirtz et 
al., 2005). It is also important that pharmaceutical drug funding decisions have 
impact on patients, physicians and clinical staff which adds an emotional component 
to the complex decision situation enticing committee members to consider perceived 
subjective criteria (Janknegt, 2001). 
 
The importance of clinical experience was confirmed by the quantitative and the 
qualitative data analyses. Hospital experience and recommendations by other 
committee members were always ranked in the top ten decision criteria for all types 
of drugs in the survey. In addition, the interview data endorsed the impact of this 
criterion. Nonetheless, the interviewees stressed that recommendations by other 
members are not sufficient as a standalone reason and thus cannot be used alone for a 
positive decision.  
 
The interviews indicated also that emotional criteria have an impact on the decision-
making behaviour of committee members. For example, the qualitative interview 
data analyses showed that drugs for patients with oncology indications or children 
are less challenged than other drugs due to the member’s empathy. The interviews 
also provided examples, where members made use of emotional criteria to defend 
their argumentation against perceived objective criteria, such as costs of the drug.  
In contrast to severity of disease, patient’s quality of life is another subjective 
criterion of minor importance. Especially health related quality of life studies were 
not ranked in the top ten criteria in the quantitative data analysis.  In addition, the 
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qualitative data analyses also did not show any significant impact of quality of life 
information on the decision-making process. However, hospital formulary committee 
members consider the patient’s perspective with another criterion: severity of 
disease. Ranked high in the quantitative data analysis and also mentioned as very 
important during the interviews, decision-making is influenced by a high severity of 
disease. This is usually always valid for oncology and orphan diseases. 
 
These observations from the empirical/actual domain directly counteract the 
preferred usage of perceived objective criteria as mentioned in section 8.2.1. Hence, 
the educational background and training of physicians and pharmacist which is the 
generative mechanisms for the experienced preference of perceived objective criteria 
conflicts with the generative mechanism of human empathy which strengthen the 
acceptability of subjective data. 
 
8.2.4 Administration/ Practical criteria 
Although ranked in the quantitative data analysis in the top ten important criteria for 
monoclonal antibodies/ immunomodulators and medical devices, the qualitative data 
analyses did not show a very high importance for administration criteria. This might 
be a consequence of the low impact of nurses in the hospital formulary decision-
making process. Some interviewees indicated that they consider feedback and 
objections by nurses because they are usually the concerned people regarding the 
administration of pharmaceutical drugs. However, these criteria seem to be only of 
minor importance. 
 
8.2.5 Decision-making guidelines and documentation 
Previous research indicated that most of the time there is no guideline and in cases 
where a guideline is available, the criteria which should be used in the decision-
making process are often not explicitly mentioned or there is no information on 
relative importance (Martin et al., 2003; Mittmann & Knowles, 2008; Plet et al., 
2013). Findings from the survey data and the expert interviews confirmed this and 
demonstrated for the empirical/actual domain that guidelines on the decision-making 
process rarely exist and if they exist, they only provide rough guidance with no 
details. Additionally, the survey had a very low response rate. Hence, visible in the 
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empirical/actual domain is a reluctance of formulary committee members to support 
transparency in decision-making. The mechanism in the real domain is the 
reluctance of hospitals to justify their decisions and the concern to be vulnerable to 
outside critique. For example, results from the quantitative data analysis showed that 
only 49% of the respondents have guidelines in their hospital. In addition, the 
qualitative data analyses indicated that the written guidelines only mention perceived 
objective criteria, such as clinical trials data or economic data, and seldom refer to a 
relative importance of decision criteria. This outcome was not so clear in the 
quantitative data analysis. Approximately one third of the respondents who have 
written guidelines stated that the guidelines also refer to perceived subjective criteria, 
such as recommendation by the pharmacist or clinical experience. These different 
results cannot be fully explained. 
 
Another outcome for the empirical/actual domain, taken from the expert interviews, 
was that the case documentation for an application usually has no standard format 
and it always shows only specific facts making the overall case positive. In particular 
the short time to present the case during the committee meetings limits the 
possibilities to show all relevant data. Hence, the mechanism behind this is that case 
documentation is influenced by the individual goals of the applicant and the limited 
time to present case data. 
 
8.2.6 External impact 
The impact of external influences on decision-making and the relative importance of 
this criterion are vaguely described in the literature. Possibly because of the 
sensitivity of the topic, only three studies (Dranove et al., 2003; Jenkings & Barber, 
2004; Späth et al., 2003) gained insights on the external influence on hospital 
formulary committee decision-making.   
Späth et al. (2003) recognized in their study that relations between the 
pharmaceutical industry and the decision-makers influence the decision of those 
committees. Dranove et al. (2003) identified a positive correlation between the 
number of sales force visits and the possibility of making a positive adoption 
decision for a pharmaceutical drug. A study by Jenkings and Barber (2004) showed 
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that hospital formulary committees seem to adapt their discussion behaviour 
dependent on the relationship between the industry and the hospital.  
 
The quantitative survey results confirmed the perceived sensitivity of this topic since 
they revealed a lack of transparency in regards to the relationships between 
committee members and the pharmaceutical industry. Respondents’ answers in the 
survey indicated that the cooperation (e.g. clinical trials) between members of the 
hospital formulary and a pharmaceutical manufacturer is seldom communicated. 
43% of the respondents stated that this happens rarely or never. In addition, it was 
also shown that formulary committee members try to justify close connections to the 
industry and emphasise independent decision-making. Altogether this indicates that 
working with the industry has a negative undertone. This means for the real domain 
that committee members are afraid of being suspected for biased decision-making 
and/or for bribing. The qualitative analyses results revealed more details on external 
influence.  Although members of the committee emphasise their independence in 
decision-making, the qualitative data also demonstrated a strong influence of external 
factors. Listing applications are often initiated by the pharmaceutical industry. 
Especially for new drugs the pharmaceutical industry has a strong influence due to 
the lack of available data. In addition, the industry “builds” convinced advocates if 
they involve committee members in clinical trials. Supported by the quantitative and 
qualitative data analyses which show limited transparency in regards to external 
influence it can be assumed that members of the committee do not like to talk very 
openly about those relationships.   
Literature also revealed a potential negative influence of this external influence. 
Pressure from the industry´s sales force or potential bribing was seen critically and 
usually led to a more rigid evaluation of the pharmaceutical drug (Jenkings & 
Barber, 2004). This outcome was also confirmed by the expert interviewees. 
Committee members were aware of the external influence but did not seem to be 
very happy about it. They tried to put emphasis on their independence in the final 
decision.  
 
Other research concentrated very much on the external impact by the pharmaceutical 
industry but missed information on other external influencing factors, such as health 
insurances or the importance of external reputation. In the empirical/actual domain it 
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was observed that hospitals are very interested that therapies initiated in the hospital 
are not interrupted, continue in the outpatient setting and that hospitals care about 
their relationships with physicians in the outpatient setting. Having in mind that the 
German hospital system works with Diagnosis Related Groups (DRG) payment (a 
fixed fee payment) in the hospital setting, this usually means that payers have very 
limited influence on pharmaceutical drug use (in the hospital). Despite this, the 
identified mechanism in the real domain is that payers have an impact on the hospital 
decision-making due to the reimbursement power of health insurances in the 
outpatient setting. Consequently, pharmaceutical drugs are only listed if funding is 
also ensured outside of the hospital which means a strong but indirect impact of 
health insurances on the committee’s decision-making due to the funding 
mechanisms in the German healthcare system.  
The external reputation of the hospital was not mentioned in the identified literature 
but plays an important role in the drug funding decision-making of the hospital 
formulary committee. Interview data showed that hospitals compete against each 
other in providing innovative and patient-friendly therapies and some treatments are 
crucial for the representation of the hospital expertise, independent of any economic 
criteria. Hence, a generative mechanism is the motivation of hospitals to optimise 
their external reputation. This is based on observations in the empirical/actual 
domain that innovative, new pharmaceutical drugs are often handled differently 
compared to existing drugs, especially when those drugs are already used for 
therapies in competitor hospitals. Besides the motivation of hospitals to optimise 
their external reputation, this event of the empirical/actual domain was also 
mentioned in the context of high uncertainty about new pharmaceutical drugs. This 
shows that different generative mechanisms can be deduced from the same 
observable event and that generative mechanisms might overlap. 
 
In conclusion this means that the decision-making framework needs to be adapted to 
reflect the strong influence of budget impact, type of a drug or the clinical 
experience. On the other hand, administration and patient’s quality of life do not 
influence the decision-making a lot. Members of the committee rather apply empathy 
for their decision-making. The framework needs to consider the impact of the case 
documentation and the different external influences, such as the pharmaceutical 
industry or health insurances. 
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8.3 Decision-makers in the hospital formulary committee 
This section mainly answers research question RQ-3:  
RQ-3. What is the level of influence of each stakeholder group on drug 
funding decisions of hospital formulary committees? 
 
Literature showed that depending on the hospital formulary committee, the 
involvement of nurses, financial administrators, pharmacologists, patients and 
hospital administration is different. Whereas nurses, pharmacologists and hospital 
administration are part of some hospital formularies it is very seldom that financial 
administrators or patients are involved (Plet et al., 2013; Späth, Charavel, Morelle & 
Carrere, 2003). This was also confirmed for German hospitals by the quantitative and 
qualitative analyses. 
 
Different studies confirm a strong influence of physicians and specifically 
pharmacists on the hospital formulary committee decision-making (Alsultan, 2011; 
Fijn et al., 1999; Gallego et al., 2009). This result from other countries can also be 
confirmed for Germany. The quantitative survey showed a similar importance 
ranking for pharmacists and physicians but confirmed the general high importance of 
these two groups. It also showed that other functional groups, such as financial 
administrators, nurses or the general manager, do not have significant impact on the 
decision-making process. Other roles than pharmacists or physicians can have 
influence on the process in very specific cases. For example, financial administrators 
can provide functional expertise in case the reimbursement of a specific drug is 
difficult to achieve. Or nurses might have impact on a decision if it is dependent on 
the administrative handling of a drug. Hence, non-pharmacists or non-physicians are 
not decision-makers in a hospital formulary committee. However, their opinion can 
potentially influence the decision-making by pharmacists or physicians. The 
conclusions from the qualitative interviews emphasised these results. Furthermore, 
the qualitative interviews revealed an even stronger influence on the decision-making 
process by the pharmacists compared to physicians. This generative mechanism can 
be indirectly observed by specific events, such as the behaviour of physicians when 
they try to convince pharmacists in advance to the committee meetings or if 
physicians talk to pharmacists in advance to the meetings to verify their chances of 
213 
success. Specific roles or an activity, such as the pharmacist as a chair of the hospital 
formulary committee or the key responsibility for preparation of documentation, is 
evidence for the strong influence of pharmacists in the committee. This has been 
confirmed by the literature review, the quantitative survey and the qualitative 
analyses.  
 
In conclusion this means that the decision-making framework needs to be adapted to 
reflect that pharmacists and physicians are the decision-makers. Besides, the 
framework needs to show that other functional roles might have influence on the 
decision-makers but they are no decision-makers themselves. 
 
8.4 Group dynamics and impact on decision-making 
This section mainly answers research question RQ-4: 
RQ-4. What are the motives and objectives of decision-makers when 
applying quantitative and qualitative criteria for drug funding 
decisions in hospitals? 
 
The qualitative data analysis confirmed that members do have an opinion before they 
go into the committee meeting. This individual preference is then adapted during the 
group discussion and dependent on many different variables.  
 
8.4.1 Power relationships 
Information on the influence of power relationships in hospital formulary committee 
decision-making is scarce. Outcomes of the literature review indicated that power 
relationships (e.g. hierarchical dependencies) have influence on hospital formulary 
committee member’s decision-making (Dranove et al., 2003; Gibson et al., 2005). In 
the study of Gibson et al. (2005), participants doubted a true representation of 
member’s opinions due to the fact that some formulary committee members reported 
directly to other more senior members. Formulary committee members were 
reluctant to discuss against the opinion of their bosses. 
 
These assumptions could not be confirmed by this study. Results from the qualitative 
data analyses emphasised the independence of member’s decision-making and 
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hierarchical dependencies. Findings from the interviews showed for the 
empirical/actual domain a low level of influence of hierarchical structures. Most 
formulary committee members were on the same or similar hierarchy level. In many 
cases there is no direct hierarchical dependency due to the structure of the hospital 
formulary, with one representative for each department.  The mechanism in the real 
domain is that between physicians, the seniority level is not the most decisive factor 
for decision-making. This does not fully preclude the impact of power relationships. 
Departments with a higher financial weight for the hospital have a higher importance 
which might increase the power in the decision-making process. In these cases it is 
the structural power which dominates the power of the individual. 
 
The chair of the committee usually has a central function and if yes and no votes are 
equal, the chair has the decisive vote. However, this formally most powerful position 
is not necessarily the position which influences decision-making of the hospital 
formulary most. The interview data analyses indicated that strong individuals in the 
committee can have influence on the committee chair. In some cases this is derived 
from the importance of a specific department as described above and in some cases 
this is derived from the communication strengths and skills of individuals. This 
means for the real domain that the role of the committee chair represents formally 
the most powerful position but often does not reflect reality or does not consider 
other potentially even more influential members. Sometimes this formal role is even 
abused by other more powerful members to build alliances which are hard to "fight" 
in the committee discussions.   
 
Findings from the survey data and the expert interviews demonstrated for the 
empirical/actual domain that some physicians are very passive during discussions on 
economic questions in the formulary committee meetings. For the empirical/actual 
domain this means that physicians usually do not interfere or are critical when it 
comes to questions outside of their competency area. One mechanism for this is the 
focus of physicians on their own department, as mentioned before, anchored in the 
real domain by physicians' view of themselves more as medical experts, than as 
managers. They realise a lack of expertise and appreciate the pharmacist's knowledge 
of economic issues. This is true, especially in cases where the physician does not 
need to defend his/her own competency area. A similar finding relates to passiveness 
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of physicians during discussions on medical questions. For the empirical/actual 
domain this means that some physicians and their departments are less influential 
than others. The mechanism in the real domain is that the level of strategic and 
economic importance of one department determines its potential impact on decision-
making. Another explanation for passiveness is the information advantage of the 
applicant and the pharmacist. This concludes into the mechanism that the perceived 
expert level of committee members with more knowledge creates a barrier for other 
members in the discussions.  
All data analyses showed for the empirical/actual domain that non-physicians and 
non-pharmacists have low influence on the decision-making process and from the 
groups who work closely with patients or nurses have a weak representation in the 
formulary committee. For the empirical/actual domain this means that other 
functions than physicians or pharmacists are only considered during decision-making 
if medical or economic criteria are not sufficient. Hence, the mechanism behind this 
is that physicians and pharmacists have a perception about other functional roles as 
being less qualified to contribute to decision-making. For example, nurses are part of 
the operations but not part of the decision-making process and thus they are usually 
not considered. 
 
8.4.2 Centrality and group size 
Results of the literature review identified an impact of the hospital formulary 
committee size which can negatively affect an adoption decision if the committee is 
larger (Dranove et al., 2003). The authors assumed a difficulty to reach a consensus 
in a bigger group or in a group with more diversity in terms of the represented 
functions. This cannot be confirmed by the qualitative data analysis. To the contrary, 
the interviews indicated that the group size does not have impact on the group’s 
decision-making.  
The empirical/actual domain identified committee members’ desire for reliable 
information and a certain level of fear or uncertainty. Considering that the members 
of the hospital formulary committee are usually very influential and powerful people 
in the hospital, the mechanism behind this is the fear of committee members to be 
blamed in front of this important audience potentially losing power and 
compromising their further career. During these pre-discussion, members also want 
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to convince other members of their application and to build alliances. For the real 
domain, this shows the committee members’ motivation to build barriers for counter-
argumentations and to increase the chances of success for their own applications. 
 
This also means that other members in the formulary do not get all critical 
information on a case which in consequence can lead to perceived easier decision-
making. It also means that group consensus can be a consensus between the two most 
powerful members with the additional effect that other members do not want to vote 
in opposition. This effect was also found in a study by Gibson et al. (2005) where 
participants described a “feeling pressured to conform and reluctant to vote in 
opposition […] or to express dissent […]” (p. 2359).  
 
This research also revealed knowledge about the centrality of specific committee 
members. In general, expertise of different functions is valued and accepted. 
Findings from the empirical/actual domain indicated that decision-making is 
dominated in some cases by physicians and not pharmacists. The level of physician’s 
dominance varied with the specificity of the decision and that the physician’s opinion 
was more important if there was lack of other data. For the real domain, this finding 
suggests that formulary committee members believe in expert colleagues in difficult 
decision situations but they also try to avoid taking responsibility in cases of great 
uncertainty. In combination with individual characteristics, such as a strong 
personality or strong rhetorical skills, the expert status can be very convincing. 
 
8.4.3 Role of the individual and the personality 
Several studies (Alsultan, 2011; Fijn et al., 1999; Gallego et al., 2009; Wirtz et al., 
2005; Gibson et al., 2005; Janknegt; 2001; Jenkings & Barber, 2004; Motheral et al., 
2000) revealed the existence of an advocate as an important decision criterion. In this 
context an advocate is meant to be the person who supports the drug addition to the 
formulary listing.  
This is also valid for German hospital formulary committees but needs to be 
differentiated.  
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Results from the quantitative analysis showed that recommendations by individuals 
and experience made in the hospital are always ranked high independently from the 
type of drug. However, the qualitative analyses also showed that the respective 
impact of an individual is dependent on several other factors, too. One is the 
personality which means that members of the committee who are perceived to be 
strong individuals can easier convince others. Another factor is the ability of a 
member to communicate, such as rhetorical skills, and the operational way how a 
member communicates his argument. A phenomenon observed in the 
empirical/actual domain, based mainly on the expert interviews, was that formulary 
committee members emphasize positive facts in their argumentations to support their 
cases with different skills. Members with good communication skills have 
advantages and chances of success are more likely only based on their individual 
ability to present and argue. For the real domain, this shows that individual character 
and communication skills of each formulary committee member are decisive for his 
ability to convince other members. For example, members present their case in front 
of the hospital formulary committee and the time for the presentation is limited. 
Hence, members need to decide how they present their case in a convincing manner 
in this limited timeframe. This becomes also visible when members use strong 
emotional arguments to support their case. 
 
In conclusion this means that the decision-making framework needs to be adapted to 
reflect the specific importance of experience and also the impact of the individual 
personality. The framework also needs to consider the two ways of how 
communication impacts the opinion of committee members: either depending on the 
general communication skills of a presenter or the way the presenter argues the case.  
 
All identified findings for the empirical, actual and real domain are shown in Table 
19. These findings on the generative mechanisms were used in chapter 9 to identify 
potential implications for different stakeholder groups.  
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Empirical/ Actual  Real (potential structures) 
Budget impact mentioned as most important criterion Financial pressure on hospitals is 
reflected in the formulary committee's 
decision-making 
Strong price orientation of pharmacists 
Strong economic focus of the hospital 
Pharmacists usually lead the formulary committee + the 
financial situation is often discussed during formulary 
committee meetings 
Cost is a dominant criterion for decision-making 
Higher budget impact means higher involvement by 
formulary committee members 
Higher costs in one department 
potentially means restrictions in others 
Formulary committee members defend their budgets 
Clinical trial populations often do not fit the real world 
hospital patient population 
There is reluctance regarding economic data (also from 
clinical trials) 
Hospitals are interested in total costs (not 
only drug costs) and costs individual for 
the respective hospital 
Some situations allow physicians to dominate decision-
making 
Formulary committee members trust in 
expert colleagues in difficult decision 
situations and they try to avoid taking 
responsibility in cases of great 
uncertainty 
The influencing power of physicians increases or 
decreases with the level of specialization 
Expert opinions become more important if there is lack 
of other data 
Often there is a low activity of committee members 
other than the applicant or the pharmacist 
The perceived expert level of committee 
members with more knowledge creates a 
barrier for discussions 
The applicant and the pharmacist have much more 
possibilities to prepare themselves for discussion 
Formulary committee members have already 
discussions about controversial topics before the 
committee meetings 
Formulary committee members do not 
want to be blamed in the committee 
meeting and infront of other members. 
Because the committee is a group with 
important representations of the most 
powerful players in the hospital.  
Formulary committee members want to increase 
reliability of the information they hold and they are afraid 
of controversial discussions 
Formulary committee members clarify the opinion of 
other important members before the meeting. 
Formulary committee members try to 
build barriers for counter-argumentation 
in order to increase the chances of 
success for their cases Formulary committee members try to build alliances 
with other important decision-makers to make it more 
difficult for other members to argue against their case 
Cooperation between members of the formulary 
committee and the industry is seldom made transparent 
Committee members are afraid of being 
suspected for biased decision-making 
and/or for bribing 
Despite strong bonds between committee members and 
the industry, Industry cooperation is perceived to be 
suspicious 
Formulary committee members try to justify close 
connections to the industry and emphasise an 
independent decision-making 
Pharmaceutical industry has influence on drug listings The pharmaceutical industry knows most 
about their own drug but participants’ 
perception is that the pharmaceutical 
industry also wants to use all possibilities 
to get a favorable decision 
Pharmaceutical industry provides information and holds 
close contact to members of the formulary committee 
Table 19: Findings for the empirical, actual and real domain. 
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Empirical/ Actual  Real (potential structures) 
For therapies which continue in the outpatient sector the 
committee members consider the impact on outpatient 
physicians 
Due to the reimbursement power of 
health insurances in the outpatient 
setting, the payers also have an 
indirect impact on the hospital 
decision-making  
Hospitals want their therapies not to be interrupted and they 
also do not want any arguments with outpatient physicians 
Innovative therapies or more patient convenience especially 
when already offered by competitor hospitals are considered 
differently in decision-making 
Innovative therapies are positive for 
the hospital reputation. Hence, 
external reputation of the hospital 
might overrule economic 
considerations 
Patients and other hospitals consider and assess the 
therapy portfolio of the specific hospital 
Pharmaceutical drugs with existing substances and new 
substances are handled differently. New substances are 
seldom rejected in the first place 
Formulary committee members emphasize positive facts in 
their argumentations to support their cases 
The individual character and 
communication skill of each 
formulary committee member is 
decisive for his ability to convince 
other members 
It is decisive how committee members build up their 
argumentation and what kind of arguments they select to 
support their case 
Low number of written guidelines and low response rate Hospitals do not want to justify their 
decisions and be vulnerable to 
outside critique 
The hospital formulary committee is a closed system and no 
transparency is wished 
The case documentation, either from the applicant and/or 
the pharmacist, shows only specific facts making the overall 
case positive 
Case documentation is influenced 
by the individual goals of the 
applicant and the limited time to 
present case data Provided information in advance to the committee meetings 
is biased as individuals are responsible for compiling these 
information 
Practical experience becomes more important Formulary committee members do 
not feel comfortable in cases of 
uncertainty --> this opens them to 
accept additional data Uncertainty increases willingness to accept softer criteria 
Perceived objective data creates more trust than expert 
opinions 
  
This is probably derived from the 
scientific background of 
pharmacists and physicians 
Objective criteria are perceived to be less biased and with 
more scientific rigor 
Practical experience alone is not sufficient for decision-
making 
Mistrust against colleagues if objective data is contradictory 
Committees are very in transparent in regards to decision 
criteria specifically on subjective criteria 
Formulary committees protect 
themselves. Subjective criteria are 
less accepted as members feel a 
lack of scientific rigor 
Formulary committees are afraid to admit the use of 
subjective criteria 
The importance of subjective criteria is diffuse and hard to 
quantify 
Subjective criteria are used more 
intuitively 
Formulary committee members do not think too much if they 
make use of subjective criteria 
Pharmaceutical drugs for oncology patients or children 
shorten the committee discussions 
Increase in empathy can positively 
influence the acceptance of 
subjective criteria Formulary committee members accept the complexity of 
specific indications, such as oncology therapies, and are 
generally reluctant to have costs discussions regarding 
therapies for children 
Table 19: Findings for the empirical, actual and real domain (continued). 
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Empirical/ Actual  Real (potential structures) 
Economic evaluations are not accepted as 
decision criterion 
Formulary committee members have lack of 
expertise and time regarding economic 
evaluations Economic evaluations are complex models with 
many input variables 
GMs are seldom part of the formulary committee Physicians + pharmacists are very protective to 
their area of competency. They are afraid of 
loosing importance and they do not want to 
leave their comfort zone. 
Physicians + pharmacists do not want influence 
from the GM or other members regarding their 
own topics 
The level of impact on the formulary committee 
member's competency area influences their 
efforts for decision-making 
Formulary committee members value other 
opinions as long as they are limited to topics 
outside of their own competency area 
For certain decisions, formulary committee 
members prepare additional data. The active 
participation increases. 
Some physicians are very passive during the 
discussions in the formulary committee meetings 
Physicians see themselves more as experts, 
not as managers. They realise a lack of 
expertise and appreciate the pharmacist's 
knowledge of medical and economic issues. 
This is true, especially in cases where the 
physician does not need to defend his/her own 
competency area. 
Physicians usually do not interfere or are critical 
when it comes to questions outside of their 
competency area 
Some departments have more influence than 
others on decision-making 
The strategic and economic importance of 
departments determines their potential impact 
on decision-making. 
Non-physicians/ non-pharmacists have much 
lower influence on decision-making than 
physicians or pharmacists 
Physicians and pharmacists have a perception 
about other functional roles as being less 
qualified. For example, nurses are part of the 
operations but not part of the decision-making 
process. 
Due to the dominance of medical and economic 
criteria, other functions are only considered if 
those criteria are not clear enough 
Nurses have a weak positioning in the formulary 
committee  
Despite the organisational lead of the committee 
chair, this role is not necessarily the most 
influencing person 
The role of the committee chair represents the 
formal most powerful position but often does 
not reflect reality. Sometimes this formal role is 
even abused by other more powerful members 
to build allies which are hard to "fight" in the 
committee discussions. 
Other formulary committee members can be 
more powerful with more impact on decision-
making 
Hierarchical structures do not impact decision-
making very much 
Between physicians, the seniority level is not 
the most decisive factor. Perceived level of 
expertise for the specific question or the 
strategic/economic importance of the 
respective department is more important. 
Most members are on the same or similar 
seniority level 
Full rejections of pharmaceutical drugs are 
seldom. It is more likely that the committee 
decides to allow a drug on a temporary basis 
Formulary committee members are afraid of 
voting against a drug and potential 
consequences if there are no clear facts which 
support the rejection. A vote against a drug 
request from another member might lead to a 
negative opinion from this member on their 
next own application. 
Formulary committee members do not want to 
finally decide in cases of great uncertainty 
Table 19: Findings for the empirical, actual and real domain (continued).
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8.5 Conclusion 
This research identified many potential structures for the real domain derived from 
the empirical findings. In the discussion it was shown that some empirical findings 
lead to more than one potential structure in the real domain, in some cases even with 
contradictory goals or connections to each other. For example, the motivation of 
decision-makers to consider the reputation of the hospital and thus the higher 
willingness to accept expensive therapies is contrary to the difficult economic 
situation of hospitals and the resulting cost awareness. Another example is the 
potential focus of physicians and pharmacists on objective data due to their scientific 
training background which conflicts with the potential impact of empathy which can 
lead to acceptance of weak objective data for oncology treatments. The impact of 
external stakeholders on decision-making, such as the influence of the 
pharmaceutical industry, contradicts the justification behaviour of decision-makers 
who emphasise the independence of their decision-making.  
 
Hence, different generative mechanisms have a positive influence on the use of either 
perceived objective or subjective decision criteria and their effect might compete 
during the decision-making process. This again confirms the theoretical fit of a dual 
processing system, such as Hammond’s cognitive continuum model (1996, 2000), as 
a basis for the hospital formulary decision-making framework. And it explains more 
in detail how a dual processing system looks like for this specific process. This 
research also confirmed that the relative importance of the decision-making criteria 
varies and is individual for each question. Thus, it does not make sense to determine 
fixed numbers for relative weights. In addition to the mechanisms which influence 
the choice of perceived objective or subjective criteria, two other main mechanisms 
have impact on the use of these criteria: uncertainty and power. These two main 
mechanisms are displayed in Figure 48 and show their influence on the choice or 
rejection of either subjective or objective decision criteria. Examples of these criteria 
are shown in the blue boxes. The green circles show examples for different aspects 
which can increase or decrease uncertainty or power. For example, mistrust towards 
the pharmaceutical industry increases uncertainty and can lead to rejection of 
objective criteria, such as data from the pharmaceutical manufacturer. Lack of 
training of decision-makers can cause uncertainty and rejection of health economic 
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evaluations. In addition, power can have significant impact on the decision-making 
process. The communication skills or the perceived expert status of an individual 
decision-maker can create power to more easily convince other members in the 
committee even with weak objective data.  
 
Generative mechanisms are not necessarily discrete. On the one hand, the level of 
individual communication skills of a decision-maker can lead to uncertainty if he 
lacks certain abilities. On the other hand, good communication skills can create 
power to convince. Hence, uncertainty and power both influence the acceptance or 
rejection of perceived objective and subjective criteria. These relationships as well as 
the dual processing system concerned with the use of objective and subjective data 
are shown in Figure 48. 
 
 
Figure 48: Dual processing system with impact of uncertainty and power. 
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8.6 The final hospital formulary decision-making framework 
The final decision-making framework now displays the two main decision-making 
groups: pharmacists and physicians. Additionally, other members of the hospital 
formulary or non-formulary members of the hospital are added as “Influencers”.  
 
In the first step, a dual processing system works for the individual preference 
building. It is influenced by perceived objective and subjective criteria sub-sets as 
well as external impact by the pharmaceutical industry, health insurances or other 
hospitals. One additional factor is the case documentation which is usually prepared 
by the pharmacist.  
 
A possible pre-alignment with other selected members of the hospital formulary is in 
between the individual preference building and the following group decision-making 
process. Every member of the hospital formulary has an individual preference which 
can be adapted during the group discussion. The group discussion is influenced by 
strong individuals, the strengths of the alliances of the pre-meeting alignments, the 
level of involvement of the respective committee member, the level of information 
and the importance of the respective department. 
Finally, all individual preferences are aggregated into one group decision. 
 
The final hospital formulary decision-making framework with all mentioned changes 
is shown in Figure 49. 
 
 
  
Figure 49: Final hospital formulary decision-making framework. 
2
2
4
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9 Implications for stakeholders 
 
The final hospital formulary decision-making framework (Figure 49) is the graphical 
representation and the summary of the hospital formulary decision-making process. 
Figure 48 shows more in detail how the dual processing system with impact of 
uncertainty and power influences step 1 of the final hospital formulary decision-making 
framework. It allows a better understanding of how the individual formulary committee 
member decides on the use of objective or subjective decision criteria to form his 
preliminary decision preference. In step 2 of the final hospital formulary decision-
making framework, group decision-making mechanisms can impact the individual 
preferences to form an aggregate group decision. Table 19 shows detailed findings for 
the empirical, actual and real domain including potential explanations for generative 
mechanisms. This adds further descriptive information to the understanding of the whole 
decision-making process. Hence, Figure 48, 49 and Table 19 are the main outcomes of 
this thesis and should ideally be used in combination to understand the drug funding 
hospital formulary decision-making process. The following implications for stakeholders 
were deduced from the combined view of the main outcomes. 
9.1 Transparency 
Transparency seems to be low for some parts of hospital formulary committee decision-
making. In regards to an official documentation or protocol the transparency exists to 
protect members from being accused of bribery. Nonetheless, this transparency is only 
formal and does not fully reflect how decision-making is done. Usually only the decision 
is documented but not the reasons for the decision. This lack of transparency makes 
hospitals vulnerable. If, however, sufficient documentation exists and the rationale is 
explained the decision should be less vulnerable to outside critique. If committee 
members believe that they take well-founded decisions then there should be no problem 
to show this, at least to the hospital employees.  
 
Another aspect of lack of transparency is the missing clear communication to other 
members of the committee of existing relationships between members of a hospital 
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formulary and the pharmaceutical industry.  Considering the strong influence of 
individual members of the hospital formulary, more explicit communication including a 
clear description and guidance for the decision-making process and a more detailed 
documentation of decisions could simplify the understanding of decisions. This increase 
of transparency can avoid suspicions by other members, facilitate the retrospective 
understanding of decisions and increase the acceptance of decisions also for non-
formulary members of the hospital. 
 
9.2 Acceptance of subjective criteria 
The use of perceived subjective criteria is not fully accepted by the formulary committee 
members. Either this is due to the scientific background of committee members or the 
fear that subjective criteria can only be used as a weak justification for decisions or that 
people just do not realise that they use such criteria.  However, decision-making 
involves the use of subjective criteria and this happens with a significant impact on 
decision-making. Hence, physicians, pharmacists and all other involved stakeholders 
should accept this in order to make decision-making more honest and transparent. 
Subjective criteria should also be formally accepted as a normal and valuable component 
of a decision-making process. For example, this could be done with listing them in a 
decision-making guideline.  
9.3 Economic implications 
Generally the focus on economic issues is strong. Critical medical decisions are 
probably still independent of economic considerations but economics have already an 
influence. This should not increase as medical reasons should be leading in taking those 
decisions. The study showed that economic criteria are very important for hospital 
formulary committee members but that local adaptation of economic calculations, such 
as health economic evaluations, is often missing. This outcome has the implication for 
the pharmaceutical industry to produce economic data which is interesting for their 
customers. Economic measures, including budget impact calculations or health 
economic evaluations, should consider the individual local situation as much as possible. 
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This can be done with co-operations, post authorisation studies together with hospitals to 
challenge the economic data with real world environments. 
 
There is high medical expertise in a hospital. It does not make sense that medical 
decisions taken in the hospital are changed or discontinued in the outpatient area as it 
jeopardises the treatment success. One considerable change would be necessary to 
ensure the independence of decision-making and a successful treatment. Ideally 
reimbursement for those therapies should be independent of the two different budgets 
(inpatient/outpatient) and should be guaranteed if initiated in the hospital. This structural 
change would require significant efforts from different stakeholders in the German 
healthcare system, such as politicians, health insurances and hospitals. However, due to 
the fact that health insurances would loose the indirect power to influence such 
treatments (and costs) it is highly unlikely that this change will happen. 
 
9.4 More knowledge sharing and training 
In regards to the local adaptation of economic data, there is also an implication for 
hospital formulary committees. Many members of the committee do not have the basic 
understanding for economic concepts, such as health economic evaluations. In order to 
allow an optimised informed decision-making, it is necessary that hospital formulary 
committees improve training on such topics. Economic topics might not be the main 
competence of physicians but it supports a better understanding of key criteria which can 
be used for decision-making and which are increasingly more important for hospitals. 
Physicians could also be trained on economics or health economics already during their 
studies. This allows them to better assess interrelations between medical and economic 
issues and to discuss at the same level as the pharmacists. In addition, training in 
communication skills supports formulary committee members with lower 
communication skills to better present their cases. It also facilitates that committee 
members express themselves. 
Either the chair of the formulary committee or senior management executives should 
encourage committee members to take their roles serious and to prepare themselves 
appropriately.  
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In addition, timelines for preparation should be extended, provided documentation 
should be more extensive and standardised to allow easy reading and less bias. Case 
documentation should be based on standard forms or questions to reduce potential bias. 
A framework should be generated which facilitates the compilation of documentation 
and a level of standardization. 
Pre-meeting discussions should be avoided and more time to discuss topics would be 
beneficial. To allow more in-depth discussions, the frequency of committee meetings 
could be increased. An open and respectful discussion culture should be established to 
allow an honest exchange of opinions. An overall goal for the hospital should be 
guidance for all discussions. 
 
Most of the proposed changes in this section are not difficult to implement. However, 
some of the changes, such as the discussion culture require an active change 
management which needs buy-in and active support by the hospital's top management. 
Otherwise the changes would only be formal changes without impact on the real 
situation. Additionally, these changes require time from all participants which could be 
an obstacle for implementation. 
 
9.5 Governance and group involvement 
Hospital formularies seem to have an indirect governance issue characterised by single, 
highly influential members who basically steer the listing of pharmaceutical drugs. As a 
result, decision-making in formularies is operationally seen easier but might miss the 
goal of having a real discussion and consensus in the group. Hospital formulary 
committees need to decide if they want to act as dependent on single individuals as they 
do today and to use the committee only as a formal justification body. Or if they want to 
broaden the discussion, actively involve more members of the committee and thus enrich 
also the roles of people. For example, the administration of a pharmaceutical drug is an 
important dimension of the drug's profile. Stronger representation of nurses in the 
formulary committees is an important change to appreciate this fact. One major 
prerequisite is that people want to be more involved, since a higher involvement requires 
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more efforts of the single member of the committee. In this respect, the business unit 
organisation structure of many hospitals is probably counter-productive. This works 
perfectly well in other business areas, but hospitals are different to enterprises. 
To finish, the chair of a committee should not be biased and considering the already 
strong roles of physicians and pharmacists it makes sense to have a chair from a 
different professional function. 
 
In this section the proposed changes have political weight. As discussed in the chapter 
before, usually the formulary committee is led by strong individuals or people working 
in the (financially) most important departments. The consequences of the proposed 
changes would mean a decrease of power in this group and an increase of power in other 
groups. Hence, today's influential committee members would need to accept these 
changes as they usually drive structural changes. Since those are local changes in the 
hospital they are not impossible but difficult to implement.   
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10 Reflexive view 
 
In this thesis, there are some specific aspects to consider which might have impact on 
the thesis results. These aspects are induced by the professional role of the researcher as 
a healthcare professional working for a pharmaceutical company. Due to this role, the 
researcher’s interpretations of data might be influenced and the professional experience 
of the researcher might have impacted resulting conclusions (Creswell, 2003). In 
addition, all interview respondents were aware of the researcher’s professional role, 
because of the transparency principle of this research. This knowledge might have 
influenced the interviewee’s willingness to reveal all of their opinions.  
The professional role of the researcher also potentially impacted the chances to get 
access to hospital formulary committee members. For example, this is reflected in the 
low response rate of the survey and the low willingness to participate in the expert 
interviews. On the other hand, the professional role of the researcher also facilitated 
access to all of the interview participants, since they were all part of the professional 
network. For future research this obstacle needs to be considered. If people were not 
willing to participate mainly due to the sensitivity of the topic, it would be difficult to do 
research on this topic without an appropriate professional network. Other studies in this 
field also experienced lower response rates specifically for German hospitals (Haslé-
Pham et al., 2005; Thürmann et al., 1997). In addition, the professional role of the 
researcher also enabled access to a data source which is usually non-accessible for 
scientific research. The company market research data which contributed to the 
explanation of the hospital formulary decision-making process was originally meant to 
be used only for the creation of market access strategies. One of the goals was to 
increase the understanding of the hospital formulary committee decision-making to 
optimize the targeting for market access and marketing activities. Despite some 
limitations to use this data which were described earlier, the closeness of this goal to the 
goals of this research made it a valuable data source to add further perspectives.    
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11 Concluding remarks and future research 
 
This study aimed for an explorative research on hospital formulary decision-making in 
Germany. The objectives of this study were to identify the generative mechanisms which 
influence decision-making of pharmaceutical drug funding. In this regard, the research 
objectives were the identification and assessment  of criteria used in funding decisions 
for pharmaceutical drugs in hospital formulary committees and their relative importance, 
the evaluation of the influence each stakeholder group has on drug funding decisions and 
the identification and evaluation of the motives and objectives of decision-makers when 
making funding decisions for pharmaceutical drugs. 
 
The outcomes of this study should motivate future research on hospital formulary 
decision-making, since information about this topic is scarce. Due to the resource 
limitations of this study, future research could look more detailed on differences 
between hospitals and more in-depth research could be done for specific decision 
criteria.  The governance aspect (as described in section 9.5) and an increased 
involvement of committee members could be an interesting topic for further research. 
Are other less powerful members of the committee interested to be more involved? Are 
they aware of their smaller impact possibilities? 
 
The descriptive hospital formulary committee decision-making framework as well as the 
detailed outcomes of this study could be used in combination to allow hospitals to better 
understand their own processes and compare it to other hospitals with the aim for 
improvement. Interview participants remarked that the exchange of information with 
colleagues from other hospitals regarding the formulary committee decision-making 
happens rarely. For that reason many hospitals cannot compare their own process and 
identify potential strength and weaknesses. This study helps those hospitals to get a 
clearer picture of what is happening in other German hospital formularies. 
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12 Personal Reflection 
 
During the last years writing my doctoral thesis, I gained knowledge about research 
philosophies, the ways of knowing and creating knowledge and the underlying theories. 
Of course I have learned much about my research topic and the issues around it. My 
behaviour in regards to time balancing and time planning as well as my self-discipline 
has significantly improved.  
 
Regarding the reflection process my opinion is that reflection is not only helpful for 
research projects but can also be supportive in my work life. The reflection process by 
Biggs (1998) allows people and in this case specifically practitioners to constantly think 
about their behaviour and possible alternatives.  
 
I believe that my research topic and the research questions have changed significantly 
over time. In summary the research questions have become very specific compared to 
the questions I were able to ask at the beginning. I was actually very surprised with the 
low response rate of my survey although former research indicated low participation 
willingness, especially for German hospitals. For this reason I was very pleased with my 
expert interviews which I think provided in-depth information on this very confidential 
decision-making process.  
 
But this whole development of my research project is just one achievement. Over this 
whole journey I have changed as a person. I have learned a lot about other people who 
can broaden my views although they might be very different in their ideas and their 
characters. Speaking to other researchers from very different disciplines I discovered 
that working in heterogeneous teams might lead to better results than working in very 
homogeneous teams due to the broad variety of perspectives and opinions which come 
together. 
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Appendix 1: Final result of the first systematic literature review. 
 
# Title Author Journal Level Year Region Focus on Methodology
1
Decision makers' views on health care 
objectives and budget constraints: results 
from a pilot study Al, Feenstra, Brouwer Health Policy National 2004 NL Several criteria Semi-structured interviews
2
The role of pharmacoeconomics in 
formulary decision making in different 
hospitals in Riyadh, Saudi Arabia Alsultan Saudi Pharm. J. Regional 2011 Saudi Arabia
Economic data and 
other criteria Structured survey questionnaires
3
Drug formulary decision-making in two 
regional health authorities in British 
Columbia, Canada
Armstrong, Mitton, Carleton, 
Shoveller Health Policy Regional 2008 Canada
Political and social 
factors
Observation of Pharmacy and Therapeutics 
meetings, analysis of meeting 
documentation and semi-structured 
interviews
4
Priority setting of health interventions: 
the need for multi-criteria decision 
analysis Baltussen, Niessen
Cost-Effectiveness and Resource 
Allocation National, regional 2006 not specified Several criteria Literature review
5
Setting healthcare priorities in hospitals: 
a review of empirical studies
Barasa, Molyneux, English, 
Cleary Health Policy and planning National, local 2014 Various Several criteria Systematic review
6
"Yes", "No" or "Yes, but"? Multinominal 
modelling of NICE decision-making Dakin, Devlin, Odeyemi Health Policy National 2006 UK Several criteria Quantitative analysis on NICE decisions
7
Transparency in Evidence Evaluation And 
Formulary Decision-Making
Dean, Ko, Graff, Localio, Wade, 
Dubois Pharmacy and Therapeutics Regional 2013 USA
Several criteria and 
transparency of the 
process
Expert panel to develop tool which was 
validated by a survey + pilot test of the tool
8
Determinants of HMO Formulary 
Adoption Decisions Dranove, Hughes, Shanley Health services research Regional 2003 USA
Relationships and 
motivations Focus group and surveys
9
A systematic review of the use of 
economic evaluation in local decision-
making Eddama, Coast Health Policy
National, regional, 
local 2008 UK, USA Economic evaluation Systematic review  
2
4
4
 
 # Title Author Journal Level Year Region Focus on Methodology
10
Use of economic evaluation in local 
health care decision-making in England: A 
qualitative investigation Eddama, Coast Health Policy Regional 2009 UK Economic evaluation
In-depth interviews, observations of decision-
making meetings and analysis of result 
documents
11
Drug and Therapeutics (D&T) committees 
in Dutch hospitals: a nation-wide survey 
of structure, activities, and drug selection 
procedures
Fijn, Brouwers, Knaap, De-Jong-
Van den Berg
British journal of clinical 
pharmacology Regional 1999 NL Several criteria Structured survey questionnaire
12
Decision maker's perceptions of health 
technology decision making and priority 
setting at the institutional level Gallego, Fowler, van Gool Australien Health Review Regional 2008 Australia
Political and social 
factors Semi-structured interviews
13
Funding and access to high cost 
medicines in public hospitals in Australia: 
Decision-makers' perspectives Gallego, Taylor, Brien Health Policy Regional 2009 Australia
Criteria for high cost 
drugs In-depth semi-structured interviews
14
Cost-Effectiveness Analysis and the 
Consistency of Decision Making George, Harris, Mitchell Pharmacoeconomics National 2001 Australia
Cost effectiveness and 
other criteria
Submissions to the national HTA 
organization were analyzed
15
Priority setting in hospitals: Fairness, 
inclusiveness, and the problem of 
institutional power differences Gibson, Martin, Singer Social science & medicine Regional 2005 Canada Power differences Case study 
16
Role of clinical, patient-reported outcome 
and medico-economic studies in the 
public hospital drug formulary decision-
making process: results of a European 
survey
Haslé-Pham, Arnould, Späth, 
Follet, Duru, Marquis Health Policy Regional 2005
France, 
Germany, NL, UK
Clinical studies, 
patient-reported 
outcomes and medico-
economic studies Postal survey
17
Rewarding innovation? An assessment of 
the factors that affect price and 
reimbursement status in Europe Hutchings Journal of Medical Marketing National 2009
Germany, UK, 
France, Italy, 
Spain
Different systems 
have different weights Literature review   
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4
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# Title Author Journal Level Year Region Focus on Methodology
18
Using Health Outcomes Data to Inform 
Decision-Making Janknegt Pharmacoeconomics Regional 2001 NL
Tool to support 
decision-making Literature review
19
System of Objectified Judgement Analysis 
(SOJA) as a tool in rational and 
transparent drug-decision making
Janknegt, Scott, Mairs, Timoney, 
McElnay, Brenninkmeijer Online Article Regional 2007 NL
Tool to support 
decision-making Literature review
20
The System of Objectified Judgement 
Analysis (SOJA) Janknegt, Steenhoek Drugs Regional 1997 NL
Tool to support 
decision-making Literature review
21
What constitutes evidence in hospital 
new drug decision making Jenkings, Barber Social science & medicine Regional 2004 UK
Political and social 
factors
Observation and cross case analysis of Drugs 
and Therapeutic Committee meetings
22
Priority setting at the micro-, meso- and 
macro-levels in Canada, Norway and 
Uganda Kapiriri, Norheim, Martin Health Policy
National, regional, 
local 2006
Canada, Norway, 
Uganda Several criteria Case studies and key informant interviews
23
Dear policy maker: Have you made up 
your mind? A discrete choice experiment 
among policy makers and other health 
professionals Koopmanschap, Stolk, Koolman
International Journal of 
Technology Assessment in 
Health Care National 2010 NL Several criteria
DCE  + pilot study + follow-up focus group 
discussion
24
Pharmaceutical Technology Assessment: 
Perspectives from Payers Leung, Halpern, West J Manag Care Pharm Regional 2012 USA Several criteria Semistructured telephone interviews
25
Priority setting in a hospital drug 
formulary: a qualitative case study and 
evaluation
Martin, Hollenberg, MacRae, 
Madden, Singer Health Policy Regional 2003 Canada Several criteria Qualitative case study
26
Priority-setting decisions for new cancer 
drugs: a qualitative case study Martin, Pater, Singer The Lancet Regional 2001 Canada Several criteria
Observation of provincial disease 
management organisation meetings, analysis 
of meeting documentation and interviews  
2
4
6
 
 # Title Author Journal Level Year Region Focus on Methodology
27
A survey of pharmacy and therapeutic 
committees across Canada: Scope and 
responsibilities Mittmann, Knowles
The Canadian journal of clinical 
pharmacology Regional 2008 Canada
Status of hospital P&T 
committees Surveys
28
Role of pharmacoeconomics in drug 
benefit decision-making: Results of a 
survey
Motheral, Grizzle, Armstrong, 
Cox, Fairman Formulary Regional 2000 USA Several criteria Surveys
29
Finding legitimacy for the role of budget 
impact in drug reimbursement decisions
Niezen, de Bont, Busschbach, 
Cohen, Stolk
International Journal of 
Technology Assessment in 
Health Care National 2009 NL Budget impact
Literature review + semi-structured 
interviews
30
Use of pharmacoeconomic data in making 
hospital formulary decisions
Odedina, Sullivan, Nash, 
Clemmons
American journal of health-
system pharmacy Regional 2002 USA
Economic data and 
other criteria Cross-sectional telephone survey
31
Ontario’s Formulary Committee
How Recommendations Are Made PausJenssen, Singer, Detsky Pharmacoeconomics Regional 2003 Canada Economic evaluation
Analysis of meeting transcripts, interviews 
with committee members
32
Drug and Therapeutics Committees in 
Danish Hospitals: A Survey of 
Organization, Activities and Drug 
Selection Procedures Plet, Hallas, Nielsen, Kjeldsen
Basic & clinical pharmacology & 
toxicology Regional 2013 Denmark Hospital formularies Descriptive cross-sectional survey
33
A Prescription for Improving Drug 
Formulary Decision Making
Schiff, Galanter, Duhig, 
Koronkowski, Lodolce, Pontikes, 
Busker, Touchette, Walton, 
Lambert PLoS medicine Regional 2012 USA
Tool to support 
decision-making Literature review
34
A qualitative approach to the use of 
economic data in the selection of 
medicines for hospital formularies: a 
French survey
Späth, Charavel, Morelle, 
Carrere Pharmacy World and Science Regional 2003 France
Economic data and 
other criteria Qualitative interviews
35
The greatest happiness of the greatest 
number? Policy actors' perspectives on 
the limits of economic evaluation as a 
tool for informing health care coverage 
decisions in Thailand Teerawattananon, Russell BMC Health Services Research National, regional 2008 Thailand
Economic evaluation 
and political and 
social factors
Semi-structured interviews and simple 
descriptive statistics
36 Economic Evidence at the Local Level
van Gool, Gallego, Haas, Viney, 
Hall, Ward Pharmacoeconomics Regional 2007 Australia Economic evaluation Literature review  
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# Title Author Journal Level Year Region Focus on Methodology
37
Economic evaluations of healthcare 
programmes and decision making van Velden, Severens, Novak Pharmacoeconomics
National, regional, 
local 2005
USA, Canada, 
NL, Australia Economic evaluation Systematic review
38
Drug reimbursement in Finland - a case of 
explicit prioritising in special categories
Vuorenkoski, Toiviainen, 
Hemminki Health Policy National 2003 Finland
Political and social 
factors Interviews with thematic framework analysis
39
Decision-making in priority setting for 
medicines - a review of empirical studies
Vuorenkoski, Toiviainen, 
Hemminki Health Policy National, regional 2008
Canada, France, 
Finland, UK
Decision making 
process and criteria 
used Literature review of empirical studies
40
The role of pharmacoeconomics in 
formulary decision-making
Walkom, Robertson, Newby, 
Pillay Formulary Regional 2006
UK, USA, France, 
Canada, NL, 
Australia, 
Sweden, Spain, Several criteria Literature review
41
Reimbursement decisions in health policy - 
extending our understanding of the 
elements of decision-making Wirtz, Cribb, Barber Health Policy National, regional 2005 UK
Political and social 
factors In-depth interviews
42
Use of health-related quality of life 
information in managed care formulary 
decision-making Wu, Sause, Zacker
Research in Social and 
Administrative Pharmacy Regional 2005 USA
Health related quality 
of life Mail survey
43
Cost-Effectiveness Analysis and the 
Formulary Decision-Making Process Wang, Salmon, Walton
Journal of Managed Care 
Pharmacy Regional 2004 USA
Cost effectiveness and 
other criteria Literature review
44
Cost-effectiveness analysis and formulary 
decision making in England: Findings from 
research Williams, Bryan Social science & medicine Regional 2007 UK Cost effectiveness Literature review  
2
4
8
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Appendix 2: Final result of the second systematic literature review. 
 
# Title Author Journal/ Book title/ Source Year Focus on
1
How individual preferences get aggregated in groups - 
An experimental study Ambrus, Greiner, Pathak
UNSW Australian School of Business Research 
Paper 2013
Social Decision Scheme and 
centrality
2 Social choice and individual values Arrow Social choice and individual values 1963 Aggregated group preference 
3 From novice to expert Benner The American Journal of Nursing 1984 Intuition
4
Clinical wisdom and interventions in acute and critical 
care: A thinking-in-action approach
Benner, Hooper-Kyriakadis & 
Stannard
Clinical wisdom and interventions in acute and 
critical care: A thinking-in-action approach 2011 Intuition
5 The theory of committees and elections Black The theory of committees and elections 1958 Aggregated group preference 
6
Group Decision Making under Conditions of 
Distributed Knowledge: The Information Asymmetries 
Model
Brodbeck, Kerschreiter, 
Mojzisch & Schulz-Hardt Academy of Management Review 2007 Group performance
7 Group decision and social interactions Davis Psychological Review 1973 Social Decision Scheme
8
Group decision making and quantitative judgements: 
a consensus model Davis
In E. Witte & J. H. Davis (Eds.), Understanding 
group behavior: Consensual action by small 
groups 1996 Social Decision Scheme
9
Intuition from the perspective of cognitive-
experiential self-theory Epstein Intuition in judgment and decision making 2008 Dual Processing
10
The heuristic-analytic theory of reasoning: extension 
and evaluation Evans Psychonomic Bulletin & Review 2006 Dual Processing
11
Beyond group-level explanations for the failure of 
groups to solve hidden profiles: The individual 
preference effect revisited
Faulmüller, Kerschreiter, 
Mojzisch, Schulz-Hardt Group Processes & Intergroup Relations 2010 Individual preference 
12 Altruistic punishment in humans Fehr & Gächtner Nature 2002 Subjective factors
13
Thinking, feeling and deciding: the influence of 
emotions on the decision making and performance of 
traders
Fenton-O’Creevy, Soane, 
Nicholson & Willman Journal of Organizational Behavior 2011 Rational decision-making
14 Conflict, decision and dissonance Festinger Conflict, decision, and dissonance 1964 Centrality
15 Gut feelings. The intelligence of the unconscious Gigerenzer 
Gut feelings: the intelligence of the 
unconscious 2007 Rational decision-making
16
The common knowledge effect: information sharing 
and group judgement Gigone & Hastie Journal of Personality and Social Psychology 1993 Information sharing 
17
The impact of information on group judgement: a 
model and computer simulation Gigone & Hastie
Understanding group behavior: Consensual 
action by small groups 2013 Information sharing 
18
Heuristics and biases: the psychology of intuitive 
judgement Gilovich, Griffith, Kahneman
Heuristics and biases: The psychology of 
intuitive judgment 2002 Dual Processing
19
Preference-Consistent Evaluation of Information in 
the Hidden Profile Paradigm: Beyond Group-Level 
Explanations for the Dominance of Shared 
Information in Group Decisions Greitemeyer, Schulz-Hardt Journal of personality and social psychology 2003 Individual preference 
20
Human judgement and social policy: irreducible 
uncertainty, inevitable error, unavoidable injustice Hammond
Human judgement and social policy: 
Irreducible uncertainty, inevitable error, 
unavoidable injustice 1996 Intuition versus analysis
21 Judgements under stress Hammond Judgments under stress 2000 Intuition versus analysis
22
Feelings and consumer decision making: the appraisal-
tendency framework Han, Lerner & Keltner Journal of Consumer Psychology 2007 Subjective factors
23
Cognitive and consensus processes in group 
recognition memory Hinsz Journal of Personality and Social psychology 1990 Information sharing 
24
The emerging conceptualization of groups as 
information processors Hinsz, Tindale & Vollrath Psychological bulletin 1997 Information processing systems  
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# Title Author Year Focus on
25
Victims of groupthink: A psychological study of 
foreign-policy decisions and fiascoes Janis
Victims of groupthink: A psychological study of 
foreign-policy decisions and fiascoes 1972 Information sharing 
26
A perspective on judgement and choice: mapping 
bounded rationality Kahneman American psychologist 2003 Rational decision-making
27 The American Jury Kalven & Zeisel The american jury 1966 Individual preference 
28
Centrality in sociocognitive networks and social 
influence: an illustration in a group decision-making 
context
Kameda, Ohtsubo & 
Takezawa Journal of personality and social psychology 1997 Cognitive centrality
29
Group decision making: the effects of initial 
preferences and time pressure Kelly & Karau Personality and Social Psychology Bulletin 1999 Information sharing 
30
Intuition: a critical review of the research and 
rhetoric King & Appleton Journal of Advanced Nursing 1997 Intuition
31
Discussion of shared and unshared information in 
decision-making groups
Larson, Foster-Fishman & 
Keys Journal of personality and social psychology 1994 Information sharing 
32
Recalling Shared vs. Unshared Information 
Mentioned During Group Discussion: Toward 
Understanding Differential Repetition Rates Larson, Jr., Harmon Group processes & intergroup relations 2007 Recalling shared information
33
Portrait of The Angry Decision Maker: How Appraisal 
Tendencies Shape Anger’s Influence on Cognition Lerner & Tiedens Cognition & Emotion 2006 Subjective factors
34
Beyond valence: Toward a model of emotion-specific 
influences on judgment and choice Lerner & Keltner Journal of Behavioral Decision Making 2000 Subjective factors
35
Reflective and reflexive judgement processes: a social 
cognitive neuro-science approach Lieberman
Social judgments: Implicit and explicit 
processes 2003 Dual Processing
36 The role of affect in decision making Loewenstein & Lerner Handbook of affective science 2003 Rational decision-making
37
Two models of group behaviour in the solution of 
eureka-type problems Lorge & Solomon Psychometrika 1955 Aggregated group preference 
38
Information Sharing and Team Performance: A Meta-
Analysis
Mesmer-Magnus & 
DeChurch Journal of Applied Psychology 2009 Group performance
39
Culture and systems of thought: holistic vs. analytic 
cognition
Nisbett, Peng, Choi, 
Norenzayan Psychological review 2001 Dual Processing
40
Acceptance of uncommon information into group 
discussion when that information is or is not 
demonstrable Parks & Cowlin 
Organizational Behavior and Human Decision 
Processes 1996 Information sharing 
41
The functions of affect in the construction of 
preferences Peters The construction of preference 2006 Rational decision-making
42
The multiplicity of emotions: a framework of 
emotional functions in decision making Pfister & Böhm Judgment and Decision Making 2008 Subjective factors
43
Unfairness, Anger, and Spite: Emotional Rejections of 
Ultimatum Offers Pillutla & Murningham Organizational Behavior and Human Decision Processes1996 Subjective factors
44
Emotions in Finance. Distrust and Uncertainty in 
Global Markets Pixley
Emotions in finance: Distrust and uncertainty 
in global markets 2004 Intuition versus analysis
45
Information processing theory of human problem 
solving Simon Handbook of learning and cognitive processes 1978 Rational decision-making
46 The empirical case for two systems of reasoning Sloman Psychological bulletin 1996 Rational decision-making
47 On the reliability of group judgments and decisions Smoke & Zajonc
Mathematical methods in small group 
processes 1962 Aggregated group preference  
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# Title Author Year Focus on
48
Individual differences in reasoning: implications for 
the rationality debate Stanovich & West Behav Brain Sci 2000 Dual Processing
49
Pooling of unshared information in group decision 
making: biased information sampling during 
discussion Stasser & Titus Journal of personality and social psychology 1985 Information sharing 
50
Effects of information load and percentage of shared 
information on the dissemination of unshared 
information during group discussion Stasser & Titus Journal of personality and social psychology 1987 Information sharing 
51
Influence processes and consensus models in decision-
making groups Stasser, Kerr & Davis In Psychology of Group Influence 1989 Social Decision Scheme
52
Expert roles and information exchange during 
discussion: the importance of knowing who knows 
what
Stasser, Stewart & 
Wittenbaum Journal of experimental social psychology 1995 Centrality
53
Information sampling in structured and unstructured 
discussions of three- and six-person groups Stasser, Taylor & Hanna Journal of Personality and Social Psychology 1989 Information sharing 
54 Group processes and productivity Steiner Group processes and productivity 1972 Aggregated group preference 
55
Reflective and impulsive determinants of social 
behaviour Strack & Deutsch Personality and social psychology review 2004 Dual Processing
56
The interaction of the explicit and implicit in skill 
learning: a dual-process approach Sun, Slusarz & Terry Psychological review 2005 Dual Processing
57
Shared information, cognitive load, and group 
memory Tindale & Sheffey Group Processes & Intergroup Relations 2002 Information sharing 
58 Group decision making Tindale, Kameda & Hinsz Sage handbook of social psychology 2003 Group decision-making
59
A model of the hierarchy of behaviour, cognition and 
consciousness Toates Consciousness and cognition 2006 Dual Processing
60
Assigned experts with competitive goals withhold 
information in group decision making
Toma, Vasiljevic, Oberlé, 
Butera British Journal of Social Psychology 2013 Information sharing
61
Effects of partially shared persuasive arguments on 
group induced shifts: a group problem solving 
approach Vinokur and Burnstein Journal of Personality and Social Psychology 1974 Individual preference 
62
Memory performance by decision-making groups and 
individuals
Vollrath, Sheppard, Hinsz & 
Davis
Organizational Behavior and Human Decision 
Processes 1989 Information sharing 
63 The theory of games and economic behaviour
von Neumann & 
Morgenstern Theory of games and economic behavior 1947 Rational decision-making
64 Strangers to ourselves Wilson
Strangers to ourselves: Discovering the 
adaptive unconscious 2002 Dual Processing
65
A social validation explanation for mutual 
enhancement Wittenbaum, Bowman Journal of Experimental Social Psychology 2004 Centrality
66
On emotion specificity in decision making: Why 
feeling is for doing
Zeelenberg, Nelissen, 
Breugelmans & Pieters Judgment and Decision making 2008 Subjective factors
67
Heading into the unknown: Everyday strategies for 
managing risk and uncertainty Zinn Health, Risk & Society 2008 Intuition versus analysis  
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Appendix 3: Web-Survey. 
 
English translation of all survey questions 
 
1. What is your position in the hospital? 
2. Are you personally involved in formulary decision-making (include or exclude a 
pharmaceutical drug) 
3. How many hospitals do you represent in the hospital formulary committee? 
4. Number of beds in the represented hospital/ hospital group? 
5. How does formulary decision-making regarding inclusion/ exclusion of 
pharmaceutical drugs work in your hospital? 
a. Committee with fixed members 
b. Committee with varying members 
c. Single discussions between pharmacist and physician 
d. Other 
6. How many people usually sit together to make those decisions? 
a. 2 people 
b. 3-5 people 
c. 6-8 people 
d. 9-12 people 
e. More than 12 people 
7. Who chairs the hospital formulary committee? 
a. Pharmacist 
b. Physician 
c. Head physician 
d. General Manager 
e. Other 
8. How many people from the respective functional role usually attend the 
committee meetings? 
a. Pharmacist 
b. Physician 
c. Head physician 
d. General Manager 
e. Nurse/ Head nurse 
f. Patients/ Patient representative 
g. Controller/administrator 
h. Other 
9. How often does the committee meet to discuss inclusion or exclusion of 
pharmaceutical drugs? 
10. Does your hospital have guidelines for the inclusion or exclusion of 
pharmaceutical drugs? 
253 
11. In the guidelines... 
a. ...decision criteria are mentioned. 
b. ... the relative importance of decision criteria is given. 
12. My decision-making... 
a. ...always follows the criteria given in the guidelines. 
13. What decision criteria are given in the guidelines? 
a. Number of indications 
b. Type of administration 
c. Budget impact 
d. Data from observational trials 
e. Data from clinical trials 
f. Recommendation from physician/head physician 
g. Recommendation from pharmacist 
h. Recommendation from colleagues 
i. Recommendation from patient groups 
j. Former experience with manufacturer 
k. Health economic evaluations 
l. Information material provided by the manufacturer 
m. None 
n. Experience in the hospital 
o. Experience from other hospitals 
p. Quality of life data 
q. Supply reliability of manufacturer 
r. Price of the drug 
s. Off-label potential 
t. Disease severity 
u. Existing alternatives 
14. How do you feel about your current decision-making process? 
15. Do hierarchical dependencies between members of the committee exist? 
16. Is there transparency in regards to relationships between committee members and 
pharmaceutical manufacturers (e.g. participation in clinical trials)? 
17. Are supportive tools applied, such as SOJA, Multi criteria decision analysis or 
computer software? 
18. Does every committee member receive a documentation package which includes 
information on the respective pharmaceutical drug? 
19. Who is responsible for this documentation package? 
a. Pharmacist 
b. Physician/ Head physician 
c. General Manager 
d. Other 
20. What kind of information is included in the documentation package? 
254 
a. Data from clinical trials 
b. Disease severity 
c. Health economic evaluations 
d. Budget impact 
e. Price of the drug 
f. Experience in the hospital 
g. Experience from other hospitals 
h. Recommendation from colleagues 
i. Information material provided by the manufacturer 
j. Recommendation from pharmacist 
k. Recommendation from physician/head physician 
l. Data from observational trials 
m. Quality of life data 
n. Type of administration 
o. Supply reliability of manufacturer 
 
p. Number of indications 
q. Recommendation from patient groups 
r. Former experience with manufacturer 
s. Existing alternatives 
t. Off-label potential 
u. Other 
21. Do you use the information of the documentation package? 
22. Do you have budget responsibility? 
23. Is the financial situation of the hospital topic during the committee discussions? 
24. In your opinion, what is the impact on decision-making of each functional 
group? 
a. Pharmacist 
b. Physician 
c. Head physician 
d. General Manager 
e. Patient/ Patient representative 
f. Controller 
g. Other 
25. Which decision rule is applied for decision-making on inclusion or exclusion of 
pharmaceutical drugs? 
a. Simple majority – more than half of the members vote yes 
b. Consensus – a decision is only taken if all members accept the decision 
c. A single person decides 
d. Other 
26. Is your decision-making different for different types of pharmaceutical drugs? 
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27. For which types of pharmaceutical drugs do you apply different criteria? 
a. Antifungal 
b. Enzyme replacement therapies 
c. Medical devices 
d. Monoclonal antibodies 
e. Sera/ Immunoglobulins 
f. Cytostatic 
28. Which decision criteria do you apply for (see list in 27)? 
a. Number of indications 
b. Type of administration 
c. Budget impact 
d. Data from observational trials 
e. Data from clinical trials 
f. Recommendation from physician/head physician 
g. Recommendation from pharmacist 
h. Recommendation from colleagues 
i. Recommendation from patient groups 
j. Former experience with manufacturer 
k. Health economic evaluations 
l. Information material provided by the manufacturer 
m. Experience in the hospital 
n. Experience from other hospitals 
o. Quality of life data 
p. Supply reliability of manufacturer 
q. Price of the drug 
r. Off-label potential 
s. Disease severity 
t. Existing alternatives 
29. Which decision criteria do you apply for (see list in 27)? 
a. See list in 28 
30. Which decision criteria do you apply for (see list in 27)? 
a. See list in 28 
31. Which decision criteria do you apply for orphan drugs? 
a. See list in 28 without "data from clinical trial" 
32. Do you want to receive the study results by email and do you agree that your 
email address is saved for this purpose only? 
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Appendix 4: Web-Survey cover letter. 
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Appendix 5: Interview guide 
 
Introduction 
Aim:  
 Development of a decision-making framework with all relevant decision criteria 
for the specific situation of inclusion of a pharmaceutical drug on the formulary. 
Consideration of: soft/ subjective criteria  
 Objective of the thesis: structured and transparent process, emphasise differences 
between hospitals and possible explanations.  
 
Comment on: 
Interview will be recorded; data of the interview will be made anonymous. 
Ask for consent to use the data in the context of this thesis. 
 Interviewee needs to agree on this! 
 
 
General information 
What is the current position of the interviewee? 
 
(For how long is the interviewee already involved in decision-making on inclusion of 
pharmaceutical drugs in the hospital formulary?)  
 
 
Process 
Is transparency important for decision-making? 
Why yes/why no? 
 
What kind of decision-making is conducted in the hospital (Committee, individuals, 
etc.)? 
Who is involved? 
 
Is time pressure an issue? 
If yes, how is this being managed? 
 
 
Decision-making criteria 
Definition/ explanation for qualitative criteria  criteria which are not directly 
measurable 
 
What are the most important qualitative decision-making criteria independent of the type 
of pharmaceutical drugs? 
Probe for explanation! 
 
What is the impact of gut feeling on decision-making? 
Is decision-making always consistent (always based on the same criteria)? 
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If no, which factors lead to the inconsistencies? 
 
Why do differences between the decision-making criteria exist? 
Probe for reasons! 
 
In case of weak quantitative data (e.g. not many clinical trials, not showing the right 
data) – how does decision-making work? 
Probe for reasons! 
 
How important are recommendations of colleagues (Physicians, pharmacists, etc.)? 
Are those recommendations challenged? If yes, how? 
Are recommendations of colleagues more important than "hard facts", such as clinical 
trials data? 
 
Should the impact of economic data, such as health economic evaluations, budget 
impact, price, be bigger? Probe for reasons? 
 
How does the interviewee manage conflicting goals, such as optimisation of the 
economic situation and the improvement of a treatment situation? 
What impact does this have on decision-making? 
 
 
Group 
Who has the most influence on decision-making? 
Probe for explanation! 
 
How big is the impact of other group members on the interviewee's decision-making? 
Probe for explanation! 
 
Do hierarchical structures influence decision-making? 
If yes, how and how much? 
 
How does the interviewee think about involvement of patients/ patient groups in hospital 
formulary decision-making? 
 
Should specific groups be more involved in the decision-making process? 
Which groups? 
Probe for reasons! 
 
How big is the influence of pharmaceutical companies on the interviewee's decision-
making? 
 
How big is the influence of health insurances on the interviewee's decision-making? 
 
How big is the influence of politicians on the interviewee's decision-making? 
What types of compromises are accepted during discussions in the hospital formulary 
committee? 
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Appendix 6: Sample transcript for the expert interviews 
 
I: First of all, thanks a lot for taking the time for this interview. As already emphasised 
before, this is a doctoral study conducted at the University of Gloucestershire, regarding 
a decision model adapted to the specific situation "addition of pharmaceutical drugs in 
the formulary list of hospitals". One specific focus of this thesis is the usage of soft 
criteria or qualitative criteria. The overall goal is to demonstrate a transparent decision 
process which could also be adopted by other hospitals. Another goal is to emphasise the 
differences between hospitals in Germany and possible explanations for this. 
Basically this interview is anonymous. This means that the interview data will be 
transcribed and made anonymous in order not to show your name anywhere. I will now 
ask formally: Do you agree that this interview can be used for this doctoral thesis, then 
please answer "yes"! 
 
B1: Yes, no problem!  
 
I: In addition, I will audio record this interview. Please also answer with "yes" if you 
agree! 
 
B1: I agree to this! 
 
I: Perfect, thanks! Two general questions: What type of positions do you have? 
 
B1: I am Head Physician in a hospital. 
 
I: How long have you been involved in decision-making on adding drugs to the hospital 
formulary list? 
 
B1: 25 years. 
 
I: Good. Let's talk about the decision-making process in your hospital. Which type of 
decision-making do you have there? Is it a formulary committee or do you have one to 
one discussions between pharmacist and physician? 
 
B1: In our hospital we have regular formulary committee meetings, every half year. The 
pharmacist leads these meetings and invites a determined group of people, including the 
general manager, the Head of Nurses and of course the Medical Director. However, in 
our hospital the Medical Director is also Head Physician of one department. All Head 
Physicians of the departments are invited, as well as financial administrators and in rare 
cases also the Head of the Finance department. They will be invited separately like the 
specialist on hospital hygiene if special topics need to be discussed. 
 
I: From your perspective, should decision-making be transparent? 
 
B1: Definitely yes! 
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I: Why? What are the reasons? 
 
B1: Because decisions of the hospital formulary committee are budget relevant. If one 
department for whatever reasons thinks about an artificial hip joint (as an example), then 
this is an expensive decision which possibly limits the resources for other things, at least 
temporarily. In this case there needs to be good reasons to argue in the hospital 
formulary committee meeting, why they want to use more or other products. This needs 
to be easy to understand, also for non-orthopaedists and non-orthopaedic surgeons, such 
as internal specialists.  
 
It is also the other way round. If the internal specialist wants to introduce something 
which is new, which is innovative and has impact on the overall budget, he needs to be 
able to explain his request in a competent manner during the committee meeting. Others 
then need to agree since this is usually a majority decision.  
 
In such a case, also the financial administrator and the general manager have to 
potentially agree. 
 
I: The financial administrator decides? 
 
B1: No, I have commented on it in the questionnaire, because the financial administrator 
definitely provides impact or his recommendation, but he does not decide. 
 
I: OK, good. Do you face time pressure on your decision-making? 
 
B1: No, no! The topics for the bi-annual committee meeting are known to everyone in 
advance, they will be communicated by the pharmacist who organises everything and 
who is also the chair. This allows members to prepare if the decision concerns them. The 
pharmacist provides recommendations what he wants to delete and which drugs should 
be discussed for addition to the formulary list (applied by whomever in advance). This 
way, everybody can well prepare if he wants to support the application or if he wants to 
stay neutral. Hence, there is no time pressure. If there are questions with time pressure, 
those will be temporarily solved between the pharmacist and the physician and 
afterwards be presented in the formulary committee meeting. 
 
I: OK, does this mean that the discussions continue until every agenda item is 
considered? I assume the meeting has a fixed duration? 
 
B1: Yes, every agenda item is considered. Many of those items are already prepared and 
distributed in advance via email. Everybody can think about agreement or disagreement 
with the protocol of the last meeting or the recommendations of the pharmacist. Many 
times, the presentations of the pharmacist are so well prepared that one can simply agree 
with it.  
 
I: OK, good. Let's move to the next theme which is about the decision criteria. Could 
you please mention five qualitative criteria which are very important from your 
perspective? This should be independent of the type of drug. 
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B1: I need to differentiate between the drugs I apply for and the other ones where I need 
to agree or disagree. In the latter cases I heavily rely on the case presentation of the 
respective department. If we are talking about more general things, such as Heparin 
which is a common topic in all formulary committees, we want to limit this to one or 
two products for the hospital. Here the internal specialist, the orthopaedist, the 
orthopaedic surgeon, the neurologist as well as the psychiatrist need to find a consensus 
to agree on only two products. Often, this is not so easy. One needs to prepare for this 
discussion and the quality measures. Quality for me also means user quality. For 
example, how many employees are needed to prepare and infuse Heparin? In addition, 
you have quality of patient satisfaction and application safety which is sometimes 
heavily discussed. In these cases, a nurse needs to provide insights, how much time and 
resources are required to prepare one vial compared to a ready-to-use vial. You have a 
lot of different aspects with such decisions. 
 
I: I believe there is a misunderstanding. If I talk about qualitative criteria, I mean criteria 
which are not directly measurable. I am not talking about quality measures, but about 
criteria which are not directly measurable. Regarding the comments you have just made: 
the time which is needed by the nurse to prepare an injection is a quantitative criterion 
since you can measure the time. And there are other criteria which are not directly 
measurable. Do you have any criteria in mind which you think are important to mention? 
 
B1: For example, acceptance by the patient. If I get a subcutaneous injection once or 
twice daily or if I only need to take a pill with the same efficacy, this is a qualitative 
criterion. Another qualitative criterion is the safety of a drug. This is a criterion for me 
which is not directly measurable. You can read about this in assessment reports, pre-
analysis reports and company reports but company information is always pro domo. This 
is why you need to read this critically! But if the patient safety is guaranteed, this is a 
qualitative criterion.  
 
I: Are there any situations where you decide based on gut feeling? For example, 
situations in which the arguments are not sufficient to make a rational decision and 
where you decide rather emotionally? Can you remember a situation where this 
happened or would you exclude this? 
 
B1: No, I would exclude this for me. In the first place I trust the presentation or the 
statements of the respective department which tries to list a specific pharmaceutical 
drug. If a pharmacist proposes a change for a drug, I see this differently. There I 
question myself, if…I better take an example. If product A can be purchased cheaper 
from a different company, the presence of company A or B plays a role for me. If it is 
just a small difference in price, I would decide based on my gut feeling always for the 
company, which is more present in my area. Decisions based on gut feeling do exist. Of 
course you have to argue this against the pharmacist. For example, I could mention that 
the company does a lot of services for me and for this small advantage in costs I would 
not risk to loose this service. Here you sometimes have these decisions. Certainly the 
other company might have a similar service, but this is not known to me. 
 
275 
I: Presence means in this case the service a company provides to your department? 
 
B1: Exactly! This can be brochures for patients, this can be training or seminars for 
physicians or nurses, whatever is offered "around" the product and what is known to me. 
 
I: Is your decision-making always consistent? Do you always use the same decision 
criteria, even if you think about different types of pharmaceutical drugs? 
 
B1: Yes and no, this depends. One example is the oncologist who has a very broad 
spectrum of necessities. Oncology drugs are often very expensive and a difficult 
decision for many hospital budgets. However, with oncology patients one is also in a 
different situation compared to patients who require an artificial hip. Here a comparison 
between product A and product B seems much more feasible. But with oncology 
patients, if the oncologist argues intensively that he needs his product A or B, you would 
rather agree without discussing too much. 
 
I: This means that you trust a lot in the expert opinion and the recommendation of the 
respective department? 
 
B1: Exactly! But this is what I would also expect the other way round. If I want to 
introduce a drug in my department, I expect colleagues to accept my proposal, unless 
they have a really big counter-argument, but then I would expect to hear this in advance.  
 
I: But this should happen in advance to the committee meeting, correct?! 
 
B1: Exactly! This is what I would expect! If I have an important counter-argument 
against a drug proposed by one of my colleagues, I would call him in advance to ask 
why he wants to have this drug and not the alternative solution. And are the study results 
really so convincing? Here I would not wait for the next committee meeting, but rather 
talk to my colleague in advance to understand why he prefers this specific drug. 
 
I: Then I need to dig deeper here! Is there no real discussion in the committee meeting? 
 
B1: Of course, of course there is, especially from the pharmacy on the one hand. Clearly 
they have the responsibility to present the price, the supplier issues of company X for 
example, which we do not know and cannot estimate In addition, to discuss all questions 
around drug safety, storage conditions, etc...These are a lot of aspects which play a role 
and where the pharmacist can have a different opinion than the physician who wants to 
have his drug added to the list. And there is the financial administrator, who says, we 
have this or that possibility to get reimbursement. If there is no special allocation, this 
would stress our budget significantly. Consequently there is a need for discussion. 
 
I: And finally who gains the acceptance? 
 
B1: Mmmmhh... 
 
I: Well, you mentioned quite conflicting goals. 
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B1: Of course, on the one hand you have the medical perspective and on the other hand 
you have the economic perspective. A third aspect is something that we [as physicians] 
cannot really judge on: the reliability of the manufacturer, the supply reliability and so 
on. Well…usually there is a trial listing for a drug, if the head physician defends the case 
intensively, if he really needs it. And if there are open questions or discussions we 
cannot solve, we take the drug temporarily on the list until the next committee meeting 
where the pharmacist should report back on those questions, if he encountered problems 
with the supply, if the costs were higher than expected or others. In addition to the 
pharmacist, the physicians who used the drug should also report on their experiences.    
 
I: In cases with a difficult evidence situation, such as a situation where the existing 
clinical trials data does not fulfil the gold standard of evidence-based medicine (no 
randomised, placebo controlled trial), how do you decide? Which criteria play a big role 
for you? For example, if you have clinical trials with small patient numbers... 
 
B1: These pharmaceutical drugs will not be listed. Instead, they can be ordered on a 
case-by-case basis. It is a preference that people make their experiences if they are 
convinced by a substance. And if the evidence situation is not clear, the Head Physician 
of the department can place a single order or an order with a limited volume. Following 
this, he is then asked to report back to the committee and talk about his experience. 
 
I: In this case this means that this type of drug has a good chance to be added to the 
formulary list, if the test order has successful outcomes? 
 
B1: If this can be covered by a DRG (Diagnosis Related Group) and if this is reasonable 
from a cost perspective, then yes. 
 
I: From your perspective, should the importance of economic data, such as health 
economic data, budget impact or procurement cost, be higher than today?  
 
B1: No! In total, you might correct me if I am wrong, the cost factor drugs is about 10% 
of the total hospital costs. We have approximately 70-72% personnel costs. If we can 
improve the drug costs a little bit this would be good for the hospital. However, the 
impact is limited on the total budget even if we talk about several Millions.  
 
I:  Sounds right to me. How do you handle extreme expensive therapies, such as enzyme 
replacement therapies or haemophilia? In these cases, the impact of the drug costs... 
 
B1: If a department is established in this sector and wants to treat a handful of patients 
who are not appropriately covered by the health insurance system, then we need to 
discuss this with the general manager and the Medical Director. The discussion will be 
about the importance of the treatment possibility for the hospital or if the opinion is: 
"We do not need to do everything. Let's forward them to the next bigger hospital with 
such a treatment focus". Of course there are single cases where the hospital needs to 
represent something to the outside and where the decision was positive for the drug even 
if it was not fully covered. 
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I: This probably would not be, as far as I understood this correctly, something for the 
hospital formulary but rather a separate discussion. 
 
B1: The opinion of the experts is of course helpful. If a physician can argue why a 
therapy, which is not appropriately reimbursed and thus loss-making, makes sense 
because of the department reputation, in order to create awareness for the special 
expertise of this department, then the vote of the head physicians is surely important for 
the general manager. However, he finally decides what happens in the hospital. 
 
I: Do you these cases very often? Or how many times does this happen? Is it once a year 
or am I completely wrong? 
 
B1: No...Less than that! 
 
I: Ok, let's move on to the last topic. I want to talk about the groups who are involved in 
decision-making. From your perspective, who has the biggest impact on decisions? 
 
B1: The Head Physician! In our hospital. I know this can be totally different in other 
hospitals. For example, if the pharmacist and the general manager jointly prepare 
decisions and block other influences, but in our hospital this is, thanks god, still the 
physician who needs to take responsibility for the treatment. This is what you have to 
take yourself anyways. And this makes me very happy the way it is. The Head Physician 
of the department definitely has the biggest decision competency for the inclusion of a 
new drug on the formulary list. The pharmacist is his closest consultant. The general 
manager usually does not interfere.  
 
I: Does this depend on hierarchical dependencies? Well, is the pharmacist in any way 
from an organisational, hierarchical perspective subordinated to the Head Physician? Or 
are these functions on the same level? 
 
B1: He is a consultant. The pharmacist is our consultant. He can support the preparation 
of a decision. He can also report his arguments against the inclusion of a drug or a new 
substance, but thanks god this difficult discussion is often done in advance. If I want to 
introduce a new drug the first thing I do is to call the pharmacist, ask him about his 
opinion about this drug, the pros and cons, also about the manufacturer, pricing, price 
negotiation. This means, if we go to the hospital formulary, I have already coordinated 
with the pharmacist. 
 
I: Generally speaking: are there any hierarchical dependencies between members of the 
formulary committee?  
 
B1: Formally, the general manager is boss of everyone, who works in the committee. 
But he is a businessman. Thus, he has no medical competency. 
 
I: Does he think the same way? 
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B1: In our hospital this was never different and he would be challenged if he had a 
different opinion. His lack of medical competency is a fact. Certainly he can ask for 
consultancy. If he informs himself upfront, he could theoretically ask other pharmacists 
or general managers or physicians to build his own opinion. However, this is no opinion 
based on his medical competency. This is external knowledge. He can use this for his 
argumentation or he can tell the committee that he has heard from a different hospital 
that this has worked well or not so well. And if this is a good argument, we need to face 
this and talk about it, this is clear. But he is well advised to focus on the economic side 
of things, if I may say so. For example, together with financial administration he could 
assess the possibility to get appropriate DRG reimbursement for an expensive new drug. 
If financial administration then says: "The consequence is that we have a deficit of 1,000 
EUR for each treatment, we cannot do this!", then the respective department needs to re-
consider the importance of the substance.  
 
I: Good. In some countries, patient representatives or patients groups are invited to the 
formulary committee meetings to be part of decision-making. This usually happens in a 
consulting role of course. What is your opinion on this? Does this make sense to you? 
 
B1: Rather no. There are definitely reasonable possibilities to involve patient 
representatives, specifically in areas such as oncology or with chronic inflammatory 
diseases. In these cases, the patient representatives usually try to add their wishes with 
support of the respective Head Physician of the department. If the Head Physician 
believes in the option, then he proposes this during the committee meeting. In my 
opinion it does not make sense to invite patient representatives to the committee 
meetings due to the fact that a lot of confidential internal topics are also discussed during 
these meetings. But if patient representatives use the Head Physicians of the respective 
departments to include their perspectives, this is something good. 
 
I: Good, from your perspective should specific groups already participating in the 
committee meetings be more involved in decision-making? Or is the current distribution 
of functional groups optimal? 
 
B1: I think this is optimal! Well, I would not know which group is missing to take a 
decision. For the hospital it is important to involve the general manager, the nurses and 
financial administration. Apart from that, the pharmacist and the physicians are the 
decision-makers in the hospital formulary committee. 
 
I: How strong do you think is the impact of the pharmaceutical industry on your 
decision-making? You mentioned before that the provided service of a manufacturer 
does play a role and can influence positively or negatively. How would you describe this 
influence? 
 
B1: The influence should not be underestimated. 
 
I: Does this relate to the service of the pharmaceutical company? Or is that... 
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B1: If a new substance should be introduced, the decision-maker of the respective 
department needs to be armed appropriately. This means, if he has no own experience 
one needs to explain how he can gain experience. There are a lot of possibilities how he 
can achieve this. For example, he could be invited to treaters in other hospitals, in other 
departments or to congresses where the new substance is used or discussed. I believe 
that in the initial phase, the introduction of a new substance, the pharmaceutical industry 
has a big influence, inevitably. 
  
I: How much do local or regional payers impact decision-making in your opinion? 
 
B1: Health insurances? 
 
I: Yes, health insurances. 
 
B1: Concerning the hospital formulary committee I neither see any requirements for 
health insurances to influence decision-making nor I see that health insurances have 
tried this. I have never heard of this. 
 
I: The drug costs are usually included in the DRGs and here I would see an already 
existing, potential influence… 
 
B1: No. Health insurances do not assess a single activity. They pay a total sum of X for 
a treatment. How the total sum for a treatment was compiled, if hospital A invests more 
in nursing time or hospital B invests more for drugs to achieve the treatment goal and 
why there can be different negotiated prices, this depends on the negotiation skills of the 
General Management and the health insurances. This does not relate to single drug costs. 
 
I: You have already indicated this before. Different stakeholders in the decision-making 
process have different goals. We have talked about the pharmacists who might focus on 
supplier reliability. We have talked about financial administration that might focus on 
DRG reimbursement questions and then we have talked about physicians with a medical 
goal. How can a balance be achieved? 
 
B1: I think this works automatically since the respective Head Physician of a department 
is budget responsible at the same time. He has drug costs directly shown in his papers 
and he needs to justify those. Or he needs to save somewhere more money to spend it on 
very expensive drugs. In these cases financial administration can consult on how to 
manage and improve the DRG reimbursement of single treatments in order to come out 
positive and earn some money on a DRG treatment. The Head Physician of the 
respective department will inform himself already in advance about the economic 
consequences of a decision question before he hands in any application for inclusion. 
However, first of all the medical side is important and then comes the price.  
 
I: OK, but due to the budget responsibility as a Head Physician of a department you 
cannot deny the importance of the economic aspects, independent of the medical… 
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B1: This does not play an important role in the hospital formulary anymore. These are 
single cases where one says: “You cannot allow this” or “We cannot allow this in this 
specific department”. And there are also single cases where we say: “OK, this is 
expensive and it will be impossible to manage the DRG reimbursement in a way to make 
this whole case positive, but the department needs to be representative to the outside.” 
For these cases there needs to be this possibility. Even if we know in advance that the 
case will be negative we need to swallow the bitter pill although this will never get out 
of hand. However, sometimes you have a situation where you need to act like this. For 
example, we have ten Heparins on the formulary list because every department had its 
own preference and here the pharmacist said: “I need to improve logistics. I cannot store 
all Heparins at the same time as we lack space. In addition, my negotiation power is 
limited due to the variety of Heparins. The Head of Nurses added: “The application 
safety is not optimal with many different Heparins due to a higher risk of confusion and 
a higher risk of over- or under-dosing. This is what I cannot expect from my team“. In 
this case we had a majority vote where we said: „We have limited the available Heparins 
to drug A and drug B. Everybody can decide on which of the two drugs to use, but the 
other eight drugs will no longer be used here”. Full stop! There was a little bit of an 
uproar, but finally this has been implemented.  In this case there was a command of the 
medical director necessary to put the people…a little bit under pressure. Head 
Physicians of departments can sometimes be a little bit weird.  
 
I: We are done with the interview! I would like to thank you very much for your 
participation! 
 
B1: You are welcome. Good luck! 
 
 
